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ntroduction and outlineI              besity in adults, adolescents and children Currently more than 13 % of the Dutch population is obese (Body Mass 
Index (BMI) > 30 kg/m2) (1). Incidence of (morbidly) obese patients all over 
the world is rising as well (2-3). Besides, in 2008 childhood obesity affected 
17% of the children and adolescents in the United States (4). If current trends 
persist, there will be 2.16 billion overweight (BMI > 25 kg/m2) and 1.12 billion 
obese individuals worldwide in 2030 as compared to 388–405 million obese 
individuals in 2005 (5). 
Extreme obese patients, morbidly obese patients (BMI > 40 kg/m2), are 
reported to have various pathophysiological changes, such as an increased 
blood flow, cardiac output and oxygen consumption (6-7). In addition, 
morbidly obese patients suffer from increased risk for co-morbidities like 
diabetes type II and cancer (6). Due to these pathophysiological changes 
and co-morbidities, obese patients are more likely to utilize healthcare 
resources (8). 
Dosing guidelines for most commonly used drugs in this population are not 
available due to the lack of studies providing adequate pharmacokinetic 
and pharmacodynamic data. Mostly the dose is rather based on clinical 
experience of the prescriber than on evidence based medicine. Serious 
problems may arise due to over- and underdosing, increasing adverse 
events and the risk of suboptimal efficacy, respectively. Therefore studies 
indentifying optimal body size descriptors for different drugs in order to 





       he influence of morbidly obesity on the pharmacokinetics and 
pharmacodynamics of propofol in adults and adolescents
For morbidly obese patients it is known that anaesthesia is not without risk. 
These patients are often difficult to intubate, are prone to desaturation due 
to altered pulmonary physiology and are known to have a different cardiac 
state (9-10).   
Propofol, 2,6-di-isopropylphenol, is widely used for induction and 
maintenance of anaesthesia in both non-obese and obese patients as it 
has a rapid onset of action and fast recovery. The incidence of nausea and 
vomiting is the least of all anaesthetic agents (11). Propofol is a highly 
lipophilic drug which is protein-bound for 98%, mainly to albumin (12). While 
propofol clearance is mostly hepatic and for a small part extra-hepatic, it is 
known for being a high extraction drug (13). Pharmacokinetics of propofol in 
non-obese patients are characterized by a three-compartment model with a 
reported propofol clearance value of 1.4 to 2.2 L/min (14-15). 
Propofols mechanism of action is not well defined but is probably due to 
enhance γ-aminobutyric acid (GABA)- mediated transmission (16). Propofol 
is rapidly redistributed and together with its high clearance from blood this 
leads to rapid recovery from anaesthesia (17). It has depressant effects on the 
cardiac contractility and causes reduction in venous and arteriolar systemic 
vascular resistance, resulting in a decrease in arterial blood pressure and a 
decrease of the pre- and afterload, respectively (18). In order to minimize the 
risk of side effects, optimal dosing of anaesthesia using propofol is needed. 
Depth of propofol anaesthesia can be evaluated with Bispectral index (BIS) 
values, a derivative of the electroencephalographic (EEG) and therefore of 
brain activity of the cerebral cortex. BIS values varying from a dimensionless 
BIS value of 0 (complete cortical EEG suppression) to 100 (fully awake) (19). 
The BIS has been developed as a tool to measure the level of consciousness 
during anaesthesia and has benefits in comparison to clinical measures of 
anaesthesia, because it assesses sedation continuously and provides an 
objective, quantitative measure of the level of anaesthesia. The BIS has 
been approved to be used in the operating room for both children (20) and 
adults (21). As there are to date no dosing guidelines available for propofol 
anaesthesia in morbidly obese in both children and adults, effects of propofol 
have to be evaluated using both propofol concentrations and BIS values. 
       he influence of morbidly obesity on the pharmacodynamics of low 
molecular weight heparines
Despite significant advances in the prevention and treatment of venous 
thromboembolism events (VTE), pulmonary embolism is a common cause of 
hospital death (22), being responsible for approximately 150,000 to 200,000 
deaths per year in the United States (23). Obesity is a known risk factor for 
VTE (24) with a relative risk for deep venous thrombosis of 2.50 (95% CI = 2.49 
− 2.51) compared to non-obese patients (25). The relative risk for pulmonary 
embolism in hospitalized patients was more than two times higher in obese 
patients than in non-obese patients and even further increased in obese 
adolescents (26). Incidence of VTE after laparoscopic bariatric surgery for 
patients receiving thromboprophylactic therapy is relatively low with 0.9%. 
However, this risk increases to almost 3% 6 months after surgery (27).
Several derangements of normal haemostasis are thought to contribute 
to the prothrombotic state of obesity: enhanced platelet activity, 
procoagulant state, impaired fibrinolysis and activation of endothelial 
cells. The procoagulant state consists of increased tissue factor, fibrinogen, 
factor VII, factor VIII and thrombin generation (28). In contrast to non-obese 
patients, VTE is more difficult to diagnose as thoracic imaging often cannot 
be performed because of the weight limitations of the scanning equipment 
or otherwise the image quality is often poor (29). 
Increased risk of VTE and difficult diagnosis makes optimal prophylactic 
therapy essential for this special group of patients. Low-molecular-weight 
heparines (LMWH) have been shown to substantially reduce the risk of 
VTE. LMWH contain fragments of heparin and have a molecular weight of 
4 - 6 kDa and differ in their individual manufacturing processes and their 
in vitro potency (30). The major anticoagulant effect of LMWH is caused by 
binding to anti-thrombin (AT). Binding induces a conformational change 
in the molecule which accelerates its inhibitory activity on clotting factors 
Xa, IIa, IXa and XIIa. Compared to heparin, LMWH have a reduced ability to 
inactivate thrombin, because they consist of smaller fragments that cannot 
bind simultaneously to AT and thrombin (31) and less potent anti-factor IIa 
activity but have a stronger anti-factor Xa activity (31-32). Besides, LMWH 
have less effect on coagulation parameters, such as the activated partial 
thromboplastin time (32). 
Nadroparin is a widely used LMWH in the Netherlands and is the standard 
drug for thrombotic prophylaxis in the St. Antonius Hospital, Nieuwegein. 
The ratio anti-factor Xa activity to anti-factor IIa activity for nadroparin is 
2.5 - 4 : 1 compared to a ratio of 1:1 for heparin (32). Peak anti-factor Xa 
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activity of nadroparin are reached 3 - 5 h after subcutaneous administration 
with an elimination half-life of 8 - 10 h after subcutaneous injection in non-
obese patients (30). Drug clearance of all LMWH is completely renal (30-31).
Since it is not possible to measure LMWH levels directly, because it is a 
mixture of polysaccharides that includes biologically inactive species (33), 
and LMWH inhibit preferentially clotting factor Xa, anti-factor Xa assays 
have been developed and validated to determine the anticoagulant effect 
of LMWH (34). A standard curve is constructed by adding known amounts 
of LMWH to plasma and then adding a fixed amount of Xa. This results in 
the formation of an inactive antithrombin-Xa complex and residual Xa is 
measured using a chromogenic assay. The residual Xa activity is inversely 
proportional to the concentration of LMWH in the sample and may be 
quantitated from a calibration curve (35). 
In comparison to heparin, LMWH have a more predictable dose-response 
relationship and therefore there is no need for routinely monitoring of anti-
Xa levels (36). However for some special groups of patients; (morbidly) obese 
patients, patients with renal failure and pregnant patients, it can be justified 
as the dose-response relationship in these populations may be altered and 
these patients were excluded from clinical trials (34). For LMWH in general, 
the recommended prophylactic range in non-obese patients for anti-Xa levels 
4 hours after administration is 0.2-0.5 IU/ml (37). Increased risk of bleeding 
has been observed for anti-Xa levels above 0.8 IU/ml (38). The guidelines 
of the American College of Chest Physicians suggest dosing adjustment 
of LMWH for very obese patients without clear dosing recommendations 
(24). Mostly a fixed dose of LMWH for thrombotic prophylaxis is given to 
non-obese patients and this dose is increased for a certain weight (based 
on BMI or total body weight) using a fixed amount. Using a fixed dose for 
thromboprophylaxis however could lead to underdosing and an increased 
risk for developing a thromboembolic event (31, 39). As there are to date no 
evidence based dosing guidelines available for LMWH prophylactic therapy 
in morbidly obese patients, clinical effects of LMWH have to be evaluated 
using anti-Xa levels as endpoint.
          ody size descriptors for drugs in obesity
In order to develop evidence based dosing guidelines for morbidly obese 
patients, characterization of the influence of weight as covariate on variability 
between patients of pharmacokinetic and pharmacodynamic parameters of 
drugs starts often with population modelling. Covariate analysis involves 
the modelling of the distribution of the individual parameter estimates as 
a function of patient characteristics, pathophysiological factors, genetic/
environmental factors and/or the concomitant use of other drugs, which 
may influence the pharmacokinetics and/or pharmacodynamics. The 
identification of predictive covariates for variability provides the scientific 
basis for rational and individualized dosing schemes. Different body size 
descriptors are available to characterize the influence of body weight on 
pharmacokinetic and pharmacodynamic parameters. Body mass index (BMI) 
is the international metric recommended to classify obesity, e.g. BMI higher 
than 40 kg/m2 is morbidly obese (3). However, BMI is not a measure of body 
composition; it is rather more of a descriptor of body shape as it cannot 
differentiate adipose tissue from muscle mass, with only an approximate 
relationship to excess body fat (40).  Total body weight is mostly used to 
dose a drug however it is influenced by age, sex, height, muscles and obesity 
and therefore should be used with caution as body size descriptor of obesity. 
Lean body weight, as a measure of changes in body composition, is often 
suggested as an ideal metric for dosing in obese patients (41). The formula 
for estimation lean body weight was found to provide good predictive 
performance of the fat free mass measured with bioelectrical impedance 
analysis (BIA) or dual-energy x-ray absorptiometry (DXA) (42). This formula 
is not validated for children and therefore, recently, a new formula was 
developed by Peters et al. (43). However, it is unknown if these formulas 
are ideal body size descriptors in obese patients as pharmacokinetic and 
pharmacodynamic studies are lacking. It has been reported before in obese 
patients that metabolic pathways may be increased or decreased (44). 
Pharmacokinetic and pharmacodynamic studies are influenced by the 
metabolic pathways and properties of the drug and therefore there is no 
one body size descriptor that fits all drugs in obese patients.
 
             ims of the thesis
The aim of this thesis is to investigate the influence of morbid obesity on 
the pharmacokinetics and pharmacodynamics of drugs and to develop a 
model-based approach to derive drug dosing algorithms for morbidly obese 
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The influence of obesity on drug metabolism and elimination greatly 
differs per specific metabolic or elimination pathway. Chapter 2 provides 
an overview of clinical studies that reported drug clearance values in both 
obese and non-obese patients. Studies were classified according to their 
most important metabolic or elimination pathway. 
The influence of morbidly obesity on the pharmacokinetics and 
pharmacodynamics of propofol in adults and adolescents
In order to describe the influence of excessive body weight on propofol in 
obese patients, we investigate the pharmacokinetics in both non-obese 
and morbidly obese patients and the pharmacodynamics in morbidly obese 
patients in Chapter 3 using Bispectral index (BIS) values as pharmacodynamic 
endpoint. As reports on the influence of perioperative remifentanil on the 
pharmacokinetics and pharmacodynamics of propofol are conflicting and for 
morbidly obese patients unexplored, in Chapter 4 morbidly obese patients 
receiving propofol-remifentanil anaesthesia and morbidly obese patients 
receiving propofol-epidural anaesthesia are compared. Given the developed 
PK PD model in Chapter 3, Chapter 5 addresses the validation of this model 
in clinical practice using BIS values as clinical endpoint. The subsequent 
chapter (Chapter 6), provides a pharmacokinetic model of propofol in 
morbidly obese adolescents as the prevalence of obesity is rising in younger 
patients. As the effect of weight gain can be due to aging and obesity, in 
Chapter 7 we perform a pharmacokinetic meta-analysis using data of both 
non-obese and morbidly obese adults, adolescents and children.
The influence of morbidly obesity on the pharmacodynamics of low molecular 
weight heparines
Chapter 8 was the starting point for investigating the influence of obesity 
on the pharmacodynamics of low molecular weight heparines (LMWH). 
It describes the pharmacodynamics of tinzaparin using anti-Xa levels as 
endpoint in a morbidly obese patient of 252 kg. As there is no consensus 
if and how the dose of LMWH needs to be adjusted in obese patients, we 
describe in Chapter 9 the current practice of thromboprophylaxis in obese 
surgical patients among surgeons in the Netherlands. Correlations between 
anti-Xa levels and different body size descriptors after a capped dose of 5,700 
IU nadroparin in morbidly obese patients are studied in Chapter 10. Chapter 
11 addresses the pharmacodynamics of nadroparin in both non-obese and 
morbidly obese patients using anti-Xa levels as pharmacodynamic endpoint. 
As it is impossible to investigate all available drugs in morbidly obese 
patients using the method of Chapter 11, in Chapter 12 we extrapolate the 
PD model of nadroparin to another LMWH tinzaparin and compare these 
results with a reference model that was developed using a comprehensive 
covariate analysis of the tinzaparin data to provide the best description of 
these data based on statistical criteria.
Discussion and perspectives
Finally, the theme of this thesis is summarized and the potentials of 
pharmacokinetic and pharmacodynamic modelling in obese patients are 
discussed in Chapter 13.
O
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              bstract
The prevalence of obesity in adults and children is rapidly increasing across 
the world. Several general (patho)physiological alterations associated with 
obesity have been described, but the specific impact of these alterations 
on drug metabolism and elimination and its consequences for drug dosing 
remains largely unknown.
In order to broaden our knowledge of this area, we have reviewed and 
summarized clinical studies that reported clearance values of drugs in 
both obese and non-obese patients. Studies were classified according to 
their most important metabolic or elimination pathway. This resulted in a 
structured review of the impact of obesity on metabolic and elimination 
processes, including phase I metabolism, phase II metabolism, liver blood 
flow, glomerular filtration and tubular processes.
This literature study shows that the influence of obesity on drug metabolism 
and elimination greatly differs per specific metabolic or elimination 
pathway. Clearance of cytochrome P450 (CYP) 3A4 substrates is lower in 
obese as compared with non-obese patients. In contrast, clearance of drugs 
primarily metabolized by uridine diphosphate glucuronosyltransferase 
(UGT), glomerular filtration and/or tubular-mediated mechanisms, xanthine 
oxidase, N-acetyltransferase or CYP2E1 appears higher in obese versus non-
obese patients. Additionally, trends indicating higher clearance values were 
seen for drugs metabolized via CYP1A2, CYP2C9, CYP2C19 and CYP2D6, 
while studies on high-extraction-ratio drugs showed somewhat inconclusive 
results. Very limited information is available in obese children, which 
prevents a direct comparison between data obtained in obese children and 
obese adults.
Future clinical studies, especially in children, adolescents and morbidly 
obese individuals, are needed to extend our knowledge in this clinically 
important area of adult and paediatric clinical pharmacology.
A
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Currently more than 30% of the US population is obese (Body Mass Index 
(BMI) >30 kg/m2) (1-2), while approximately 5% have been reported to 
be morbidly obese (BMI > 40kg/m2) (3). In Europe the prevalence of adult 
obesity ranges from 9-29% depending on the country (4) and increases every 
year. Also for children strong upward trends are observed. According to the 
national health and nutrition examination survey, conducted in 2007 – 2008, 
17% of US children are obese(5). Upcoming economies, such as China and 
India, also show an alarming increase of obesity in both adults and children 
with more than 30% of Chinese adults being overweight (6). If current trends 
persist, there will be 2.16 billion overweight and 1.12 billion obese individuals 
worldwide in 2030 as compared with 388–405 million obese individuals in 
2005 (7). 
In view of this trend, it is important to understand the impact of obesity 
on drug metabolism and elimination and its consequences for drug dosing 
in the (morbidly) obese population. Obesity and morbid obesity are 
associated with several (patho)physiological changes that may influence 
the pharmacokinetics of drugs. Among other factors, obese patients have 
relatively more fat and less lean tissue per kilogram of total body weight 
than non-obese individuals (8-9). Blood volume is observed to be increased, 
particularly in the morbidly obese (10-11). In addition, studies have confirmed 
that obese patients suffer from low-grade inflammation (12), which is 
probably the underlying cause of the high prevalence of non-alcoholic 
steatohepatitis (NASH)(13-14). NASH has been reported to either increase 
or decrease drug metabolizing enzyme activity (15-18). The net effect of 
obesity on drug metabolism is also influenced by cardiac output and liver 
blood flow, both of which are shown to be increased in obese patients (19). 
Concerning renal function, a state of glomerular hyperfiltration similar to the 
condition seen in early-stage diabetic nephropathy and sickle cell disease 
has been reported in obese individuals (20-21). Until now, the influence of 
obesity on tubular processes has been unknown. 
In summary, many (patho)physiologic alterations associated with obesity 
have been described in the literature, yet the impact of these alterations 
on specific drug metabolic and elimination pathways has not been clearly 
summarized. Numerous publications have described obesity-related 
alterations in all aspects of drug pharmacokinetics, including absorption, 
distribution, metabolism and elimination of drugs (9, 22-30). In addition, 
several publications have tried to provide practical guidelines for dosing in 
this population (9, 23-28). In recent publications the influence of obesity on 
drug metabolism and renal elimination was stated to be inconclusive and 
inconsistent, with drug clearance being the most important pharmacokinetic 
parameter for maintenance dosing regimens (9, 22, 24, 27, 30). In some 
cases, results from animal or in vitro studies have been used to fill the 
knowledge gaps (27, 30). So far, many pharmacokinetic studies have been 
performed in obese patients and these studies may represent a wealth 
of knowledge on clearance of specific drugs in obesity. In this review our 
goal was to order and sort pharmacokinetic studies by their primary drug 
metabolic or elimination pathway to gain insight into how these pathways 
change with obesity. Therefore, drugs representative for a specific pathway 
were included in the review, in order to generate knowledge on obesity-
related changes in the most important metabolic and elimination pathways 
in humans. As such, this review provides insight into how obesity affects 
specific drug metabolism and renal elimination pathways in both obese 
adults and obese children, on the basis of results of pharmacokinetic studies 
in obese and non-obese individuals. For this purpose a direct comparison 
between drug clearance in obese and non-obese individuals is necessary: 
therefore clinical trials that included both obese and non-obese individuals 
were reviewed in this analysis.
          earch Strategy and Selection Criteria
Approach
We studied individual drug metabolism and elimination processes by 
using drug clearance values as surrogate markers for these processes. To 
allow for direct comparisons between obese and non-obese individuals, 
clinical studies that investigated drug pharmacokinetics in both obese and 
non-obese patients were collected. The drugs reported in these clinical 
studies were categorized by their currently known rate-limiting clearance 
processes, and absolute clearance values were summarized in tables, 
which is an approach that has been applied before (29). In addition, weight-
normalized clearance values were added to provide information on the 
weight-normalized changes in clearance values between non-obese and 
obese individuals. These weight-normalized clearance values were either 
directly extracted from the original publication or derived by dividing 
mean clearance by mean total body weight. As an alternative to total body 
weight, consideration was given to normalizing clearance values for lean 
body weight, as this parameter is often proposed as a body size descriptor 
for obese patients (27, 31). Unfortunately, this parameter was reported in 
only very few studies included in this review; therefore, it was not possible 
I
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to report clearance values adjusted for lean body weight.
Clearance processes were divided into metabolism and renal elimination. 
For drug metabolism, phase I metabolism, phase II metabolism and liver 
blood flow were considered. Drugs for which information about the rate-
limiting cytochrome P450 (CYP) process was inconclusive were included 
in the Miscellaneous Phase I Metabolism section (section Other Phase I 
Metabolic Enzymes). For renal elimination, two processes involved in drug 
elimination by the kidneys were identified: glomerular filtration and tubular 
processes (tubular secretion and tubular reabsorption).
Inclusion criteria
Papers from the international peer reviewed literature reporting drug 
pharmacokinetics in obese and normal-weight adults or children were 
eligible for inclusion. Drugs were included if cleared by a specific metabolic 
or renal elimination pathway, as reported in international peer reviewed 
literature. This reference about the drugs main metabolic or elimination 
route was included in the tables. 
Search terms and search results
The PubMed database was used for the search for papers in which the 
pharmacokinetics of a drug were studied in both an obese and non-obese 
population. The following search terms were used:
-  (Clearance[All Fields] AND (“obesity”[MeSH Terms] OR “obesity”[All 
Fields])) AND (controls[All Fields] OR normal[All Fields] OR healthy[All 
Fields]), yielding 562 results on 2nd of March 2011.
-  ‘[Substrate]’ and ‘obesity’ and ‘pharmacokinetics’. Substrates mentioned 
in Cytochrome P450 Drug Interaction Table were used(32). A total of 91 
(CYP3A4), 10 (CYP2E1), 35(CYP2D6), 43(CYP1A2), 23 (CYP2C19), 14 (CYP 
2C9), 1 (CYP 2C8), 7 (CYP2B6) papers of interest were found between 
March and May of 2011. 
-  ‘[Kidney process]’ and ‘obesity’ and ‘pharmacokinetics’. A total of 18 
(glomerular), 5 (tubular secretion) and 2 (tubular reabsorption) papers of 
interest were found between May and June of 2011.
Additionally, references in the selected articles were checked for additional 
publications to include in this review.
Exclusion criteria
From studies investigating pharmacokinetics of drugs in both obese and 
non-obese patients, the following studies were excluded: studies on drugs 
for which the metabolic or renal elimination pathway was reported to be 
miscellaneous, unknown or inconsistent, as concluded from peer reviewed 
literature; studies investigating endogenous substances (including insulin); 
pharmacodynamic studies; animal studies; case reports; and in vitro studies.
           rug metabolism
Drug metabolism predominantly occurs in the liver through enzymes 
responsible for the modification of functional groups (phase I reactions) and 
the conjugation of endogenous substituents to drugs to make them even 
more polar (phase II conjugation) (33). 
In 90% of obese patients, histologically proven liver abnormalities as fatty 
infiltration are present (34). Non-alcoholic fatty liver disease (NAFLD) may 
range from simple liver steatosis without inflammation to NASH with active 
hepatic inflammation. NASH prevalence is difficult to assess, because the 
diagnosis can only be confirmed using a liver biopsy. However, it is estimated 
that up to 20% of the obese population and up to 50% of morbidly obese 
patients have NASH (35), and its incidence correlates with BMI (kg/m2) (36). 
While fatty infiltration of the liver may result in altered enzyme activity of 
phase I or II systems, this enzyme activity may also be subject to changes 
caused by other obesity-associated (patho)physiological changes such as 
the chronic state of inflammation (12, 16).
To describe the enzyme activity of phase I and II systems in obesity, we 
provide in this section an overview of clinical studies investigating drugs of 
which clearance is dependent on phase I or II reactions or liver blood flow 
and which were studied in both obese adults or children and non-obese 
adults or children in one report. 
Phase I metabolisme 
Phase I enzymes catalyse the modification of functional groups of a 
substrate (i.e. oxidation, reduction and hydrolysis), and the majority of 
these enzymes consist of CYPs. CYPs are predominantly located in the 
endoplasmatic reticulum of hepatocytes. Other sites include the gastro-
intestinal tract, where significant amounts of gene expression of various CYP 
isoforms have been detected (37-38). CYP enzyme metabolism contributes 
to approximately 75% of all drug metabolism (39). In this section we provide 
an updated review of all studies that have investigated phase I-mediated 
drug clearance in both obese and non-obese patients in one report.
Cytochrome P450 (CYP) 3A4
CYP3A4 is involved in the phase I metabolism of approximately 50% of 
all drugs (40). In Table I, an overview of the studies comparing clearance 
D
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of CYP3A4-metabolized drugs in both obese and non-obese individuals is 
presented. The pharmacokinetics of ten CYP3A4 substrates in obese versus 
non-obese subjects have been reported, including alfentanyl, midazolam, 
triazolam, alprazolam, cyclosporine, carbamazepine, docetaxel, taranabant, 
trazodone and N-methyl-erythromycin.
As an in vivo probe of CYP3A4 activity, N-methyl-erythromycin, midazolam, 
triazolam, alprazolam and cyclosporine are widely applied (41-46). In this 
respect, it was reported that obesity was significantly associated with 
lower metabolism of [14C]-N-methyl-erythromycin, measured as exhaled 
14CO2 in both men and women (r2= 0.91 and r2 =0.90, respectively) (41-
42), indicating reduced CYP3A4 metabolic activity. Similarly, triazolam 
clearance was significantly lower in obese patients (47). For midazolam (48), 
alprazolam (47) and cyclosporine (49-50), clearance values were reported 
to be lower in obese versus non-obese individuals, though this was not 
statistically significant, potentially because of the limited power of these 
studies.
A trend towards lower CYP3A4 activity associated with obesity was also 
found for other major CYP3A4-cleared drugs. Carbamazepine clearance 
in non-obese versus obese patients was only marginally higher (51). Upon 
major weight loss, carbamazepine clearance in six obese patients was 
significantly increased (52). As an explanation, it has been suggested that a 
fatty liver, as observed by abdominal ultrasound, may hinder carbamazepine 
metabolism either by inhibition of important biochemical reactions or by 
reduction in liver blood flow. After weight loss, ultrasound images showed 
a disappearance of fatty changes, in line with an increase in carbamazepine 
clearance. Clearance of alfentanil, which is also predominantly metabolized 
by CYP3A4 (53), was almost halved in obese as compared with non-obese 
patients (54). The pharmacokinetics of taranabant, primarily metabolized 
by CYP3A4 (55), were studied using data from 12 phase 1 clinical trials and 
one phase 2 study, including 385 obese individuals (BMI range 30-43 kg/
m2) (56). While the authors found a lower estimated oral clearance in obese 
individuals, they attributed this result to either increased protein binding or 
a decrease in CYP3A activity. 
For two CYP3A4 substrates no difference in clearance was reported in obese 
versus non- obese patients. Trazodone, for which CYP3A4 is the major 
isoenzyme involved in the formation of its metabolite (57-58), showed no 
difference in clearance between obese and non-obese patients. Furthermore, 
docetaxel clearance values of adults patients were not significantly different 
between non-obese, obese or morbidly obese adults (59). 
In studies of patients before and after gastric bypass surgery an increase 
in activity of CYP3A4 metabolism in obese individuals was reported. 
Cyclosporine requirement in patients after gastric bypass surgery was 
significantly increased from 1.8 to 3.5 mg/kg/d (p=0.02,) in order to maintain 
similar cyclosporine trough levels (60). Similarly it was reported that higher, 
tacrolimus, sirolimus (CYP3A4 (61-62)) and mycophenolic acid (CYP3A4, 
CYP2C8 (63)) doses were needed in transplant recipients with a gastric 
bypass to ensure exposure similar to that in a non-bypass patient (64). 
In contrast, atorvastatin bioavailability 3 – 6 weeks after gastric bypass 
surgery was found to be both increased and decreased as compared with 
before surgery (65-66). The observations made in these gastric bypass 
studies seem to reflect an increase in CYP3A4-mediated clearance in after 
weight loss. However, these observations may also be explained by the 
surgical procedures or an increase in activity of CYP3A4 located in the 
intestines, both causing reduced absorption of oral drugs. Finally, it could 
be a combination of the factors mentioned. To our knowledge, no studies 
have investigated the oral bioavailability of CYP3A4 substrates in obese 
(gastric bypass) patients versus non-obese patients, and as such, we cannot 
distinguish between these factors. 
In summary, 7 out of 13 studies presented in Table I show a significantly 
lower clearance of CYP3A4 substrates in obese patients and 4 studies show 
non-significantly lower absolute clearance values. Body weight-normalized 
clearance values, as depicted in Table I, show that drug clearance per kilogram 
body weight is halved in obese individuals. The underlying mechanism 
of impaired CYP3A4 metabolism and the potential consequences for 
CYP3A4 drug-drug interactions in obese patients are unclear and should 
be subjects of future research. Furthermore, it should be noted that the 
majority of patients included in these studies were mildly obese, while only 
a few morbidly obese patients (BMI >40 kg/m2) were included. To date, the 
pharmacokinetics of CYP3A4-metabolized drugs have not been studied in 
obese children or adolescents. 
CYP2E1
Although CYP2E1 metabolism represents only about 5% of phase I drug 
metabolism (39), the impact of obesity on CYP2E1 activity has been the 
subject of several studies, in which also a significant proportion of morbidly 
obese patients were included. Chlorzoxazone, enflurane, sevoflurane and 
halothane represent the four model drugs for CYP2E1 activity reviewed 
here, of which the results are summarized in Table II.
Chlorzoxazone pharmacokinetics were studied in several clinical trials, as 
this drug is a highly selective probe of CYP2E1 metabolism (67). In women, it 
was shown that morbid obesity is associated with increased 6-hydroxylation 
of chlorzoxazone, which is consistent with induction of CYP2E1 (68). For 
obese patients, with or without non-insulin-dependent diabetes mellitus, 
it was found that CYP2E1 activity was 40% higher as compared with non-
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obese subjects (67, 69). 
More recently, CYP2E1 activity in obesity was further studied by Emery 
et al. (18). Unbound oral clearance (Clunbound/F) of chlorzoxazone was 
approximately threefold higher in morbidly obese compared with non-
obese individuals (p<0.001). Six weeks and 1 year post-weight-reducing 
surgery, chlorzoxazone Clunbound/F in patients was reduced. The authors 
suggest a causal relationship between the induction of CYP2E1 activity 
and hepatic fatty infiltration, based on liver biopsy assessment. They 
found a trend towards higher CLunbound/F with increasing severity of 
liver fatty infiltration or steatosis (p=0.06). More specifically they showed 
that CLunbound/F was significantly higher among subjects with steatosis 
involving >50% of hepatocytes, compared with those with steatosis in ≤ 50% 
of hepatocytes (p=0.02) (18). 
Volatile anesthetics, including enflurane, sevoflurane and halothane, are 
partly metabolized by CYP2E1 as well. Ionic fluoride is formed by CYP2E1 
oxidation of enflurane and sevoflurane, and therefore represents a reliable 
marker of CYP2E1 metabolism (70-71). A third volatile anesthetic, halothane, 
undergoes CYP2E1 biotransformation, which results in trifluoro-acetic acid 
(72). After a similar dose of enflurane maximal ionic fluoride concentrations 
were found to be significantly higher in obese compared with non-obese 
patients (73-74). A similar result was seen for sevoflurane in obese versus 
non-obese patients (75). A second sevoflurane study did not find a significant 
difference in ionic fluoride concentrations between obese and non-obese 
patients (76). After similar doses of halothane, significantly higher trifluoro-
acetic acid concentrations in obese patients at 1 and 3 hours after dosing 
were found ( 77). 
The studies summarized in Table II show a consistent and significant increase 
in clearance of different CYP2E1 substrates in obese as compared with non-
obese subjects, indicating induction of CYP2E1 activity in obesity. When 
normalized for body weight, clearance values are more or less equal among 
obese and non-obese individuals, which indicates that CYP2E1 activity 
increases with body weight. As an explanation, liver fatty infiltration, which 
is expected to increase with increasing body weight may be the underlying 
cause of the CYP2E1 enzyme activity increase with body weight(18). In obese 
children, no studies on CYP2E1-metabolized drugs have been performed 
yet.
With regard to the higher CYP2E1 activity observed in obese patients, it can 
be anticipated that caution should be practiced when using paracetamol 
(paracetamol) in obese patients, as CYP2E1 catalyses the formation of the 
toxic metabolite N-acetyl-p-benzo-quinone imine (NAPQI). Two studies 
have looked into paracetamol pharmacokinetics in both obese and non-
obese patients (78-79). Both studies are discussed in the Phase II metabolism 
section, 90% of paracetamol is conjugated via phase II metabolism and only 
5–10% of paracetamol is metabolized by CYP2E1 (80). Moreover, one study 
(79) did not report metabolites, but only paracetamol clearance values, while 
the other did not measure NAPQI or the metabolites formed after NAPQI 
(APAP-C or APAP-M) (78). Therefore, the above-stated warning may be 
considered somewhat speculative, and further studies are needed to assess 
the role of CYP2E1 in paracetamol metabolism and toxicity in both obese 
adults and children − in particular, given the importance of paracetamol in 
paediatric therapeutics. 
CYP2D6
CYP2D6 metabolism represents about 10-15% of phase I drug metabolism 
in humans (40). The activity of this CYP isoform may differ greatly 
between individuals depending on its genetic polymorphisms (81-82). Two 
CYP2D6 substrates, dexfenfluramine and nebivolol, have been subjects of 
pharmacokinetic studies in obese and non-obese individuals, as shown in 
Table III.
For dexfenfluramine metabolism, there was a trend towards higher 
dexfenfluramine clearance and higher metabolite/parent ratio in obese 
versus non-obese subjects (83). Nebivolol clearance was significantly a 
higher in obese subjects as compared with non-obese individuals (84). As 
nebivolol clearance is relatively high (> 1 L/min), it may be more dependent 
on liver blood flow than on intrinsic CYP metabolism. However, as the 
CYP2D6 phenotype has been found to influence the clearance of nebivolol, 
it was included in this section (85).
In summary, these few studies indicate trends towards increased CYP2D6-
mediated metabolism in obese versus non-obese patients.
CYP1A2
CYP1A2 metabolism represents a small part (~5%) of total phase I drug 
metabolism. Smoking has an inducing effect on CYP1A2 activity (86). 
Caffeine and theophylline have been indicated as CYP1A2-specific probes 
(87-88) and have been studied in obese versus non-obese populations by 
different research groups (Table IV). 
In adults, caffeine clearance was not significantly different between non-
smoking obese and non-smoking non-obese patients and between obese 
patients before and after weight loss (89). Two earlier caffeine studies in 
adult obese and non-obese subjects also did not show a significant difference 
in caffeine clearance (90-91).
In In children aged between 6 and 10 years, Chine et al. evaluated oxidative 
enzyme activity of CYP1A2, using the urinary metabolic ratio of caffeine 
metabolites (92). The authors observed non-significantly lower CYP1A2 
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enzyme activity in obese as compared with non-obese children.
Theophylline clearance showed a significant decrease in 16 obese women 
after a 6.2 (1.5) kg weight loss (93). In a study with 200 individuals, no 
significant difference in theophylline clearance between moderately obese 
and non-obese subjects was found (94). However, after correcting for the 
influence of smoking, higher total body clearance associated with obesity 
was found for a select group of young non-smoking subjects (p<0.025). In a 
third study, it was shown that theophylline clearance correlates with total 
body weight and not with ideal body weight (95).
In summary, trends of higher clearance values in obese as compared with 
non-obese patients indicate a slight increase in CYP1A2 activity. When 
corrected for body weight, clearance values showed both higher and lower 
clearance values for obese individuals as compared with non-obese subjects 
(Table IV). 
CYP2C9
CYP2C9-mediated metabolism represents about 10% of phase I drug 
metabolism in humans. For this review, four CYP2C9 substrates (ibuprofen, 
phenytoin, glimepiride and glipizide) were identified and are presented in 
Table V.
Phenytoin and ibuprofen are widely accepted CYP2C9 substrates (96-97). 
Phenytoin and ibuprofen clearance showed a trend towards higher (98) 
and significantly (99) higher clearance in obese patients, respectively. Non-
significantly higher CYP2C9 activity in obese subjects was also seen for 
glimepiride and glipizide. Glimepiride is metabolized primarily by CYP2C9 
to the active M1 hydroxy metabolite, the cyclohexyl hydroxymethyl 
derivative (100). Glimepiride clearance of the parent drug and of the 
CYP2C9-dependent metabolite M1 were not significantly different in obese 
versus non-obese type-2 diabetes patients. However, the cumulative urine 
excretion of M1 over 24 hours post dose was 30% (p<0.05) higher in obese 
versus non-obese subjects, while both groups received equal doses (101). 
For glipizide (a CYP2C9 substrate (102)), clearance was slightly higher, 
which was not statistically different in obese as compared with non-obese 
subjects, though the difference in body weight was rather limited (103).
In summary, these studies indicate slightly increased CYP2C9-mediated 
clearance in obese as compared with non-obese patients. Body weight-
normalized clearance values show a slight decrease in CYP2C9-mediated 
clearance per kilogram of total body weight (table V).
CYP2C19
CYP2C19 biotransformation is involved in approximately 5% of all phase I 
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largely differ depending on genetic polymorphisms (104). Only one clinical 
study, which is presented in Table VI, investigated the pharmacokinetics of 
CYP2C19 probes, i.e. diazepam and methyl diazepam (104-105). Diazepam 
clearance was higher in the obese group, and no difference in desmethyl 
diazepam clearance in obese versus non-obese individuals was found (106-
107). Body weight-normalized clearance values show a slight decrease in 
CYP2C19-mediated clearance for obese individuals (Table VI).
Other phase I metabolic enzymes
Xanthine oxidase
Besides CYP enzymatic pathways, there is a wide variety of other enzymes 
contributing to phase I metabolism of drugs. However, often no appropriate 
substrate for a particular enzyme has been identified (108). We have 
identified two studies in children, investigating the pharmacokinetics of the 
xanthine oxidase-metabolized compounds mercaptopurine and caffeine 
(Table VII).
Mercaptopurine undergoes extensive biotransformation by xanthine oxidase 
(109). In children mercaptopurine clearance values were found to be higher 
in overweight or obese children as compared with non-obese children. In 
addition, a significant correlation between drug exposure and fat body 
mass, expressed by the weight/height percentile, was demonstrated (110). 
Xanthine oxidase also mediates the biotransformation of the caffeine 
metabolite 1-methylxantine into 1-methyluric acid, which can be measured 
in urine. The metabolic ratio for xanthine oxidase, measured using the 
metabolites in urine, was higher in obese children than in non-obese children 
between 6 and 10 years of age (92). Obese children also showed elevated 
interleukin-6, C-reactive protein, and leptin levels, whereas adiponectin 
levels were decreased as compared with the non-obese children (92). It was 
suggested that these pro-inflammatory cytokines and adipokines upregulate 
xanthine oxidase gene expression and activity. Another explanation for the 
increase in xanthine oxidase activity may be the increase in liver volume 
associated with obesity. 
In conclusion, xanthine oxidase-mediated clearance was significantly 
increased in obese versus non-obese children in both studies. To our 
knowledge, no studies on xanthine oxidase in adults have been performed.
Miscellaneous phase I metabolism enzymes
In addition to typical substrates for phase I drug metabolic enzymes, 
there are many other drugs that undergo hepatic biotransformation by a 
combination of phase I and phase II enzymes. As a result, even when the 
exact share of each involved enzyme is known, it is difficult to predict into 
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Table VIII we have summarized all studies in obese and non-obese patients 
that have investigated the pharmacokinetics of drugs in which multiple 
enzymes are involved. Here we will only discuss antipyrine, while for the 
outcomes of other drugs, we refer to Table VIII. 
Antipyrine (phenazone) is widely used as a model drug in the assessment 
of hepatic oxidative capacity in humans, as more than 99% of a given 
dose is excreted into urine as metabolites. The major metabolic routes 
are N-demethylation to norphenazone (CYP2C8, -2C9, -2C18, -1A2), 
4-hydroxylation (CYP3A4, -1A2, -2B6) and 3-methylhydroxylation (CYP1A2, 
-2C9), which together account for 50% − 80% of the dose (111). Two antipyrine 
studies reviewed here did not find significantly different clearance values 
between the obese and non-obese patient groups (106, 112). 
The outcomes of the antipyrine studies are representative for the general 
conclusion from the studies in Table VIII. In summary, 8 out of 13 studies 
did not show significantly different clearance values in obese versus non-
obese subjects. Of the 5 studies that did find a difference in clearance values, 
obese clearance values were either higher (doxorubicin, ethinyl-estradiol 
and bisoprolol (113-115)) or lower (amiodarone and doxorubicinol (116-117)) 
as compared with clearance values in the non-obese group. Per kilogram 
of body weight, all clearance values were lower in obese as compared with 
non-obese individuals. The limited influence of obesity on these particular 
clearance values may in part be explained by compensating mechanisms 
among the different enzymatic pathways involved. However, it should be 
noted that the differences in body weight between the obese and non-obese 
subjects in all of the studies in Table VIII are relatively small. As this is a mixed 
group of drugs, it is difficult to generalize the results.  
Summary of phase I metabolism
In summary, phase I enzymatic processes showed higher, lower or similar 
activity in obese as compared with non-obese subjects, depending on the 
enzymatic pathway. CYP3A4 mediated clearance was consistently lower, 
while CYP2E1-mediated clearance showed higher activity among obese 
versus non-obese adults. For CYP2E1, it has been demonstrated that an 
increase of CYP2E1-mediated clearance is correlated with both total body 
weight and the degree of liver steatosis, supporting the concept that liver 
fibrosis and inflammation associated with the increase in body weight are 
the underlying cause of increased CYP2E1 enzyme activity. 
Clearance mediated by phase I metabolizing enzymes (CYP1A2, CYP2C9, 
CYP2C19 and CYP2D6) showed trends of higher clearance values in obese 
versus non-obese subjects, although in the majority of studies, this was not 
statistically significant, and the number of studies was limited. In contrast, 
CYP1A2 activity in children was non-significantly lower in obese versus non-
obese children. Xanthine oxidase activity was significantly higher in obese as 
compared with non-obese children. Overall, the differences in body weight 
between obese and non-obese individuals wasere relatively small, and few 
or no morbidly obese patients were included in these studies.  
   hase II metabolism
Phase II metabolic processes include glucuronide-, N-acetyl-, methyl-, 
gluthatione- and sulfate- conjugation of substrates. Uridine diphosphate-
glucuronosyltransferase (UGT) enzymes catalyze the conjugation of various 
endogenous substances and exogenous compounds, and are by far the most 
important phase II processes for metabolism of drugs (~50%) (40). 
Uridine Diphosphate Glucuronosyltransferase (UGT)
The human UGT superfamily is comprised two families (UGT1 and UGT2) 
and three subfamilies (UGT1A, UGT2A, and UGT2B). Many of the individual 
UGT enzymes are expressed not only in the liver but also in extrahepatic 
tissues, (including the gastrointestinal tract, adipose tissue and kidneys), 
where the extent of glucuronidation can be substantial (118). As the liver is 
the main UGT enzyme organ, it is suggested that liver disease or increased 
organ size, often co-occurring with (morbid) obesity, is somehow correlated 
with UGT activity. The expression of specific UGT enzymes in visceral and 
subcutaneous adipose tissue may also provide an explanation for increased 
UGT in activity in obesity (119).
Here we will discuss studies of four drugs that primarily undergo UGT 
conjugation, i.e. paracetamol, garenoxacin, oxazepam and lorazepam. The 
studies are summarized in Table IX. In contrast to CYP isoforms, individual 
UGT enzymes responsible for specific drug biotransformation processes 
were mentioned in an additional column of Table IX .  
Paracetamol is extensively metabolized by UGT enzymes (120-121). In both 
adult men and women, significantly higher clearance values were found 
in obese compared with non-obese individuals (79). Between adolescents 
with and without NAFLD, no difference in total body weight-normalized 
clearance was found, indicating higher absolute clearance values in obese 
adolescents (78). Furthermore, the ratio of paracetamol/paracetamol-
glucuronide metabolite in urine was significantly increased in obese 
adolescents, indicating increased UGT metabolism.
In a population pharmacokinetic analysis of garenoxacin (a major UGT 
substrate (122)), it was found that clearance values increased with total 
body weight. In the final pharmacokinetic model, an obesity factor (>130% 
P
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ideal body weight) used as a covariate for clearance significantly improved 
the model (123). 
For both oxazepam and lorazepam, it was found that clearance values were 
significantly higher in obese as compared with non-obese control subjects 
(124). A determinant role of UGT in the metabolism of both compounds 
has been shown in the literature (120, 125). On the basis of the differences 
in oxazepam and lorazepam clearance values, the authors concluded that 
obesity is associated with an increased conjugating capacity and that this 
increase is in proportion to total body weight. It should be noted that many 
subjects in this study received more than one study drug, which may limit 
the interpretation of these results.
In conclusion, all studies show a significantly increased clearance in obese 
as compared with non-obese subjects. As a consequence, body weight-
normalized clearance values were equal or only slightly lower for obese 
as compared with non-obese individuals, except for oxazepam clearance, 
which showed a significant increase in body weight-normalized clearance.
Other metabolic phase II routes
Apart from UGT, the pharmacokinetics of N-acetyltransferase (~5% of 
phase II drug metabolism) and glutathione S-transferase-metabolized 
drugs have been investigated in obese versus non-obese subjects. Caffeine, 
procainamide and busulfan have been indicated as substrates, as presented 
in Table X. 
N-acetyltransferase is responsible for the N-acetylation of procainamide 
(126). Procainamide plasma clearance was slightly higher in obese as 
compared with non-obese adults, although this was non-significant 
(127). In obese children, a 5-fold increase in the metabolic ratio of the 
N-acetyltransferase pathway of caffeine was observed when compared 
with non-obese children (92), when only considering the slow-acetylator 
genotype. 
For busulfan, both obese (BMI between 27 and 35 kg/m2) and severely obese 
patients (BMI >  35 kg/m2) showed significantly higher oral clearance values 
as compared with non-obese patients (128). Per kilogram of body weight, 
clearance was significantly lower in obese versus non-obese patients. This 
was confirmed in a more recent trial with busulfan in obese and non-obese 
adults (129). While CYP3A4 involvement is suggested (130), the glutathione 
S-transferase A1-1 isoform is the major and possibly determinant pathway 
of busulfan metabolism (131). In obese children (aged 0 − 21 years) busulfan 
clearance per kilogram of body weight after a test dose and a regular dose 
was lower than in non-obese children (132). 
In conclusion, other type phase II-metabolized substrates show higher 
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children, while weight-normalized clearance values were lower in obese as 
compared with non-obese patients.
Summary of phase II metabolism 
For glucuronidation processes, all studies in Table IX show a significant 
increase in UGT biotransformation in obese as compared with non-obese 
subjects. Weight-normalized UGT clearance values were equal to or only 
slightly lower in obese as compared with non-obese patients. However, the 
number of studies with UGT-metabolized drugs is small. The underlying 
mechanism of this phenomenon remains unsolved, although NAFLD was 
demonstrated to be associated with higher paracetamol clearance values in 
adolescents (78). 
N-Acetylation catalyzed by N-acetyltransferase shows a significant increase 
in obese children and a non-significant increase in adults. Glutathione 
transferase of busulfan in obese children and adults was lower in non-obese 
adults and children when normalized for body weight.
         iver blood flow 
High-extraction-ratio drugs are rapidly metabolized and therefore sensitive 
to changes in liver blood flow, but are relatively insensitive to changes in 
enzyme activity and are thus a potential marker of liver blood flow. The 
influence of obesity on liver blood flow is not fully specified. NASH increases 
fat deposition in the liver, causing sinusoidal narrowing and altered 
functional morphology of the liver (133). In contrast, because of increased 
blood volume and cardiac output, liver blood flow is not necessarily reduced 
in obese subjects (19). 
In Table XI, studies of eight high extraction ratio drugs in obese and non-
obese subjects are summarized and include propofol, propanolol, labetalol, 
verapamil, lidocaine, fentanyl, sufentanil and paclitaxel.  
Propofol is extensively metabolized by various UGT enzymes (118) and its 
clearance is limited by liver blood flow (134). Van Kralingen et al. (135) and 
Cortinez et al. (136) studied propofol pharmacokinetics in a wide range of 
body weights and found that total body weight as a covariate for clearance 
significantly improved the predictive performance of the population 
pharmacokinetic model. 
Four different studies reported propranolol clearance values in obese versus 
non-obese patients. Three studies did not show altered clearance values 
between obese and non-obese patients (137-139), and one study found 
significantly lower propranolol clearance values in obese versus non-obese 
L
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patients (140). Propranolol clearance is strongly determined by liver blood 
flow as it approaches liver blood flow values (141). On the other hand, 
propranolol tends to decrease liver blood flow by ~20-30% by blocking the 
beta-adrenoreceptor, explaining the relative lower clearance value seen for 
propranolol compared with other drugs in Table XI (141). 
Labetalol clearance in obese patients showed a trend towards being 
increased (138). For verapamil and lidocaine no difference in clearance 
between obese and non-obese was found (142-143). As lidocaine clearance 
is determined mainly by liver blood flow (144), the authors concluded that 
extreme total body weights did not change liver blood flow. 
Sufentanil and fentanyl are predominantly metabolized by CYP3A4 (145), 
but their total clearance is mainly determined by liver blood flow (146-
147). Sufentanil showed higher clearance values in obese versus non-
obese patients: however, this difference was not statistically significant 
(148). The difference in body weight between the two groups studied was 
small (90 versus 74 kg). The pharmacokinetics of fentanyl were studied in a 
population with a wide range of total body weights, showing a non-linear 
positive correlation between total body weight and fentanyl clearance 
(149). Reported paclitaxel clearance values in obese and non-obese patients 
are extremely high (291 − 431 L/h), indicating liver blood flow-dependent 
clearance (150). Clearance values for paclitaxel in obese patients were 
higher than values of non-obese patients: however, this was not statistically 
significant (59).  
In conclusion, only a few high-extraction-ratio drug studies in Table XI 
showed altered clearance values in obese versus non-obese adults. Body 
weight-normalized clearance values show a large decrease in clearance per 
kilogram. For instance, the clearance per kilogram values of propranolol 
and lidocaine are almost halved. A straightforward conclusion from these 
studies is complicated because of the heterogeneity of the drugs. Liver 
blood flow is about 2–2.5 L/min, while clearance values of some drugs listed 
in Table XI are less than 1 L/min, obscuring the justification of their role as 
a model drug for liver blood flow. When considering drugs with clearance 
values of more than 1.5 L/min (propofol, sufentanil and paclitaxel), all 
studies show higher clearances in obese patients. Propanolol was excluded 
from this comparison, as this drug shows high variability in drug clearance 
values among studies (Table XI). The observation of increased clearance is 
not statistically significant for sufentanil and paclitaxel, probably because 
of the small difference in total body weight in these studies. Unfortunately, 
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Summary of liver blood flow
According to the results of propofol, sufentanil and paclitaxel studies, liver 
blood flow is likely to be increased in obese patients. However, only a few (very) 
high-extraction-ratio drugs have been studied and the difference in body 
weights between patients groups was limited for sufentanil and paclitaxel. 
To our knowledge, no studies have investigated the pharmacokinetics of 
high-extraction-ratio drugs in children.
           enal elimination
The kidneys are the primary organs involved in the elimination of drugs. 
The processes involved in drug elimination through the kidneys include 
glomerular filtration, tubular secretion and tubular reabsorption. The 
exact effect of obesity on these functions is not clear (25). Renal function 
seems to be affected as obese patients showed a 62% increase in the mean 
estimated glomerular filtration rate (eGFR) (151). This finding was observed, 
irrespective of the presence of hypertension by an increase of renal blood 
flow (152). Obesity is related to a state of glomerular hyperfiltration, which 
resembles that seen in early-stage diabetic nephropathy and sickle cell 
disease (20-21, 153). It has been argued that overweight may ultimately 
lead to end-stage renal disease because focal glomerular sclerosis and/or 
diabetic nephropathy have been observed in a small study in 17 morbidly 
obese patients who presented with proteinuria (154). In obese children it was 
found that the glomerular filtration rate increases with BMI (155). In contrast 
to obese adults, obese children showed a higher degree of albuminuria, a 
marker for glomerular dysfunction (156-157). Therefore, it was concluded 
that albuminuria indicates early renal glomerular dysfunction as a 
consequence of childhood obesity (156). However, obese children compared 
with non-obese children did not differ in their glomerular filtration rates as 
no overt changes in eGFR were detected (157). 
The influence of obesity on renal tubular secretion and renal tubular 
reabsorption is not well known, and no objective clinical measure of these 
drug clearance pathways presently exists (151). Tubular dysfunction can be 
defined as the presence of at least two of the following criteria: nondiabetic 
glycosuria, urine phosphate wasting, hyperaminoaciduria, beta-2-
microglobulinuria, and increased fractional excretion of uric acid (158-
159). For obese children, an increased degree of beta-2-microglobulinuria, 
suggesting increased tubular dysfunction, has been described (156).
In this section, we will provide an overview of clinical studies investigating 
drugs that are primarily eliminated renally and were studied in both non-
R
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obese and obese adults and children. 
             lomerular filtration
In Table XII, an overview of studies comparing clearance of drugs that are 
mainly excreted by glomerular filtration in obese and non-obese individuals 
is presented. These drugs include vancomycin, daptomycin, carboplatin, 
low-molecular-weight heparins and cimetidine. 
Vancomycin clearance in morbidly obese patients is reported to increase with 
total body weight compared with non-obese patients (160). No significant 
increase of daptomycin clearance was described in obese patients with a 
mean total body weight of 114 kg (161). However, in patients with a higher 
mean total body weight (126 kg), significantly higher daptomycin clearance 
was reported (162). Carboplatin is mainly eliminated by glomerular filtration 
and partly by tubular secretion (163). Both a linear increase of carboplatin 
clearance with total body weight (164) and ideal body weight (165) have 
been described. A comparison of carboplatin clearance values between 
obese and non-obese patients showed no significant difference (59). The 
low-molecular-weight heparins enoxaparin, tinzaparin and dalteparin show 
higher total drug clearance in obese patients compared with non-obese 
patients (166-168). Studies on the influence of obesity on drug clearance 
mediated by glomerular filtration in obese children are very limited. In 
obese children, lower anti-Xa levels after the same dose of enoxaparin were 
reported, suggesting higher enoxaparin clearance in obese children (166). 
In contrast to these studies, total metabolic clearance of cimetidine was not 
altered in obese patients compared with non-obese patients (167). 
In conclusion, the majority of these studies show higher clearance values 
with increasing body weights, indicating increased glomerular filtration 
in obese patients. Weight-normalized clearance values did not show a 
consistent trend for the influence of overweight on glomerular filtration, as 
normalized clearance values were either equal or lower in obese as compared 
with normal-weight patients.
        ubular secretion 
Drugs that are (partly) eliminated by tubular secretion and have been 
investigated in obese patients are summarized in Table XIII and include 
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Approximately 50% of administered procainamide is eliminated as 
unchanged drug by glomerular filtration and active tubular secretion (168). 
Renal procainamide clearance was shown to be higher in obese patients 
because of elevated tubular secretion, as no significant difference in 24-
hour creatinine clearance was observed between obese and non-obese 
patients (127). Significantly higher clearance values were also reported for 
cisplatin and ciprofloxacin, which are eliminated by tubular secretion (59, 
169-171). For both topotecan and digoxin, there was a trend towards higher 
drug clearance in obese patients, which is assumed to result from increased 
tubular secretion (59, 172). For tubular secretion, normalized clearance 
values per kilogram were equal or slightly lower in obese as compared with 
non-obese patients.
In conclusion, these studies indicate higher tubular secretion in obese as 
compared with non-obese individuals. To date, no information is available 
on the impact of obesity on the tubular secretion of drugs in children. 
        ubular reabsorption
Studies on the influence of obesity on the tubular reabsorption of drugs 
are scarce (Table XIV). Tubular reuptake of lithium in obese patients was 
reported to be lower, as lithium clearance was significantly increased in 
obese patients and glomerular filtration did not differ between these obese 
and non-obese patients (173). In contrast, proximal tubular reabsorption of 
sodium in obese patients is reported to be increased because of glomerular 
hyperfiltration (174).
Summary of renal elimination
The reviewed studies show that clearance of renally eliminated drug is 
higher in obese patients because of increased glomerular filtration and 
tubular secretion. The influence of obesity on the tubular reabsorption is 
unknown, as there is a lack of evidence on this topic.
 
           iscussion and conclusions
In this review, we have summarized the effects of obesity on drug metabolism 
and elimination. Studies that investigated pharmacokinetics of drugs in both 
obese and non-obese individuals were classified according to the drug’s most 
important metabolic or elimination pathway. This allowed us to structurally 
T
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review the influence of obesity on each individual metabolic or elimination 
pathway. Metabolic processes were subdivided into phase I metabolism, 
phase II metabolism and liver blood flow-dependent metabolism. Renal 
elimination was subdivided into glomerular filtration and tubular processes.
The reviewed studies show that the impact of obesity on drug metabolism 
and elimination differs greatly, depending on the metabolic or elimination 
pathway primarily involved in the handling of the investigated drug. In 
particular, CYP3A4-mediated drug elimination was found to be consistently 
lower, while UGT-, CYP2E1-, arylamine N-acetyltransferase type 2- and 
xanthine oxidase-mediated drug metabolism was consistently higher 
among obese as compared with non-obese subjects. Clearance mediated 
by phase I metabolizing enzymes CYP1A2, CYP2C9, CYP2C19 and CYP2D6 
show trends towards higher clearance values in obese individuals.
Studies on drug clearance mediated by liver blood flow are somewhat 
inconclusive, although, on the basis of a few highly extracted drugs, an 
increase in liver blood flow can be noted in obese patients.
Regarding drug elimination, the reviewed studies show an increase of 
glomerular filtration and tubular secretion in obese patients. The influence 
of obesity on tubular reabsorption is unknown. 
Many of the observed trends were also reflected in weight-normalized 
clearance values, which were halved (e.g. CYP3A4), almost equal (e.g. 
CYP2E1) or slightly decreased in obese as compared with non-obese 
individuals (e.g. CYP2C9 and tubular secretion). For other drug clearance 
pathways, trends in body weight-normalized clearance were not as 
pronounced (e.g. the glomerular filtration rate and CYP1A2). It should be 
emphasized that these body weight-normalized clearance values may 
provide information on quantitative differences in clearance values but do 
not explain the relationship between total body weight and drug clearance 
values.
The large number of studies included in this review shows that there is a 
substantial amount of information available on the impact of obesity on 
drug metabolism and elimination. However, in many of these studies, the 
difference in body weight between obese and non-obese subjects is rather 
small. More specifically, the obese subjects included in the reviewed studies 
are not as obese as the patients currently seeking medical care. From this 
perspective, information on drug metabolism and elimination in morbidly 
obese patients (BMI >40 kg/m2) and super-obese patients (BMI >50 kg/m2) is 
largely lacking and requires future research.
Regarding obesity in children, only five studies investigated pharmacokinetics 
of a drug in obese versus non-obese children, of which four were recently 
published (78, 92, 117, 132). Regarding renal elimination, no pharmacokinetic 
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results from studies in obese adults to obese children is widely applied because 
often no clinical studies in obese children are available (24, 175). For the UGT 
mediated metabolism of paracetamol this may be justified, as paracetamol 
clearance in both adolescents (78) and adults (79) was increased. This strong 
similarity in results was not seen for other drugs that were studied in both 
adults and children such as caffeine (92). Moreover, the expression and 
activity of enzymatic pathways in children may be different compared with 
adults and are dependent on maturational status (age). In addition, obesity 
may influence the maturation process(es) itself, and the starting point of 
weight gain may also influence the maturation process(es), representing 
additional factors of variability in drug metabolism and elimination among 
obese adults and children. Taking this into consideration, extrapolation from 
adult observations may give false predictions of clearance values in children 
(and vice versa) and should be performed with care.
While it is impossible to study and assess the pharmacokinetics of every 
drug in obese subjects, future clinical trials should aim to quantify the impact 
of obesity on specific drug elimination pathways and on the underlying 
associated mechanisms (e.g. steatosis and inflammation). In this approach, 
study outcomes can be extrapolated to other drugs eliminated by the same 
pathway. This extrapolation can be achieved by using model drugs and 
within the context of a multidisciplinary research team including physicians, 
pharmacists, pharmacologists and pharmacometricians. Primarily, future 
research in this area should focus on individual metabolic and elimination 
pathways in adults and children that show increasing or decreasing trends in 
activity among obese versus non-obese individuals. As concluded from this 
review, these pathways include CYP3A4, CYP2E1, xanthine oxidase, UGT, 
N-acetyltransferase, glomerular filtration and tubular processes. Mainly, 
CYP3A4 deserves immediate research attention. Finally, particularly obese 
children and adolescents, and morbidly obese (BMI >40 kg/m2) and super-
obese patients (BMI >50 kg/m2) should be included in these studies.
In conclusion, this systematic review of pharmacokinetic studies in obese and 
non-obese patients shows that the impact of obesity on drug metabolism 
and elimination greatly differs per drug metabolic or elimination pathway. 
However, the clinical trials reviewed here often only included overweight 
to moderately obese patients. As the prevalence of obesity and total body 
weights of both children and adults are still increasing and this trend will 
persist, future studies assessing the impact of morbid obesity on specific 
drug elimination pathways in both children and adults are warranted.
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              bstract
Background and objectives
In view of the increasing prevalence of morbidly obese patients, the 
influence of excessive total body weight (TBW) on the pharmacokinetics 
and pharmacodynamics of propofol was characterized in this study using 
bispectral index (BIS) values as pharmacodynamic endpoint.
Methods
A population pharmacokinetic and pharmacodynamic model was developed 
with the nonlinear mixed-effects modelling software NONMEM VI, on the 
basis of 491 blood samples from 20 morbidly obese patients (TBW range: 
98 - 167 kg) and 725 blood samples of 44 lean patients (TBW range: 55 - 98 
kg) from previously published studies. In addition, 2246 BIS values from the 
20 morbidly obese patients were available for pharmacodynamic analysis. 
Results
In a three-compartment pharmacokinetic model, TBW proved to be the most 
predictive covariate for clearance (CL) in 20 morbidly obese patients (CL = 
2.33 L/min * (TBW/70)0.72). Similar results were obtained when the morbidly 
obese patients and 44 lean patients were analysed together (CL = 2.22 L/
min * (TBW/70)0.67). No covariates were identified for other pharmacokinetic 
parameters. The depth of anaesthesia in morbidly obese patients was 
adequately described by a two-compartment biophase-distribution model 
with a sigmoid maximum possible effect (Emax) pharmacodynamic model 
(concentration at half-maximum effect (EC50) 2.12 mg/L) without covariates.
Conclusion
We developed a pharmacokinetic and pharmacodynamic model of 
propofol in morbidly obese patients, in which TBW proved to be the major 
determinant for clearance, using an allometric function with an exponent of 
0.72. For the other pharmacokinetic and pharmacodynamic parameters, no 




           ackground
In Western countries, the prevalence of obesity is increasing, resulting in 
percentages of 20% in men and 25% in women in the US, respectively (1). 
The prevalence of morbidly obese patients is also rising (2-3). However, 
there have been a few studies on the influence of (morbid) obesity on the 
pharmacokinetics and pharmacodynamics of commonly used drugs (4-5). 
Therefore, systematic pharmacokinetic and pharmacodynamic studies in 
this special group of patients are urgently needed.
Propofol is widely used for induction and maintenance of anaesthesia in both 
lean and (morbidly) obese patients. There have been few reports focusing 
on the influence of excessive total TBW (TBW) on the pharmacokinetics of 
propofol. Servin et al. (6) originally used an adjusted TBW to dose propofol in 
morbidly obese patients, and upon pharmacokinetic analysis they observed 
a linear relationship between TBW and clearance. Schuttler and Ihmsen 
(7) found that propofol clearance depend on TBW, using an allometric 
equation with an exponent of  0.71; however, no morbidly obese patients 
were included in their study. Another study used simulations to propose lean 
body weight (LBW)  as weight input for propofol dosing (8). More recently, it 
was reported that TBW was the size descriptor for all clearances and volume 
values of propofol in obese patients (9). While these conflicting reports on 
the pharmacokinetics of propofol may be a result of an unbalanced range 
in body weight and/or inclusion of only a limited number of morbidly 
obese patients in the analyses, there are still no reports available on the 
pharmacodynamics of propofol in morbidly obese patients. 
Therefore, the aim of this study was to evaluate the pharmacokinetics 
and pharmacodynamics of propofol in morbidly obese patients, using 
the Bispectral index (BIS) as a pharmacodynamic endpoint. For both the 
pharmacokinetics and pharmacodynamics, a systematic covariate analysis 
was performed using TBW, body mass index (BMI), ideal body weight (IBW) 
and LBW as weight covariates. For the pharmacokinetic analysis, data of 44 
lean patients were available from previously published studies (10-11). 
               ethods
Patients
Twenty morbidly obese patients who were scheduled to undergo 
laparoscopic gastric banding or gastric bypass surgery were enrolled in a 
prospective study (ClinicalTrials.gov identifier NCT00395681). Patients were 
included if they were aged between 18 and 60 years, had an American Society 
of Anesthesiologists (ASA) physical status classification of II or III, had a 
BMI of over 40 kg/m2 at inclusion, and normal renal and hepatic function 
as assessed by routine laboratory testing. All patients undergoing bariatric 
surgery were asked to lose weight preoperatively, as this has shown to 
improve the outcome. Therefore, patients were not excluded from the study 
as long as their BMI was higher than 35 kg/m2 on the day of surgery and on 
the day of study. The exclusion criteria included pregnancy, breastfeeding, 
epilepsy and known allergy for propofol, soy bean oil or egg lecithin. The 
study protocol was approved by the hospitals ethics committee, and written 
informed consent was obtained from by each participating patient. 
Forty-four lean patients had been enrolled earlier as part of two other 
studies; detailed information can be found in the references (10-11). Four 
patients from one of these studies (10) were excluded from the covariate 
analysis of the combined dataset of morbidly obese and lean patients, 
because there was no information available on the height of those patients. 
Anaesthetic Procedure
All morbidly obese patients received standardized anaesthesia without 
premedication. Before induction, an antecubital infusion line, an indwelling 
arterial blood pressure line and leads for a three-lead ECG were installed, 
and a BIS electrode was placed on the patient’s forehead. Patients were 
randomized to receive a bolus injection of propofol 200 mg or 350 mg over 
60 seconds using total intravenous anaesthesia (TIVA) pump (Asena target-
controlled infusion (TCI) and TIVA; Alaris Medical Systems) for induction of 
anaesthesia, together with 1% lidocaine 2 ml to avoid pain during injection 
(12). Thereafter, upon administration of fentanyl 250 μg and atracurium 
besilate 50 mg, the trachea was intubated and mechanical ventilation 
was initiated by the anaesthesiologist. Anaesthesia was maintained with 
a continuous infusion of 2% propofol at an initial infusion rate of 10 mg/h/
kg TBW, which was started between 2 and 7 minutes after the propofol 
induction dose. Remifentanil was administrated 25 µg/h/kg IBW (13) and 
atracurium besilate at 0.3 mg/h/kg TBW, according to local practice. The 
propofol infusion rate was subsequently adjusted in order to keep BIS values 
between 40 and 60, the systolic arterial blood pressure between 80 and 160 
mmHg, and the heart rate between 60 and 90 beats per minute. Propofol 
infusion rate adjustments of 50 – 150 mg/h could be made at the discretion 
of the anaesthesiologist, with no more than one infusion rate adjustment 
per 5 minutes. The remifentanil infusion rate was kept constant throughout 
the procedure, in order to rule out any influence of changes in remifentanil 
concentrations on BIS values or haemodynamic parameters. 
B




In the previously published lean patient group, 24 female patients received 
a bolus injection of propofol 2.5 mg/kg for induction of anaesthesia, and 
anaesthesia was maintained with isoflurane (10). Another 20 lean intensive 
care patients received continuous propofol infusions for 2-5 days, with 
propofol doses based on the Ramsay six-point scale (11). In both previously 
published studies, no BIS values were available. 
Blood sampling and analytical methods
In morbidly obese patients, arterial blood samples (2 mL) were collected at 
the following timepoints: at baseline prior to the start of the propofol bolus, 
approximately 1.5, 2.5 and 4 minutes after the propofol bolus; 3, 7, 15, 25 and 
45 minutes after the start of the propofol infusion; just before and at 5 or 15 
minutes after dose adjustment; just before discontinuation of the propofol 
infusion; and at 1, 3, 5, 7, 10, 20, 30, 60, 90, 120 and 150 minutes after the end 
of the infusion. 
In one of previously published lean patients (10), arterial blood samples were 
collected at 1, 1.5, 2, 2.5, 3, 4, 5, 8, 11, 15, 20, 30, 45, 60, 90, 120, 150 and 
180 minutes after the induction dose of propofol. In the other previously 
published study of lean patients (11), arterial blood samples were collected 
four times daily during propofol maintenance infusion for 2-5 days. 
Whole-blood samples for propofol analysis were mixed thoroughly and 
stored at 4°C until analysis by high-performance liquid chromatography 
with fluorescence detection at 276 nm and 310 nm. With this method, the 
coefficients of variation for the intra-assay and inter-assay precision were 
less than 3.7% and 9.8%, respectively, over the concentration range from 
0.05 to 5.0 mg/L, and the lower limit of quantification was 0.05 mg/L (14).
Data analysis and internal validation
The analysis was performed by means of non-linear mixed-effects modelling 
using NONMEM (version VI, release 1.1; GloboMax LLC, Hanover, MD, USA) 
(15) with S-plus (version 6.2; Insightful software, Seattle, WA, USA) to 
visualize the data. Population pharmacokinetic and pharmacodynamic data 
were sequentially analysed by using the individual pharmacokinetic empirical 
Bayes estimates as input to the pharmacodynamic model. Discrimination 
between different models was made by comparison of the objective function 
value (OFV, i.e. -2 log likelihood (-2LL)). A p-value of < 0.005, representing 
a decrease of 7.9 in the OFV, was considered statistically significant. In 
addition, goodness-of-fit plots (observed versus individual-predicted 
concentration-time, observed versus population-predicted concentration-
time, conditional weighted residuals versus time and conditional weighted 
residuals versus population-predicted concentration-time plots) were 
used for diagnostic purposes. Furthermore, the confidence interval of the 
parameter estimates, the correlation matrix and visual improvement of the 
individual plots were used to evaluate the model. The internal validity of the 
population pharmacokinetic and pharmacodynamic models was assessed 
by the bootstrap re-sampling method using 250 replicates (15). Parameters 
obtained with the bootstrap replicates were compared with the estimates 
obtained from the original data set. 
Pharmacokinetic model
Log-transformed propofol concentration data were described by a three-
compartment model (NONMEM VI, ADVAN11, TRANS4) parameterized in 
terms of the volume of distribution of the central compartment (V1), volume 
of distribution of the first peripheral compartment (V2) volume of distribution 
of the second peripheral compartment (V3), inter-compartmental clearance 
from the central compartment to the first peripheral compartment (Q2) 
inter-compartmental clearance from the central compartment to the second 
peripheral compartment (Q3), and clearance from the central compartment 
















Figure 1 Schematic representation of the pharmacokinetic and pharmacodynamic model for propofol, 
based on a three-compartment pharmacokinetic model parameterized using V1, V2, V3, CL, Q2 and Q3 and 
a two-compartment biophase-distribution model characterizing the pharmacodynamics using ke0, ke12 and 
ke21. The propofol concentration in the central effect-site compartment is responsible for the measured BIS 
values, as described using equation 4. BIS = bispectral index; CL = clearance from the central compartment; 
ke0 = first-order equilibrium constant linking the central pharmacokinetic compartment to the central effect-
site compartment which equalsthe rate constant for drug loss from the central effect-site compartment; 
ke12 = rate constant from the central effect-site compartment to the peripheral effect-site compartment; 
ke21 = rate constant from the peripheral effect-site compartment to the central effect-site compartment; Q2 
=  inter-compartmental clearance from the central compartment to the first peripheral compartment; Q3 
= inter-compartmental clearance from the central compartment to the second peripheral compartment; 
V1 = volume of distribution of the central compartment; V2 = volume of distribution of the first peripheral 
compartment; V3 = volume of distribution of the second peripheral compartment.
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The inter-individual value (post hoc value) of the parameters of the ith 
individual was modelled by (equation 1): 
 
         (Eq. 1)
where θmean is the population mean and ηi is a random variable with a mean of 
zero and variance of ω2, assuming log-normal distribution in the population. 
The intraindividual variability, resulting from assay errors, model 
misspecifications and other unexplained sources, was best described with 
a proportional error model. This means for the jth observed log-transformed 
propofol concentration of the ith individual, the relation (Yij) is described by 
equation 2:        
        (Eq. 2)
where Cpred is the predicted propofol concentration and εij is a random 
variable with a mean of zero and variance of σ2.
Biophase-Distribution and pharmacodynamic model
Concerning the biophase distribution, the delay in BIS values in relation to 
the propofol concentration in the central pharmacokinetic compartment 
was characterized on the basis of a hypothetical ‘effect-site’ compartment, 
which is an approach that has been applied previously for propofol-induced 
BIS values (16). In this approach, it is assumed that the rate of onset and offset 
of the observed effect is governed by the rate of propofol distribution to 
and from a hypothetical effect-site compartment. Under this interpretation, 
the effect-site compartment is linked to the blood compartment by a first-
order equilibrium rate constant (ke0), which equals a rate constant for drug 
loss (keo) from the effect-site compartment. Under the assumption that in 
equilibrium, the effect-site concentration equals the blood concentration, 
equation 3 can be used:
      
         (Eq. 3)
where Cb is the blood concentration in the central pharmacokinetic 
compartment, Ce represents the effect-site concentration and ke0 is the first-
order equilibration constant. 
In addition to this previously applied one-compartment effect-site model, 
a two-compartment biophase-distribution model was also explored, 
in which distribution of propofol within the brain was represented by 
definition of a central effect-site compartment and a peripheral effect-site 
compartment. In this two-compartment biophase-distribution model, the 
rate constants from the central effect site to the peripheral effect site and 
from the peripheral effect site to the central effect site were ke12 and ke21, 
respectively. This two-compartment effect-site model was parameterized in 
amounts, with the volume of the effect-site compartments set at 1. The full 
pharmacokinetic-pharmacodynamic model is depicted in Figure 1.
For the pharmacodynamic model, the values of the BIS were related to the 
propofol concentrations in the central effect-site compartment on the basis 
of the sigmoidal maximum possible effect (Emax) model (equation 4):  
    
         (Eq. 4)
where E0 is the baseline BIS, Emax,i is the Emax of propofol on the BIS in the 
ith individual, Ce,ij is the individual-predicted propofol concentration in the 
central effect-site compartment in the ith individual at the jth timepoint, γ 
is the Hill coefficient representing the steepness of the concentration-
response relation, and EC50,i is the propofol concentration (in mg/L) at half-
maximum effect of the BIS in the ith individual. 
The interindividual variability (ηi) in the Emax, EC50 and ke0 was assumed to be 
log-normally distributed with a mean of zero and variance of ω2 (equation 
1). The residual error ε was best characterized by a proportional error model 
(equation 5):
         (Eq. 5)
where Yij represents the observed Bispectral index in the ith subject at the jth 
time point. 
Covariate analysis
Covariates were plotted independently against the individual post hoc 
parameter estimates of all pharmacokinetic and pharmacodynamic 
parameters and the conditioned weighted residuals to visualize potential 
relations. The following covariates were tested: TBW, BMI , IBW (17) and 
LBW (18), induction dose (200 versus 350 mg), sex, age, positive end-
expiratory pressure, bilirubin level and renal function ( serum creatinine 
levels). Covariates were tested using linear and allometric equations:  
      
         (Eq. 6)
where Pi and Pp represent individual and population parameter estimates, 
respectively; Cov represents the covariate; Covstandard represents a 
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Patients (n) 20 44
Sex (M / F) 4/16 16/28
Age (y) 45 (12) 52 (12)
TBW (kg) 124 (20) 74 (11)
IBW (kg) 61 (7) 63 (8)a
BMI (kg/m2) 43 (6) 25 (4)a
LBW (kg) 60 (9) 45 (10)a
Table I Baseline characteristics of 20 morbidly obese patients and 44 lean patients  
(10-11).
a = value for the 40 patients in whom height data were available.
BMI = body mass index; F = female; IBW = ideal body weight (17); LBW = lean body weight (18); M = male; 









and lean patientsa 
Simple - 6 -643 -1557
LBW CLi = CLpop  • (LBWi/55) 6 -638 -1563
IBW CLi = CLpop  • (IBWi/50) 6 -640 -1543
BMI CLi = CLpop  • (BMIi/23)
z
7 -651 -1596
TBW CLi = CLpop  • (TBWi/70)
z
7 -653 -1599
Table II Results of covariate analysis for the pharmacokinetic model of propofol in 
the dataset of morbidly obese patients and in the combined dataset of morbidly 
obese and lean patients.
a  = 40 lean patients in whom height data were available.
BMI = body mass index; BMIi = BMI of the ith individual; CL = clearance from the central compartment; CLi 
= CL in the ith individual; CLpop = population mean CL value; IBW = ideal body weight; IBWi = IBW of the ith 
individual;; LBW = lean body weight; LBWi = LBW of the ith individual; NA = not applicable; OFV = objective 
function value; TBW = total body weight; TBWi = TBW of the ith individual; z = allometric scaling factor.
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standardized (i.e. 70 kg for TBW) or median value of the covariate for the 
population; and z represents the exponential scaling factor, which was fixed 
at 1 for a linear function or an estimated value for an allometric equation. 
Potential covariates were separately entered into the model and statistically 
tested by use of the OFV and, if applicable, the 95% confidence interval of 
the additional parameter. When more than one significant covariate for the 
simple model was found, the covariate-adjusted model with the largest 
decrease in OFV was chosen as a basis to sequentially explore the influence 
of additional covariates with the use of the same criteria. Finally, after 
forward inclusion, a backward exclusion procedure was applied to justify 
the covariate. The choice of the covariate model was further evaluated as 
discussed above.
Simulations
On the basis of the final pharmacokinetic and pharmacodynamic model, 
simulations were performed to keep BIS values between 40 and 60 in 
morbidly obese patients ranging in TBW between 98 and 167 kg. In addition, 
BIS values were simulated using a linear dosing regimen (5 mg/kg/h) for 
these patients (19).  
            esults
Twenty morbidly obese patients were enrolled and 491 blood samples were 
available. From 44 lean patients, 725 blood samples were available (10-11). 
The morbidly obese patients had a mean TBW of 124 kg (range 98–167 kg) 
compared with 74 kg (range 55–98 kg) in the lean patients. All demographic 
characteristics of the morbidly obese patients and lean patients are provided 
in Table I. 
Pharmacokinetics
A three-compartment pharmacokinetic model adequately described the 
time course of the propofol whole-blood concentrations in the morbidly 
obese patients. Exploratory plots of all tested covariates (see Methods, 
Covariate Analysis section) against individual post hoc parameter estimates 
of the simple model showed potential relations between the four weight-
related covariates (TBW, LBW, IBW and BMI) and clearance. There were 
no relations between the explored covariates and other pharmacokinetic 
parameters. Subsequently, all four weight covariates were incorporated on 
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showed that body weight TBW and BMI were the most predictive covariates 
for propofol clearance in morbidly obese patients (Table II). 
For both the TBW model and the BMI model, the OFV was more than 7.9 
points lower in comparison with the simple model (p<0.005). The diagnostic 
and individual plots of the TBW model proved to be superior to the simple 
model and the BMI model, particularly with respect to population-predicted 
concentrations. Therefore, the TBW model was chosen as the final model for 
morbidly obese patients, in which the equation for clearance was (equation 
7):
CLi = CL70 kg * (TBWi/70)z      (Eq. 7)
where CLi represents CL in the ith individual, CL70 kg is the population mean 
CL value in an individual weighing 70 kg, TBWi is the TBW of the ith individual, 
70 is the standard TBW in kilograms, and k  is the allometric scaling factor, 
which was estimated to be 0.72. The pharmacokinetic parameters of the 
simple model and the final body weight model are shown in Table III. The 
stability of the final body weight TBW model was shown by the bootstrap 
analysis (Table III). In Figure 2A and 2B, the diagnostics of the final body 
weight TBW pharmacokinetic model in the 20 morbidly obese patients are 
shown.
For the analysis of both the dataset of the 20 morbidly obese patients and 
the dataset of the 44 lean patients from the previously published studies, 
a three-compartment pharmacokinetic model most adequately described 
the data. In Figure 3, the results of the covariate analysis are shown, with 
individual parameter estimates for clearance in the simple model without 
covariates versus the four tested weight covariates. For this covariate 
analysis, 40 lean patients were included instead of 44, as the height of four 
lean patients was not available. All four weight covariates were incorporated 
on clearance in the model and tested for significance (Table II). The covariate 
analysis showed that TBW was the most predictive covariate for propofol 
clearance in the combined dataset of morbidly obese patients and lean 
patients, which was similar to the results in the morbidly obese patients 
alone. In the final TBW model, which included all 20 morbidly obese patients 
and all 44 lean patients, the OFV decreased by 46 points (p <0.001), while the 
interindividual variability in clearance decreased by 33%, and diagnostic and 
individual plots of the TBW model improved in comparison with the simple 
model (Table III). Implementation of fixed exponents of 0.75 for clearance 
and 1 for volumes, as applied by Cortinez et al. (9), led to worse performance 
and an unstable model during bootstrap analysis, compared to the final 
TBW model. For the final TBW model in the 20 morbidly obese patients and 
all 44 lean patients, the equation for clearance was equation 7, where z was 













































































































































Figure 2 Diagnostic plots of the final TBW pharmacokinetic model in 20 morbidly obese patients (A and B), 
the final TBW pharmacokinetic model in 20 morbidly obese patients and 44 lean patients (C and D), and the 
final pharmacodynamic model using BIS values in 20b morbidly obese patients (E and F), including observed 
versus individual predictions (A, C and E), and observed versus population predictions (B, D and F). BIS = 
bispectral index; ln = log-normal; TBW = total body weight. The solid line indicates the trend line, the dashed 
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Figure 3 Individual propofol clearance values versus TBW, BMI, IBW and LBW for the simple three-
compartment pharmacokinetic model in 20 morbidly obese patients and 40 lean patients (n = 60). BMI = 
body mass index; TBW = total body weight; IBW = ideal body weight; LBW = lean body weight.
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estimated to be 0.67. Final diagnostic plots are shown in Figure 2C and 2D, 
and final pharmacokinetic parameter values are shown in Table III. 
Bootstrap analysis of 250 replicates of the dataset of both the morbidly 
obese patients and the lean patients confirmed the stability of the model. 
Pharmacodynamics
The pharmacodynamic dataset contained 2246 observed BIS values from 
the 20 morbidly obese patients. While a one-compartment effect-site model 
adequately described the BIS values over the time profiles of the patients, a 
two-compartment biophase-distribution model significantly improved the 
performance, which was reflected by a reduction in the OFV of 167 points 
(p<0.001). While the differences in concentrations in the central effect-site 
compartment are generally small during steady state, just after a rapid 
change in concentration in the central pharmacokinetic compartment, small 
changes can typically be observed in the conditional weighted residuals 
versus time plots of the one-compartment effect-site model versus the two-
compartment biophase-distribution model (data not shown). No covariates 
for the pharmacodynamics of propofol were found. Table IV shows the 
population parameters of the one-compartment effect-site model and the 
final two-compartment biophase-distribution model and the results of the 
bootstrap analysis of 250 replicates of the dataset of the 20 morbidly obese 
patients, confirming a stable Emax model. In Figure 2E and 2F, the diagnostics 
of the final pharmacodynamic model are shown.
Simulations 
On the basis of the final pharmacokinetic and final pharmacodynamic model, 
simulations were performed aiming for BIS values between 40 and 60 for 
patients ranging in TBW between 98 and 167 kg. The results of the simulation 
exercise showed that, upon an induction dose of propofol 350 mg (12), the 
rate of the maintenance propofol infusion should be set to 7 mg/(70 kg * 
(TBW/70)0.72)/h for 20 minutes, followed by 6.5 mg/(70 kg * (TBW/70)0.72)/h for 
20 minutes, 6 mg/(70 kg * (TBW/70)0.72)/h during 20 minutes, and 5.5 mg/(70 
kg * (TBW/70)0.72)/h until the end of surgery, in order to achieve the desired 
BIS values. These BIS values can be expected provided that co-analgesia is 
achieved with remifentanil 25 µg/h times IBW (13) and predictive muscle 
relaxation is obtained using a continuous infusion of atracurium besilate.
Figure 4 shows blood propofol concentrations, propofol effect-site propofol 
concentrations and BIS values both with the model-based dosing regimen, 
as described above, and with a linear 5 mg/kg/h propofol dosing schedule in 
a 98 kg morbidly obese patient and in a 167 kg morbidly obese patient.
 
            iscussion
In order to study the influence of morbid obesity on the pharmacokinetics 
and pharmacodynamics of propofol, a population pharmacokinetic-
pharmacodynamic model was developed, in which clearance proved to 
scale with TBW, using an allometric function with an exponent of 0.72. While 
this allometric scaling factor of 0.72 in morbidly obese patients was fairly 
similar to the allometric scaling factor of 0.67 identified in both morbidly 
obese and lean patients, no other differences in pharmacokinetics or 
pharmacodynamics were identified.
It has been previously reported that variations in propofol clearance 
between patients are mainly influenced by TBW (6-7, 9). However, these 
studies evaluated only a limited number of obese (6-7) and morbidly obese 
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Figure 4 Model-based predictions of blood propofol concentrations (A), effect-site propofol concentrations (B) 
and BIS values (C) upon a model-based dosing regimen (black lines) and a linear dosing regimen (grey lines) of 
propofol in a morbidly obese patient of 98 kg and a morbidly obese patient of 167 kg. The model-based dosing 
regimen consisted of an induction dose of propofol 350 mg, followed by 7 mg/(70kg * (TBW/70)0.72)/h for the 
first 20 minutes, 6.5 mg/(70kg * (TBW/70)0.72)/h for the following 20 minutes, 6 mg/(70kg * (TBW/70)0.72)/h for 
the next 20 minutes, and 5.5 mg/(70kg * (TBW/70)0.72)/h until the end of surgery. The linear dosing regimen 
consisted of an induction dose of propofol 350 mg, followed by 5 mg/kg/h throughout the entire procedure. 
BIS = Bispectral index; TBW = total body weight.
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is related to clearance of propofol and can therefore be used as a parameter 
for propofol dosing in obese patients (20). This suggestion was explored by 
McLeay et al. (8); however, their model was based on simulations and not 
supported by clinical data in (morbidly) obese patients. In our study in 20 
morbidly obese patients and 40 lean patients, the patients’ TBW, BMI, IBW 
and LBW were available and could be studied for their specific influence 
on any of the pharmacokinetic parameters. In morbidly obese patients, it 
was found that clearance correlated with TBW and BMI, with no significant 
difference between the two models in terms of the OFV. However, after 
analysing both the morbidly obese patient dataset and the lean patient 
dataset (range 55–167 kg), TBW proved to be superior to BMI as a covariate 
for clearance of propofol based on the basic goodness-of-fit plots together 
with the OFV (a decrease in the OFV of 3 points). As both Figure 3 and Table II 
demonstrate, IBW and LBW could not be identified as predictors of propofol 
clearance, despite the fact that there is great interest in LBW as a covariate 
for dosing based on theoretical principles (8, 20). 
In morbidly obese patients, we found that the nature of the influence of 
TBW on clearance was best described by an allometric equation with an 
exponent of 0.72. This scaling factor was not significantly different from 
the scaling factor of 0.67 that we reported for the entire TBW range of lean 
and morbidly obese patients (55 - 167 kg). These results are in accordance 
with previously reported scaling factors of 0.71 in lean patients described by 
Schuttler et al. (7) and the fixed value of 0.75 in obese patients described by 
Cortinez et al. (9). More specifically, the clearance value of 2.22 L/min for a 
patient weighing 70 kg, as reported in our study, is in good agreement with 
the clearance of 2.25 L/min for a 70 kg person reported by Cortinez et al. (9). 
In our opinion, the nonlinearity in the relation between TBW and clearance 
is important to consider when dosing propofol in morbidly obese patients. 
In anaesthesia, medication is typically administered in milligrams per 
kilogram per hour, assuming a linear relation between TBW and clearance. 
While this dosing paradigm in milligrams per kilogram per hour may lead to 
overdosing in individuals at the upper TBW range, in this study we propose 
a nonlinear model-based dosing algorithm. Using this dosing regimen, the 
nonlinearity of the influence of TBW on clearance is accounted for and, as a 
result, a fixed dosing schedule (5.5–7 mg per (kg of TBW/70)0.72 per hour) can 
be used for all patients ranging between 98 and 167 kg in TBW. While the 
proposed dosing regimen, together with the corresponding ABW, deserves 
further study in the TBW range that was included in this study (98–167 kg), it 
remains of interest to evaluate the extrapolation capacities of this function 
at higher TBW values than those that were included in the current study (e.g. 
>167 kg). It is emphasized that the proposed model-based dosing regimen 
is to be used in conjunction with full muscle relaxation and remifentanil co-
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analgesia, as other co-medication may influence the pharmacokinetics and/
or pharmacodynamics of propofol, resulting in lower or higher propofol 
infusion rates, despite the fact that the influence of TBW on propofol 
clearance remains the same. 
Concerning the other pharmacokinetic parameters, there was a trend 
towards an increased V1 in morbidly obese patients compared with morbidly 
obese and lean patients together (4.52 L versus 3.03 L, respectively) (Table 
II). Previously, linear (6, 9) and allometric (7) relationships between TBW and 
the volume of distribution have been suggested. In our study, however, even 
though a large variability in individual values of the volume of distribution was 
found, incorporation of TBW as a covariate for the volume of distribution in 
the model did not result in significant improvement of the model according 
to the criteria described in the Methods section. It seems that larger datasets 
or different sampling schemes are needed to identify this influence or that 
factors other than TBW contribute to this large interindividual variability.  
Besides the pharmacokinetics of propofol in morbidly obese patients we 
investigated the pharmacodynamics using the BIS as endpoint. As morbidly 
obese patients can be considered to suffer from chronic inflammation (21) 
and are reported to have a lower pain threshold (22), we hypothesized that 
differences in the pharmacodynamic effects of propofol in these patients 
compared with lean patients cannot be excluded. However, considering 
the pharmacodynamic parameters reported in morbidly obese patients in 
this study, it seems that the EC50 and keo are in accordance with previously 
reported pharmacodynamic parameters of propofol in lean patients 
(16, 23). We compared our results with literature values because no BIS 
data were available in our lean patients datasets for us to do a combined 
pharmacodynamic analysis on morbidly obese and lean patients. Instead, 
we studied the influence of TBW within the pharmacodynamic model of 
our morbidly obese patients, in which no significant covariates could be 
identified. On the basis of these results, and in the absence of other reports 
on the pharmacodynamic relation of propofol in morbidly obese patients, 
we conclude that there are no differences in sensitivity to the propofol 
effect, measured using the BIS, between lean and morbidly obese patients. 
In the pharmacodynamic analysis, a two-compartment biophase-
distribution model proved to be superior to a one-compartment effect-site 
model (a decrease in the OFV of 167 points). While a two-compartment 
biophase-distribution model has been previously reported for propofol in 
lean patients (23), plasma-effect-site equilibration is often assumed to be 
a mono-exponential first-order process (24). This assumption of a mono-
exponential first-order process has been firmly adopted in pharmacokinetic 
and pharmacodynamic modelling, although it was reported as early as 
1991 that this assumption appeared to be inadequate for amobarbital 
and alphaxalone and that a bi-exponential conductance function better 
described the data (25-26). An explanation for the two-compartment 
biophase-distribution function is re-distribution of the drug in the central 
nervous system. Although the differences between the two models are 
generally small during steady-state situations, just after a bolus injection 
and a large infusion rate change, differences between the models can be 
noted. As in to lean patients (23), a bi-exponential function was found to be 
superior to a one-compartment effect-site model in morbidly obese patients 
in this study.
The limitations of our study include the characteristics of the lean patient 
datasets, which were not fully comparable to those of the studied group of 
morbidly obese patients. One lean patient dataset was obtained in females 
receiving a single bolus dose of propofol and isoflurane for maintenance of 
anaesthesia (10), while the second lean patient dataset consisted of critically 
ill patients receiving a long-term infusion of propofol (11). Furthermore, our 
study in morbidly obese patients was performed during clinical practice, 
implying that substantial co-medication was given, which may have 
influenced the pharmacodynamic estimates. In particular, remifentanil 
and muscle relaxants are known to influence the pharmacodynamics of 
propofol, although the literature is conflicting on this issue (27-31). However, 
an advantage of this approach is that the resulting model-based dosing 
regimen can be used directly in clinical practice provided that the same 
anaesthetic protocol is applied. Another issue was the lack of external 
validation datasets. Furthermore, as a result of the BIS target of 40–60, a 
limited range of propofol concentrations and BIS values were obtained, 
resulting in under-studied BIS ranges, e.g. lower than 30. Further study is 
needed to describe the entire BIS range, although for clinical practice, the 
current dataset and derived model seems to be adequate.
On the basis of the results of the final pharmacokinetic and pharmacodynamic 
model of propofol in morbidly obese patients, a dosing schedule with specific 
rates in milligrams per kilogram per hour with use of an adjusted body weight 
(70 kg × (TBW/70)0.72) for a surgical procedure aiming at BIS values between 
40 and 60 was derived. An alternative strategy for propofol dosing is to target 
a specific propofol concentration, using TCI techniques. TCI anaesthesia 
is controlled by pharmacokinetic models that are based on lean patients, 
such as the Marsh model (32) and the Schnider model (33). By evaluation 
of the actual depth of anaesthesia at a specific target concentration by 
the anaesthesiologist, adjustment of the target concentration can be 
considered and entered into the TCI system. There are several reports on 
the performance of TCI in obese and morbidly obese patients. Cortinez et 
al. suggest that their model for obese patients leads to a performance that 
is similar to that of the Marsh model (9). Absalom et al. (34) warned that 
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for an excessive maintenance dose of propofol may be administered when 
LBW is used for TCI in morbidly obese patients using the Schnider model. 
Similarly, La Colla et al. (35) reported a clinically unacceptable performance 
bias with the use of TBW as input for the Marsh model and concluded that 
titration to target BIS values in morbidly obese patient remains necessary. 
While TCI can be considered an important approach to dose propofol for 
anaesthesia, it seems that TCI systems are not yet ready for this approach in 
morbidly obese patients. The results of this study can be used to fill this gap 
if implemented into the TCI system and tested in morbidly obese patients 
with TBW up to 170 kg, in conjunction with remifentanil analgesia. Until then, 
the dosing paradigm that has been derived from our final pharmacokinetic 
and pharmacodynamic model can be used to dose morbidly obese patients 
in clinical practice, with use of an adjusted TBW together with a specific 
infusion rate regimen, aiming for a BIS between 40 and 60. 
           onclusion
A pharmacokinetic model for propofol in morbidly obese patients has 
been derived, with TBW as the major determinant of clearance, using an 
allometric function with an exponent of 0.72. No covariates for the other 
pharmacokinetic parameters were identified. The obtained BIS values in 
morbidly obese patients were described with a two-compartment biophase-
distribution model, with a sigmoid Emax pharmacodynamic model without 
covariates. 
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A              bstract 
Reports on the influence of perioperative remifentanil on population 
pharmacokinetic and pharmacodynamics parameters of propofol are 
conflicting and for morbidly obese patients unexplored. In the current 
study we developed a population pharmacokinetic and pharmacodynamic 
model of propofol in twenty-six morbidly obese patients receiving propofol-
remifentanil anaesthesia or propofol-epidural anaesthesia. Remifentanil 
was neither a covariate for the pharmacokinetic nor the pharmacodynamic 
parameters of propofol using the BIS as pharmacodynamics endpoint. In 
the final model, total body weight was a significant covariate for propofol 
clearance. These results suggest that there are no differences in the 
pharmacokinetic or pharmacodynamic parameters of propofol in morbidly 
obese patients receiving maintenance propofol-remifentanil or propofol-
epidural anaesthesia when the BIS is used a pharmacodynamic endpoint.
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           ackground
The dramatic increase in obesity rates across the world has augmented 
the obese population presenting for anaesthesia for various surgical 
procedures (1). Different strategies have been described for the complex 
anaesthesia of an obese patient. Most commonly, propofol in combination 
with remifentanil is used in morbidly obese patients. Alternatively, propofol 
anaesthesia can be combined with epidural analgesia. We reported before 
a pharmacokinetic-pharmacodynamic (PK-PD) model based dosing 
algorithm for propofol in combination with remifentanil in morbidly obese 
patients (2). Besides, we reported no difference in propofol maintenance 
dose between propofol-remifentanil anaesthesia and propofol-epidural 
anaesthesia in morbidly obese patients when aiming for stable Bispectral 
index and hemodynamic values (3). For non-obese patients, results studying 
the influence of remifentanil on propofol requirements are conflicting. No 
propofol infusion adjustments were reported when propofol was combined 
with remifentanil and dosing was based on target BIS values (4). In contrast, 
lower propofol concentrations were needed during laryngoscopy when 
propofol was combined with remifentanil in non-obese healthy volunteers 
(5). While changes in propofol dose may be caused by both PK and PD 
parameters, there are no studies on the influence of remifentanil on the 
separate PK and PD parameters of propofol in morbidly obese patients 
during surgery. Therefore, our aim was to develop a population PK-PD model 
of propofol in morbidly obese patients receiving maintenance of anaesthesia 
with propofol-remifentanil or with propofol-epidural anaesthesia. Bispectral 
index (BIS) values were used as PD endpoint. 
               ethods
Previously published data of a total of twenty-six morbidly obese patients 
scheduled to undergo bariatric surgery were used for this analysis (2, 3). 
Both the original study protocols were approved by the hospitals Ethics 
Committee and written informed consent was signed by each participating 
patient. 
Before induction, an antecubital infusion line, an indwelling arterial blood 
pressure line and a 3-lead ECG were installed and a Bispectral index electrode 
was placed on the patient’s forehead. 
Twenty morbidly obese patients (group I) received either a propofol 
induction dose of 200 mg or 350 mg followed by an initial maintenance 
propofol infusion of 10 mg/kg times total body weight. Remifentanil was 
administrated 25 µg/h/kg based on ideal body weight (6). In six morbidly 
obese patients (group II), an epidural catheter was placed and anaesthesia 
was induced with a propofol bolus dose of 350 mg and maintained with a 
continuous infusion of propofol and epidural analgesia 8 ml/h of bupivacain 
0.125% with 1 μg/ml sufentanil. In this group, propofol maintenance infusion 
was initiated at 5 mg/kg times total body weight. In both groups, propofol 
infusion rate was subsequently adjusted in order to keep BIS values between 
40 and 60, the systolic arterial blood pressure between 80 and 160 mmHg 
and heart rate between 60 and 90 beats per minute (3). Whole-blood samples 
were collected on a regular basis for propofol analysis, mixed thoroughly 
and stored at 4°C until analysis by high-performance liquid chromatography 
with fluorescence detection at 276 nm and 310 nm (7). 
Data analysis was performed by means of non-linear mixed-effects modeling 
using NONMEM (version VI, release 1.1; GloboMax LLC, Hanover, MD) (8) 
with S-plus (version 6.2; Insightful software, Seattle, WA) to visualize the 
data. Population pharmacokinetic (PK) and pharmacodynamic (PD) data 
were sequentially analysed by using the individual PK empirical Bayes 
estimates as an input to the pharmacodynamic model, and with use of a 
previously reported PK-PD model for propofol in morbidly obese patients 
(2). For the covariate analysis, a p< 0.005 was applied to evaluate the 
covariates in the forward inclusion (OFV decrease >7.9), while the backward 
deletion procedure used a stricter criterion (OFV decrease >10.8; p<0.001).
            esults
Data of twenty-six morbidly obese patients were analysed (Table I). A 
three-compartment pharmacokinetic (PK) model adequately described 
the time course of the propofol whole blood concentrations in morbidly 
obese patients receiving either propofol-remifentanil or propofol-epidural 
anaesthesia (Figure 1). Total body weight was a major determinant for 
clearance (CL), reducing the objective function value with 18 points 
(p<0.005). The relationship was expressed using an allometric function CLi 
= CL70 kg • (TBWi/70)0.87 where CLi represents clearance in the ith individual, 
CL70 kg is the population mean value for clearance in an individual of 70 kg, 
TBWi is the total body weight of the ith individual, and 70 is the standard 
total body weight in kilograms. No differences in mean PK parameters 
of propofol between patients receiving either propofol-remifentanil or 
propofol-epidural anaesthesia were observed as shown in Figure 2. Separate 













Gender (M / F) 4/16 1/5
Age (years) 45 (12) 41 (9)
Total body weight (kg) 124 (20) 145 (28)
Ideal body weight (kg) 61 (7) 65 (6)
Body mass index (kg/m2) 43 (6) 49 (9)
Lean body weight (kg) (19) 60 (9) 66 (10)
Table I Baseline characteristics of twenty morbidly obese patients receiving propofol-
remifentanil (group I) and six morbidly obese patient receiving propofol-epidural 
(group II) for maintenance of anaesthesia. Data are presented as mean with standard 
deviation (SD).
M = male; F = female.
























































































Figure 1 Diagnostic plots for propofol pharmacokinetics (A and B) and pharmacodynamics (C and D) in 
morbidly patients showing individual (A and C) and population (B and D) model predictions versus observed 
values for final models. Morbidly obese patients receiving propofol-remifentanil anaesthesia are represented 
with grey open rounds and morbidly obese patients receiving propofol-epidural anaesthesia are represented 
with black open rounds. The dashed line represents the line of identity, x=y.
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estimation of volume of distribution or clearance for each of the two groups 
did not result in improved performance of the model. 
The measured BIS values over time in the 26 morbidly obese patients were 
adequately described with a two-compartment biophase distribution model 
with a sigmoid Emax pharmacodynamic (PD) model for both regimens (Figure 
1). Separate estimation of the PD parameters for each of the two groups 
did not result in improved performance of the model. Tested covariates 
did not significantly improve the PD model of propofol in morbidly obese 
patients. Figure 3 illustrates that there is no significant difference in mean PD 
parameters EC50, keo and Emax of the groups receiving propofol-remifentanil 
and propofol-epidural anaesthesia. 
            iscussion
In our study in morbidly obese patients undergoing bariatric surgery, no 
differences in pharmacokinetic (PK) and pharmacodynamic (PD) parameters 
of propofol when combined with remifentanil or epidural anaesthesia were 
observed using BIS values as PD endpoint.
D
Morbidly obese patients are at increased risk for complications during 
anaesthesia due to difficult intubation, positioning and diverse co-
morbidities (9). Therefore, there is a need to understand the influence of 
excessive body weight on the PK and PD of drugs. The effect of epidural 
analgesia on propofol anaesthesia is rather unknown, although it cannot be 
excluded that epidural analgesia has a hypnotic effect (10, 11). Previously 
we reported no differences between propofol infusion rates and propofol 
concentrations when propofol dosing was based on BIS values and 
hemodynamic parameters in combination with remifentanil or epidural 
analgesia in morbidly obese patients (3). However, in non-obese patients 
there is debate about the influence of remifentanil on the PK of propofol 
and on BIS values as the effect of remifentanil is mostly evaluated in patients 
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Figure 2 Mean values (grey line) and empirical Bayes estimates for the pharmacokinetic parameters 
clearance (left panel) and central volume of distribution (right panel) of propofol in morbidly obese patients 
receiving propofol-remifentanil (n=20) or propofol-epidural anaesthesia (n=6).
Figure 3 Mean values (grey line) and empirical Bayes estimates for the pharmacodynamic parameters 
EC50, ke0 and Emax of propofol in morbidly obese patients receiving propofol-remifentanil (n=20) or propofol-
epidural anaesthesia (n=6).
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with BIS values around 60 without surgical stimuli. In a study in non-obese 
patients, remifentanil was not found to influence the PK of propofol (12). 
However, the combination resulted in a reduction of BIS values during 
induction of anaesthesia (13, 14) and reduced propofol concentrations 
during extubation with the return of consciousness in a synergistic manner 
(15). Besides, adding remifentanil to low propofol infusion rates resulted 
in lower BIS values (16). In addition, lower BIS values for patients receiving 
higher remifentanil target concentrations were observed (17). In contrast, 
maintenance propofol infusion rates were not adjusted when propofol was 
combined with remifentanil (4) and varying the remifentanil effect-site 
concentration showed not to effect BIS values during target-controlled 
propofol infusion in non-obese patients (18). While the small sample size 
of patients receiving propofol-epidural anaesthesia is a limitation of the 
current study, our findings in morbidly obese patients are in accordance with 
the results in non-obese patients.
In conclusion, the present study in morbidly obese patients suggests that 
there are no differences in the population PK and PD parameters of propofol 
when combined with remifentanil or epidural anaesthesia during bariatric 
surgery. More data from morbidly obese patients receiving propofol-
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              bstract 
Background 
In pharmacokinetic-pharmacodynamic (PK-PD) models for morbidly obese 
patients, total body weight (TBW) has been reported the best size descriptor 
for propofol clearance using an allometric function. Most recently, a nonlinear 
total body weight-based dosing algorithm for maintenance of anaesthesia 
with propofol was developed aiming for Bispectral index (BIS) values of 40 ± 
10 in morbidly obese patients with varying body weights. The present study 
aims at evaluating this algorithm prospectively in a clinical setting. 
Methods 
After induction of anaesthesia, propofol maintenance dose was started at 
7 mg/kg ABW/h (ABW = adjusted total body weight = 70kg * (TBW/70)0.72) 
in combination with remifentanil. BIS values, haemodynamic parameters 
and the number of the propofol infusion adjustments were recorded for 
each patient. Observed BIS values were compared with BIS values predicted 
by the previously published PK-PD model for propofol in morbidly obese 
patients.
Results 
Fifty-one morbidly obese patients were included in this prospective study 
with a mean total body weight of 134 kg (range 95 – 210 kg). During 
maintenance of anaesthesia, sixty-eight percent of the observed BIS values 
were within the target range of 40 ± 10. Except during the first 20 minutes 
after induction of anaesthesia, blood pressure and heart rate were within 
predefined ranges. Mean difference in propofol maintenance infusion rates 
was -0.43 mg/min (95%CI -0.49 – -0.36) compared to the proposed model-
based infusion rates. Observed BIS values were predicted without bias 
and with accurate precision by the previously published population PK-PD 
model. 
Conclusion 
Stable and effective maintenance of anaesthesia was achieved using the 
PK-PD model-derived propofol dosing algorithm in morbidly obese patients 




     ntroduction 
The rise in prevalence of obesity leads to a growing number of obese patients 
that are treated by health care services for a variety of concomitant diseases 
(1-2). Because morbidly obese patients have an altered body composition, 
are prone to desaturation and have an altered cardiovascular state (3-4), 
safe and effective anaesthesia of morbidly obese individuals remains a 
challenge (5-6). To date, the number of studies that is available to define the 
optimal dose for anaesthesia for each individual (morbidly) obese patient is 
still limited. 
Propofol is widely used for maintenance of anaesthesia in both non-obese 
and morbidly obese patients albeit at a variety of dosing regimens (7). In 
two recent population pharmacokinetic-pharmacodynamic (PK-PD) models 
for morbidly obese patients, it was reported that total body weight (TBW) 
is the best size descriptor for propofol clearance when parameterised 
with an allometric function (8-9). Besides, no influence of body weight on 
the pharmacodynamics of propofol using Bispectral index (BIS) values in 
morbidly obese patients was found (8). Based on this population PK-PD 
model, it was proposed to dose propofol maintenance infusion in morbidly 
obese patients on an adjusted total body weight (ABW = 70kg * (TBW/70)0.72) 
in order to obtain Bispectral index (BIS) values of 40 ± 10 across the entire 
heterogeneous population of morbidly obese patients (8). 
Before this model-based dosing algorithm can be widely implemented in 
clinical practice, it is of interest to evaluate in a prospective clinical study 
whether the new PK-PD model derived dosing algorithm results in safe 
and effective anaesthesia in morbidly obese patients. Therefore, the aim 
of the present study was to prospectively evaluate the PK-PD model-based 
propofol maintenance dosing algorithm (8) in morbidly obese patients 
undergoing laparoscopic bariatric surgery in terms of BIS values and 
haemodynamic parameters. In addition, observed propofol infusion rates 
aiming for a BIS target of 40 ± 10 were compared with the proposed model-
based dosing scheme and observed BIS values were compared to BIS values 
predicted by the previously published PK-PD model of propofol in morbidly 
obese patients (8).
                
                ethods
Patients
Morbidly obese patients undergoing laparoscopic bariatric surgery were 
included in this prospective study in two large teaching hospitals (26 patients 
in Nieuwegein and 25 patients in Amsterdam). Patients were enrolled in 
the study if their age was between 18 and 60 years, they had an American 
Society of Anesthesiologists (ASA) physical status classification of ΙΙ or ΙΙΙ 
and their BMI was over 40 kg/m2 at the day of inclusion. Exclusion criteria 
included epilepsy, pregnancy, breastfeeding and known allergy to propofol, 
soy bean oil or egg lecithin. The hospital ethics committees of both hospitals 
approved the study protocol and waived the need for informed consent as 
the dosing algorithm based on the previously published pharmacokinetic-
pharmacodynamic (PK-PD) model (8) was considered best standard of care 
in these hospitals.
Anaesthetic and study procedure
Anaesthesia was standardized according to the previous study in which 
the model-based dosing algorithm for propofol was developed (8) and was 
repeated as relevant for this study. Before induction of anaesthesia, an 
antecubital infusion line was installed, a BIS electrode was placed on the 
patient’s forehead and a sphygmomanometer was placed on the patients’ 
upper arm. Unpremedicated patients received a bolus injection of 350 mg 
of propofol given over 60 seconds for induction of anaesthesia followed 
by atracurium besilate or rocuronium 50 mg and fentanyl 250 mcg (10). 
Thereafter, the trachea was intubated and mechanical ventilation was 
initiated by the anaesthesiologist. Arterial oxygen saturation and end-tidal 
carbon dioxide were monitored throughout the procedure. The surgical 
position of all patients was the anti-Trendelenburg position. Anaesthesia 
was maintained with propofol according to the dosing algorithm that was 
previously developed based on a PK-PD model in morbidly obese patients 
(8). For this dosing algorithm an adjusted body weight was calculated for 
each patient (Equation 1) (8):
Adjusted body weight (ABW) = 70kg * (TBW/70)0.72   (Eq. 1)
According to this dosing algorithm, from 3 minutes after induction of 
anaesthesia onwards, the initial infusion rate of propofol was set on 7 mg/
kg ABW/h for 20 minutes, followed by 6.5 mg/kg ABW/h for 20 minutes, 6 
mg/kg ABW/h for 20 minutes, and 5.5 mg/kg ABW/h until the end of surgery. 
I M 
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Appendix 1 shows the propofol infusion rates across different time frames of 
anaesthesia for different total body weights. 
The propofol infusion rate as initiated based on Table II could be adjusted 
by the attending anaesthesiologist in order to obtain a BIS value of 40 ± 10, 
blood pressure within ± 30% of baseline values and heart rate between 60 
– 90 beats/min. Adjustments in propofol infusion rates were made with 50 
– 150 mg/h at the discretion of the attending anaesthesiologist, and with 
preferably no more than one infusion rate adjustment per five minutes. 
Propofol infusion rates were increased if BIS values and haemodynamic 
parameters were higher than the predefined values. When BIS values 
and haemodynamic parameters were lower than the predefined values, 
propofol infusion rate was decreased. When haemodynamic parameters 
were lower than the predefined values and BIS values were higher or 
equal to the predefined range, medication to improve the haemodynamic 
parameters was administered and the propofol infusion rate was adjusted 
to bring BIS values within the predefined range. When haemodynamic 
parameters were higher than the predefined range and BIS value were 
lower than or within the predefined range, signs of inadequate anaesthesia 
were checked. When adequate anaesthesia was confirmed, medication to 
correct haemodynamics was administered. If there were signs of inadequate 
anaesthesia, the propofol infusion rate was adjusted (8).
During the procedure, remifentanil was dosed 25 mcg/kg/h based on 
ideal body weight (IBW) (11). The remifentanil infusion rate was kept 
constant, if possible, in order to rule out influence of remifentanil on 
haemodynamic parameters and BIS values. If necessary, remifentanil 
infusion rate adjustments could be made at the discretion of the attending 
anaesthesiologist. Additional fentanyl bolus doses could be administered 
if needed throughout the surgical procedure as judged by the attending 
anaesthesiologist. About 30 minutes before the anticipated end of the 
surgical procedure, morphine 10 mg was administered. 
Descriptive data analysis 
The SPSS statistical package (version 19.0 for Windows; IBM) was used 
for these analyses. Continuous data are expressed as the mean ± SD or 
as median (interquartile range) where appropriate. Observed BIS values 
during propofol infusion, systolic arterial blood pressure and heart rate 
were averaged within 5 minute time intervals for each patient. Based on 
these data, box plots were constructed indicating median, interquartile 
rage and 95% confidence intervals. The actual propofol infusion rates were 
subtracted from predefined infusion rates at one minute time intervals for all 
patients. If at any time interval from less than 75% of the patients data were 
available, this is indicated in the figures. In all figures time-point 0 indicates 
the induction of anaesthesia.
Comparison of observed BIS values with model-based predicted BIS values
Non-linear mixed-effects modeling using NONMEM (version VΙ, release 
1.1; GloboMax LLC, Hanover, MD, USA) with S-Plus (version 6.2; Insightful 
Software, Seattle, WA, USA) was used to obtain model-based BIS 
predictions. These model-based BIS predictions were generated for each 
of the participating patient on the basis of their total body weight and 
actual administrated propofol doses during the entire procedure using the 
previously published PK-PD model for propofol in morbidly obese patients 
(8). In predicted versus observed plot, the observed BIS values were visually 
compared to the individual BIS value predictions by the model. For each 
patient and for each BIS observation, a prediction error (PE) was calculated 
from which median performance error (MDPE) and the median absolute 
performance error (MDAPE) were calculated (Equation 2, 3 and 4) (12):
Prediction error (PE) at the jth BIS observed of subject i:
PEij = BISobserved - BISpredicted      (Eq. 2)
The median PE (MDPE): MDPE reflects the bias of BIS in the ith subject:
MDPEi (BIS values) = median [PEij, j = 1, . . . ,Ni]   (Eq. 3)
The median absolute PE (MDAPE): MDAPE indicates the BIS precision in the 
ith subject:
MDAPEi (BIS values) = median [|PEij|, j = 1, . . . , Ni]  (Eq. 4)
            esults
Patients and data
A total of 51 morbidly obese patients with a mean total body weight of 
134 kg (range 95 – 210 kg) and mean BMI of 45 kg/m2 (range 35 – 56 kg/m2) 
were enrolled in this study. All demographic characteristics of all patients 
are provided in Table I. Clinical data of the patients are presented until 75 
minutes after propofol induction dose administration, as at that time point 
surgery had been completed in more than 25% of the patients. In five 
patients, propofol infusion for maintenance of anaesthesia was started 1 
minute earlier than the proposed 3 minutes after the induction dose.
 





Sex (Male / Female) 18 / 33 -
Age (years) 45 (8.3) 22.0 – 63.0
TBW (kg) 134 (22.6) 95.0 – 210.0
BMI (kg/m2) 45 (5.6) 34.9 – 56.3
LBW (kg) 68 (13.7) 47.6 – 104.6
IBW (kg) 65 (11.4) 44.2 – 88.6
ABW (kg) 111 (13.7) 87.0 – 154.0
Duration of surgery (min) 74.1 (24.9) 40.0 – 158.0
Duration of anaesthesia (min) 89.3 (24.5) 51.0 – 176.0
Time between start of propofol infusion – start surgery (min)* 10.3 (4.0) 0.0 – 19.0
Time between stop of propofol infusion – extubation (min) 12.4 (5.8) 3.0 – 32.0
Time between end of surgery – extubation (min)** 14.6 (6.5) 7.0 – 33.0
Time between intubation – extubation (min) 97.0 (27.4) 30.0 – 189.0 
Table I Baseline characteristics of 51 morbidly obese patients. Data are presented as 
mean with standard deviation (SD) and associated range.
* = data available of 70.6% of the patients 
** = data available of 66.7% of the patients 
TBW= total body weight, BMI= body mass index, LBW= lean body weight (19), IBW= ideal body weight 
(25), ABW= adjusted body weight (= 70kg * (TBW/70)0.72).
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Anaesthesia
Figure 1 shows the median observed BIS values and interquartile ranges of 
the 51 morbidly obese patients during anaesthesia. It is shown that median 
and interquartile ranges were within the target BIS range of 40 ± 10 during 
anaesthesia from 5 until 75 minutes after induction of anaesthesia. In total, 
during this period 68% of the observed BIS values were within 40 ± 10. 
Figure 2 shows mean systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) relative to baseline pressures measured at preoperative 
consultation over time. Overall, SBP and DBP dropped substantially during 
anaesthesia, particularly within the first 20 minutes after induction of 
anaesthesia. Afterwards, mean SBP and DBP stayed within the predefined 
target values of ± 30% from baseline values with average drops of 26% 
(95%CI 24-28) and 27% (95%CI 26-28) during period 5-75 minutes after 
induction of anaesthesia, respectively. Figure 2 shows that mean heart rate 
values were within the predefined range of 60 – 90 beats/min during the 
whole observation period, even though, similar to blood pressure, heart rates 













































Figure 1 Median Bispectral index (BIS) values with interquartile range (box) and 95% confidence intervals 
observed in time intervals of five minutes after induction of anaesthesia in 51 morbidly obese patients.
Figure 2 Systolic blood pressure (SBP) (top panel) 
and diastolic blood pressure (DBP) (middle panel) at 
different time-points after induction of anaesthesia 
presented as percentage deviation from baseline 
values measured at preoperative consultation with 
standard deviations, and heart rate (HR) (bottom 
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Mean (SD)
Protocol medication
Propofol bolus (mg) 362.2 (41.3)
Propofol maintenance (mg/kg/h*)            6.2 (0.54)
Remifentanil (mcg/kg/h**)   23.4 (4.8)
Fentanyl (mcg) 292.2 (77.1)
Atracurium (mg) (n=26) 54.8 (12.0)
Rocuronium (mg) (n=25) 52.2 (6.5)
Morphine (mg) 10.3 (2.8)
Additional medication (bolus doses)
Ephedrine (mg) 0-20 min (#=27, n=22) 7.9 (2.5)
Ephedrine (mg) 21 min – end of surgery (#=18, n=11) 5.8 (1.9)
Phenylephrine 0-20 min (mg) (#=16, n=8) 0.12 (0.05)
Phenylephrine 21-end min (mg) (#=22, n=8) 0.11 (0.04)
Noradrenalin (mg) (n=5) 0.49 (0.2)
Table III  Medication administered according to standardized anaesthesia protocol 
and additional medication presented as mean dose with standard deviation (SD).
* based on model-based adjusted body weight (= 70kg * (TBW/70)0.72)
** based on ideal body weight
# number of bolus administrations
n number of patients 
carbon dioxide measurements were not below 3.5 kPa or 26 mmHg across 
the observation period for all patients. 
Figure 3 shows the difference between actual propofol infusion rates and 
proposed model-based infusion rates (Table II) from the start of the propofol 
maintenance infusion (at three minutes after induction of anaesthesia) until 
75 minutes after the induction of anaesthesia. Overall mean difference was 
-0.43 mg/min (95%CI -0.49 – -0.36). It seems from this figure, that during 
the first ten minutes after the induction dose of 350 mg propofol, the 
interindividual variability in infusion rates was relatively large (Figure 3).
Figure 3 Deviations in observed propofol infusion rates compared to the proposed propofol dosing algorithm 
















using propofol 10 mg/mL
100 90 63 59 54 50 45
105 94 66 61 56 52 47
110 97 68 63 58 53 48
115 100 70 65 60 55 50
120 103 72 67 62 57 52
125 106 74 69 64 58 53
130 109 77 71 66 60 55
135 112 79 73 67 62 56
140 115 81 75 69 63 58
145 118 83 77 71 65 59
150 121 85 79 73 67 61
155 124 87 81 74 68 62
160 127 89 83 76 70 63
165 130 91 84 78 71 65
170 133 93 86 80 73 66
175 135 95 88 81 74 68
180 138 97 90 83 76 69
185 141 99 92 85 78 70
190 144 101 93 86 79 72
195 146 102 95 88 81 73
200 149 104 97 89 82 75
205 152 106 99 91 83 76
210 154 108 100 93 85 77
215 157 110 102 94 86 79
220 160 112 104 96 88 80
225 162 114 105 97 89 81
230 165 115 107 99 91 82
235 167 117 109 100 92 84
240 170 119 110 102 93 85
245 173 121 112 104 95 86
250 175 123 114 105 96 88
* ABW = 70 * (Total body weight (=TBW)/70)0,72
Table II Proposed propofol maintenance infusion rates based on adjusted body weight (ABW) as derived 
from a previously published pharmacokinetic and pharmacodynamic model (8). This dosing algorithm 
consists of 7 mg/kg ABW*/h for 20 minutes, followed by 6.5 mg/kg ABW*/h for 20 minutes, 6 mg/kg ABW*/h 
for 20 minutes, and 5.5 mg/kg ABW*/h until the end of surgery.
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Figure 4 Individual predicted BIS values by the original pharmacokinetic-pharmacodynamic model (8) 
versus the observed BIS values in the current study in fifty-one morbidly obese patients.
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Both protocol medication and additional medication that was administered 
during anaesthesia according to the standardised protocol are presented 
in Table III. Mean remifentanil dose was 23.4 mcg/kg/h (SD 4.8) based on 
ideal body weight (IBW) which was slightly lower than the predefined dose 
of 25 mcg/kg/h based on IBW (Table III). Sixty-five percent of the patients 
received co-medication to correct low blood pressure and/or heart rate at 
some time during the period of anaesthesia. In most cases, ephedrine was 
used to correct low blood pressures and 60% of all ephedrine doses were 
administered during the first 20 minutes after the start of the induction of 
anaesthesia.
Comparison of observed BIS values with model-based predicted BIS values
Figure 4 shows the individual predicted BIS values by the original 
pharmacokinetic and pharmacodynamic model (8) versus the observed 
BIS values of the morbidly obese patients. These plots indicate acceptable 
bias and adequate precision of the predictions of the BIS values. Overall 
performance variables were a median performance error (MDPE) -5.2 BIS 
points (SD 13.0) representing bias and a median absolute performance error 
(MDAPE) 10.5 BIS points (SD 9.3) representing precision. 
            iscussion
The present study prospectively evaluated a pharmacokinetic-
pharmacodynamic (PK-PD) model-derived algorithm for maintenance of 
anaesthesia with propofol in morbidly obese patients thereby targeting on 
a BIS value of 40 together with stable haemodynamics. Using this propofol 
dosing algorithm in combination with remifentanil analgesia, effective 
anaesthesia was achieved with BIS values of 40 ± 10 and with haemodynamics 
that stayed within the predefined ranges across a wide range of total body 
weights from 95 to 210 kg. However, haemodynamics dropped substantially 
particularly within the first 20 minutes after induction of anaesthesia.
Prospective studies evaluating dosing guidelines derived from population 
PK-PD models on the used endpoints are scarce. The propofol dosing 
algorithm for morbidly obese patients evaluated in the present study was 
derived from a population PK-PD model in which total body weight was 
identified as key patient characteristic that can explain the interindividual 
variability of clearance of propofol in both non-obese and morbidly obese 
patients (8). Based on that model, when aiming for a stable BIS of 40 during 
maintenance of anaesthesia, an adjusted body weight (ABW); ABW = 70kg 
* (TBW/70)0.72 as dosing scalar with doses reductions every 20 minutes was 
proposed (8). In the present evaluation of this PK-PD model-based dosing 
algorithm, we showed that using these propofol doses stable BIS values of 
40 ± 10 were achieved in morbidly obese patients. Although the current bias 
and precision values for the observed BIS values were larger compared to in 
non-obese patients (13-14), the bias (MDPE) and precision (MDAPE) were 
acceptable with 10.5 (SD 9.3) and –5.2 BIS points (SD 13.0), respectively. 
There was also no difference in observed BIS values between the lower and 
higher total body weights (data not shown) indicating that the accuracy of 
the model is applicable for a wide range of total body weights. The present 
study demonstrates that PK-PD modeling in special patient groups such 
as morbidly obese patients can be of important value when developing 
evidence-based dosing algorithms for these patient groups. 
In general, there may be concerns on the haemodynamic safety of propofol 
when used for anaesthesia in morbidly obese patients. Propofol is known 
to cause a decrease in systemic arterial blood pressure due to depressant 
effects on cardiac contractility and a reduction in venous and arteriolar 
systemic vascular resistance resulting in a decrease in pre- and afterload 
(15). While in our opinion, the risk for haemodynamic instability is reduced 
by dosing on adjusted body weight (Table II) instead of linear dosing 
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pressure over the first 20 minutes of the procedure in our study (Figure 2). 
Moreover, in a large number of patients additional medication to correct 
these haemodynamic effects were given (Table III). 20 minutes after the 
induction dose, the observed decrease of the haemodynamic values during 
propofol maintenance infusion remained within the predefined margins 
and there were no signs of hypoperfusion during anaesthesia. In addition, 
we emphasize that the decrease in observed haemodynamic values could 
be slightly overpredicted because of relatively high blood pressures that 
may be measured during preoperative consultation. As such we conclude 
that haemodynamic effects of propofol in morbidly obese patients are 
acceptable when the PK-PD model derived dosing algorithm as depicted in 
Table II is used for maintenance of anaesthesia.
After induction of anaesthesia, considerable variations in BIS values, blood 
pressures and heart rates were observed during the first 20 minutes. There is 
a number of possible explanations for this. First, a cause may lie in the fixed 
propofol induction dose of 350 mg for all morbidly obese patients. Recent 
study suggested to use lean body weight as dosing scalar to calculate 
propofol induction dose for morbidly obese patients instead of dose capping 
(16). This might have resulted in a lower induction dose for the less obese 
patients and a more stable start of anaesthesia. In an additional analysis of 
the present study, however, no correlation between decrease in BIS during 
the induction phase and lean body weight could be observed (data not 
shown). Second, propofol maintenance infusion was started 3 minutes after 
the propofol induction dose while surgery did not start in all cases. Mean time 
between start of surgery and start of propofol infusion was 10.3 minutes. 
Because start of surgery causes sympathetic activation, thereby increasing 
both blood pressure and heart rate (17), a delayed start of surgery and, 
thereby, a delayed stimulus of the sympathetic nerve system, may explain 
the extensive decline of blood pressure during the first minutes of propofol 
infusion. Therefore, before implementation, the present dosing algorithm 
has to be incorporated in conjugation with local practice in terms of timing 
of anaesthesia and start of surgery. Finally, cardiovascular consequences 
of obesity such as (silent) ischemic heart disease and cardiomyopathy may 
have aggravated the haemodynamic effects during induction of anaesthesia 
independent of propofol dose. Although in our study with the developed 
propofol dosing algorithm optimal conditions for intubation were achieved 
in all patients, there remains space for further improvement of the induction 
phase of the evaluated PK-PD model-based dosing regimen.
In our study, we decided to dose propofol based on both BIS values 
and hemodynamic parameters. Besides dosing based on BIS values, an 
alternative strategy for propofol dosing is to target to specific propofol 
blood concentrations using target controlled infusion techniques (TCI). La 
Colla et al reported however a clinically unacceptable performance bias 
upon the use of total body weight as an input for the ‘Marsh’ model for TCI 
and concluded that titration on target BIS values in morbidly obese patient 
remains necessary (18). Although TCI can be considered an interesting 
approach to dose propofol for anaesthesia, it seems that the TCI systems 
are not yet ready for this approach in morbidly obese patients. The results 
of the present study show that the previously developed PK-PD model-
based propofol maintenance dosing algorithm leads to stable BIS values 
and acceptable haemodynamics in morbidly obese patients and is ready for 
clinical implementation.
            
            onclusion
Stable and effective maintenance of anaesthesia was achieved using the PK-
PD model-based propofol dosing algorithm in combination with remifentanil 
analgesia in morbidly obese patients varying in total body weight between 
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              bstract 
Background and objectives 
Given the alarming increase in obesity among children undergoing surgery, 
the main aim of this study was to characterize propofol clearance in a cohort 
of morbidly obese children and adolescents in relation to their age and body 
weight characteristics.
Methods 
A prospective pharmacokinetic study in morbidly obese children and 
adolescents undergoing elective surgery was conducted. Serial blood 
samples were collected and nonlinear mixed-effects modelling using 
NONMEM was performed to characterize propofol pharmacokinetics with 
subsequent evaluation of age and body size descriptors.
Results 
Twenty obese and morbidly obese children and adolescents with a mean age 
of 16 years (range 9–18 years), a mean total body weight (TBW) of 125 kg 
(range 70–184 kg) and a mean body mass index of 46 kg/m2 (range 31–63 kg/
m2) were available for pharmacokinetic modelling using a two-compartment 
pharmacokinetic model (n = 294 propofol concentration measurements). 
Compared with lean body weight and ideal body weight, TBW proved to be 
the most predictive covariate for clearance (CL (L/min) = 1.70 × (TBW/70)0.8). 
Central volume of distribution, peripheral volume and intercompartmental 
clearance were 45.2 L, 128 L and 1.75 L/min, respectively, with no predictive 
covariates identifiable.
Conclusion 
In the population pharmacokinetic model for propofol in morbidly obese 
children and adolescents, TBW proved to be the most significant determinant 
for clearance. As a result, it is anticipated that dosage of propofol for 
maintenance of anaesthesia in morbidly obese children and adolescents 




            ackground 
The prevalence of childhood obesity is dramatically increasing worldwide. In 
2008, childhood obesity affected 17% of the children and adolescents in the 
US (1). Moreover, morbid obesity in children is also on the rise (2) and due 
to comorbidities related to obesity, these patients are more likely to utilize 
healthcare resources, including anesthesia for bariatric surgery (3). However, 
dosing guidelines for most commonly used drugs in this population are 
not available due to a lack of studies providing adequate pharmacokinetic 
and pharmacodynamic data. Serious problems may arise due to over- 
and underdosing, increasing adverse events and the risk of suboptimal 
efficacy, respectively (4). Therefore, systematic pharmacokinetic and 
pharmacodynamic studies in this special population of patients are urgently 
needed to improve the safety and efficacy of drugs used in these patients. 
Propofol is widely used for induction and maintenance of anesthesia 
in children and adolescents. There has been extensive research on the 
pharmacokinetics of propofol in non-obese adults (5-6) and children (6-
9). Propofol pharmacokinetics proved to be altered in children compared 
with adults, showing a higher propofol clearance per kg in children (6). 
Consequently, children require higher propofol doses per kg total body 
weight (TBW) than adults to obtain a similar propofol concentration (10). 
Concerning the influence of obesity on the pharmacokinetics of propofol in 
obese adults, different reports have been published. In adults, an increase in 
propofol clearance associated with TBW has been observed (11). Recently, 
two studies showed that this increase in propofol clearance can be described 
with an allometric function on the basis of TBW as body size descriptor and 
with an exponent of 0.75 and 0.72, respectively (12-13). In contrast, to date 
there are no data available describing the influence of overweight on the 
pharmacokinetics of propofol in (morbidly) obese children and adolescents.
Therefore, the main aim of this study was to characterize the population 
propofol clearance in morbidly obese children and adolescents, ultimately 
to develop an optimal dosing algorithm. Therefore, we evaluated the 
pharmacokinetics of propofol in this special group of patients and analyzing 
the influence of age and body size descriptors such as TBW, body mass 
index (BMI), ideal body weight (IBW) and lean body weight (LBW) based on 
Janmahasatian et al. (14) and LBW based on Peters et al. (15) in order to 
account for variability in pharmacokinetic parameters.
                ethods
Patients
Obese and morbidly obese children and adolescents scheduled to undergo 
bariatric surgery or other elective surgical procedures were enrolled in 
a prospective study from July 2009 through July 2010 (ClinicalTrials.gov 
identifier NCT00948597). From prior work in children we estimated that 
a cohort of 20 subjects for this study would allow adequate estimation of 
the primary outcomes variables propofol clearance and central volume of 
distribution (9, 16). 
Patients were included if they were between 5 and 18 years of age, had 
a BMI of over 30 kg/m2 at inclusion (equivalent to body weight > 95th 
percentile for age (17)), required propofol anesthesia for at least 60 minutes 
and had no known renal or liver disorders. Exclusion criteria included known 
neurological disorders, history of severe sleep apnea, anticipated difficult 
airway access, and known allergy for propofol, soy bean oil or egg lecithin. 
The study protocol was approved by the institutional review board and 
written informed assent and consent were obtained from all participants 
and/or their guardians as appropriate.
Anesthetic procedure
All patients received standard of care anesthesia with midazolam as 
premedication (either 20 mg orally or 2 mg intravenously). Before 
induction, an antecubital venous line and standard American Society of 
Anesthesiologists (ASA) monitors (ECG, non-invasive blood pressure and 
pulse oximeter) were placed. Anesthesia was induced with propofol as an 
infusion at a standardized rate of 1000 µg/kg/min on the basis of adjusted 
body weight (11). 
Upon loss of consciousness, endotracheal intubation was performed 
after administration of either vecuronium or cisatracurium for muscular 
relaxation. Paralytic agents were titrated using a nerve stimulator to observe 
the train-of-four response at the orbicularis oculi by facial nerve stimulation 
(goal: one of four twitches). The induction dose of propofol was followed by 
propofol infusion at a rate of 250-350 µg/kg/min for 10 minutes and titrated 
in 25-50 µg/kg/min steps in order to keep the systolic arterial blood pressure 
and heart rate hemodynamics within 30% of baseline values. Fentanyl 100 
µg was administered just after induction and 50 µg doses were administered 
in case of inadequate analgesia. When inadequate anesthesia or analgesia 
was not considered to be the reason for increase in blood pressure or heart 
rate, medications to correct the hemodynamics were administered. Typically 
B M 
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labetolol 5 mg was used to reverse increased heart rate and blood pressure, 
ephedrine 10 mg increments for decreased blood pressure and heart rate, 
and phenylephrine 100 μg increments for decreased blood pressure and 
increased heart rate. The propofol infusion was discontinued when skin 
sutures were being placed. Residual muscle relaxation was reversed with 
neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.1 mg/kg, and after clinical 
confirmation of reversal, the patient was extubated awake. Morphine was 
dosed incrementally towards the end of the surgery, titrated to respiratory 
rate of 14-16 breaths per minute.
Blood sampling and analytical methods
Venous blood samples (1 ml) were collected at the following timepoints: at 
baseline prior to the start of the propofol, approximately 15, 30, 45, 60, 120, 
180 and 240 minutes after the start of the propofol infusion, just before and 
at 5 or 20 minutes after any dose adjustment, just before discontinuation 
of the propofol infusion, and at 5, 10, 15, 30, 45 and 120 minutes after 
discontinuation of the infusion. Whole-blood samples for propofol analysis 
were mixed thoroughly and stored at 4°C until analysis by high-performance 
liquid chromatography with fluorescence detection at 276 nm and 310 nm 
(within 1 month). With this method, the coefficients of variation for the intra-
assay and inter-assay precision were less than 4.5% and 7.1%, respectively, 
over the concentration range from 0.05 to 10.0 mg/L, and the lower limit of 
quantification was 0.05 mg/L (18-19).
Data analysis and internal validation
The analysis was performed by means of non-linear mixed-effects modelling 
using NONMEM (version VI, release 1.1; GloboMax LLC, Hanover, MD, 
US) (20) with S-plus (version 6.2; Insightful software, Seattle, WA, US) for 
data visualization. Discrimination between different models was made by 
comparison of the objective function value (OFV, i.e. −2 log likelihood). 
A significance level of p<0.05, corresponding to a decrease of 3.8 in OFV, 
was considered statistically significant. In addition, goodness-of-fit plots 
(observed versus individual-predicted concentration-time, observed versus 
population-predicted concentration-time, conditional weighted residuals 
versus time and conditional weighted residuals versus population-predicted 
concentration-time plots) were used for diagnostic purposes. Furthermore, 
the confidence interval of the parameter estimates, the correlation matrix 
and visual improvement of the individual plots were used to evaluate the 
models. The internal validity of the population pharmacokinetics and models 
was assessed by the bootstrap re-sampling method using 250 replicates (20). 
Parameters obtained with the bootstrap replicates were compared with the 
estimates obtained from the original dataset. 
Pharmacokinetic model
A two-compartment model and a three-compartment model were tested 
to fit the log-transformed propofol concentration data. The inter-individual 





      (Eq. 1)
where θmean is the population mean and ηi is a random variable with a mean of 
zero and variance of ω2, assuming log-normal distribution in the population. 
The intra-individual variability, resulting from assay errors, model 
misspecifications and other unexplained sources, was best described with 
a proportional error model. This means for the jth observed log-transformed 
propofol concentration of the ith individual, the relation (Yij) is described by 
equation 2: 
         
 
         (Eq. 2)
where Cpred is the predicted propofol concentration and εij is a random 
variable with a mean of zero and variance of σ2.
Covariate analysis
Covariates were plotted independently against the individual post hoc 
parameter estimates of all pharmacokinetic parameters and the conditioned 
weighted residuals to visualize potential relations. The Pearson’s correlations 
coefficient (r) was calculated and a p<0.05 was considered significant. The 
following covariates were tested: TBW, BMI, IBW (21) and LBW on the basis 
of Janmahasatian et al. (14) and LBW on the basis of Peters et al. (15), sex and 
age. Covariates were tested using linear and allometric equations (equation 
3):  




      (Eq. 3)
where Pi and Pp represent individual and population parameter estimates, 
respectively, Cov represents the covariate and Covstandard represents a 
standardized (i.e. 70 kg for TBW) or median value of the covariate for the 
population. The exponent z represents the exponential scaling factor, which 
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was fixed at 1 for a linear function or an estimated value for an allometric 
equation, while a 0.75 fixed value of the exponent was also tested (22). 
Potential covariates were separately entered into the model and statistically 
tested using the OFV and if applicable the 95% confidence interval values of 
the additional parameter. A p<0.005 was applied to evaluate the covariates 
in the forward inclusion (OFV decrease>7.9), while the backward deletion 
procedure used a stricter criterion (OFV decrease>10.8: p<0.001). When 
two or more covariates were found to significantly improve the model, 
the covariate causing the largest reduction in OFV was left in the model. 
Additional covariates had to reduce this OFV further to be retained in the 
model. The choice of the covariate model was further discussed in the Data 
analysis and internal validation section.
Comparison with non-obese children and adolescents
Individual clearance estimates obtained in this study were compared with 
propofol clearance values previously published in non-obese children by 
Schuttler and Ihmsen (6) and Kataria et al. (8), with TBW ranges of 12 – 61 
kg and 15 – 61 kg, respectively. Schuttler and Ihmsen (6) described propofol 
clearance as equation 4:, while Kataria et al. (8) expressed propofol clearance 
(CL) as equation 5: 
CL = 1.44 L/min*(TBW/70)0.75     (Eq. 4)
CL = 0.034 L/min*TBW      (Eq. 5)
When using the TBW range observed in the present study, these two different 
clearance equations were evaluated for their extrapolation potential to 
predict clearance estimates in morbidly obese children and adolescents.
           esults
Patients and data collection
A total of 23 morbidly obese pediatric patients were enrolled. One patient 
withdrew shortly before the procedure (no samples); and two patients were 
excluded because of missing data due to sampling errors. For the 20 patients 
included in the analysis 294 propofol concentration measurements were 
available. 17 patients were Caucasians and 3 patients were African-American. 
Morbidly obese patients had a mean TBW of 125 kg (range 70 – 184 kg) and 
a BMI of 46 kg /m2 (range 31 – 65 kg/m2). Demographic characteristics of the 
cohort are summarized in Table I. 
Parameter Mean (SD) Range
Sex (F/M) 12/8
TBW (kg) 125 (29) 70 – 184
BMI (kg/m2) 46 (9) 31 – 63
LBW Janmahasatian et al. (14) (kg) 63 (14) 38 – 85
LBW Peters et al. (15) (kg) 75 (14) 47 - 98
Age (y) 16 (2) 9 – 18
Table I  Baseline characteristics of 20 obese and morbidly obese children and 
adolescents.
BMI = body mass index; F = female; LBW = lean body weight; M = male; SD = standard deviation; TBW = 
total body weight.
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 Pharmacokinetics analysis
A two-compartment pharmacokinetic model most adequately described the 
time course of the propofol whole-blood concentrations in morbidly obese 
children and adolescents, parameterized in terms of volume of distribution 
of the central compartment (V1) and volume of distribution of the peripheral 
compartment (V2), intercompartmental clearance from the central 
compartment to the peripheral compartment (Q), and clearance from the 
central compartment (CL). The use of a three-compartment model did not 
result in an improved fit of the data and showed comparable estimates for 
propofol clearance to the two-compartment model. 
Table II shows the result of the step wise covariate analysis in which age and 
body size descriptors were separately tested using both linear and allometric 
functions for their influence on the pharmacokinetic parameters. The table 
shows that, in general, the influence of covariates on CL resulted in a larger 
decrease in OFV than V1. The equation to estimate LBW for children by 
Peters et al. (15) showed a significantly (p<0.005) larger decrease in OFV 
than the equation by Janmahasatian et al. (14). TBW and BMI as covariate on 
propofol clearance reduced the OFV further (Table II). As BMI consists of two 
parameters (i.e. height and TBW) and there was no significant difference in 
OFV between the TBW models and the BMI model, a model based on TBW 
was preferred over the BMI model. Using TBW as covariate for clearance, 
both linear and allometric functions were tested and showed a comparable 
decrease in OFV value compared with the base model (Table II). Similar 
results were obtained for allometric functions using an estimated exponent 
(0.80) and a fixed exponent of 0.75 (Table II). As there were no differences 
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which the allometric exponent was estimated, resulting in the final equation 
(equation 6:
CLi = CL70 kg • (TBWi/70)0.8      (Eq. 6)
where CLi represents clearance in the ith individual, CL70 kg is the population 
mean value for clearance in an individual of 70 kg, TBWi is the total body 
weight of the ith individual and 70 is the standard TBW in kilograms. Figure 1 
shows the individual post hoc estimates for propofol clearance against TBW. 
Concerning covariates for V1, Table II shows there was only modest influence 
of age and body size descriptors on V1: more specifically, a trend toward 
an increase in V1 with TBW was observed (p>0.005). This observation was 
confirmed when the individual post hoc estimates for V1 were plotted against 
TBW (Figure 1), showing a non significant Pearson’s correlation coefficient 
of 0.300 (p=0.199). There was no influence of the explored covariates and 
the other pharmacokinetic parameters (Q2 and V2) (data not shown). 
The pharmacokinetic parameter estimates of the final model in which 
clearance is normalized to TBW using an allometric function are shown in 
Table III. Compared with the base model, the interindividual variability of 
clearance was reduced by 33% in the final model (from 26.3% to 17.5%; Table 
III). The diagnostic plots of the final model proved superior to the base model, 
especially for the population predictions versus observed concentrations 
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r = 0.721 (p < 0.001)
Total body weight (kg)
Figure 1 Individual post hoc estimates for clearance (left) and central volume of distribution (right) of 



















































































































































Figure 2 Diagnostic plots for propofol pharmacokinetics in morbidly obese children and adolescents showing 
(A) individual log-normal propofol predictions versus observed logarithmic propofol concentrations and (B) 
population model log-normal propofol predictions versus observed log-normal propofol concentrations for 
the base and final total body weight (TBW) model. The solid line indicates the trend line, the dashed line 
represents the line of identity, x=y. ln = log-normal.
Figure 3 Propofol concentration time relationships for the best (Age = 15 years old, TBW = 143 kg, BMI = 44 
kg/m2) (A) and worst (Age = 15 years old, TBW = 145 kg, BMI = 54 kg/m2) (B) final TBW model predictions. The 
solid circles represent the measured propofol concentrations, the dotted lines represent the concentrations 
predicted by the population model and the solid black line represents the concentrations predicted using 
individual post hoc parameter estimates. ln = log-normal.
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the individual propofol concentrations for the morbidly obese children 
and adolescents. The stability of the final TBW model was shown by the 
bootstrap analysis (Table III).
Comparison with non-obese children and adolescents
Figure 4 shows a comparison of the present results of propofol clearance 
(CL) values versus TBW in morbidly obese children and adolescents, and the 
extrapolated equations of Kataria et al. (8) (equation 5) and Schuttler and 
Ihmsen (6) (equation  4) which were both derived from non-obese children. 
This figure shows that extrapolating the equation of Kataria et al. (8) to 
morbidly obese children and adolescents would result in overestimation 
of propofol clearance values for this group. In contrast, the equation of 
Schuttler and Ihmsen (6) would only slightly underestimate propofol 
clearance in morbidly obese children and adolescents. 




Number of patients 20 20
CL (L/h) 161 (6.0)
CL70kg (L/h)
b 103 (4.5) 102 (4.9)
V1 (L) 45.5 (19.2) 45.2 (19.5) 43.5 (21.4)
V2 (L) 126 (14.6) 128 (14.8) 134 (21.0)
Q (L/h) 107 (13.2) 105 (12.5) 109 (14.2)
OFV -401 -414 -424
Interindividual variability (%)
CL 26.3 (36.5) 17.5 (35.5) 17.3 (41.5)
V1 58.6 (38.0) 61.0 (38.3) 63.1 (47.7)
Proportional intra-individual error (%) 25.7 (19.2) 25.6 (19.1) 25.6 (19.6)
Table III  Population pharmacokinetic parameters for the base model and final total 
body weight (TBW) model for propofol in 20 morbidly obese children and adolescents.
a  The data are expressed as mean (%CV) unless specified otherwise.
b CLi = CL70kg * (TBW/70)0.8
CL = clearance; CL70kg  = clearance in an individual of 70 kg; CLi = clearance in the ith individual; CV 
= coefficient of variation of the parameter values; OFV = objective function value; Q = compartmental 
clearance between V1 and V2; TBW = total body weight; V1 = central volume of distribution; V2 = peripheral 























Total body weight (kg)
Figure 4 Propofol clearance (CL) values versus TBW for morbidly obese children and adolescents of the 
present study (black line) and models of Kataria et al. (8) and Schuttler and Ihmsen (6) (grey lines). The black 
line indicates population clearance values for morbidly obese children and adolescents obtained in this study 
(CL = 1.70 L/min * (TBW/70)0.8); black circles indicate individual post hoc clearance values from morbidly 
obese children and adolescents of the present study; grey lines indicate the linear model of Kataria et al. (8) 
and the allometric model of Schuttler and Ihmsen (6) in the TBW ranges of these studies; grey dotted lines 
indicate the estimations after extrapolation of the Kataria et al. (8) and Schuttler and Ihmsen (6) equations 
to the TBW range (70 – 184 kg) of the present study in morbidly obese children and adolescents.
D  
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            iscussion
In order to study the influence of obesity on the pharmacokinetics of propofol 
in morbidly obese children and adolescents, a population pharmacokinetic 
model was developed, in which clearance proved to scale best with TBW in 
an allometric function.
While there are no other reports on propofol pharmacokinetics in obese 
children, previous reports describing the best body size descriptor for 
propofol clearance in adults seem to be conclusive. Servin et al. were the 
first reporting an increase in propofol clearance with TBW in obese adults 
(11). More recently in two prospective studies, TBW was reported the best 
body size descriptor for propofol clearance in (morbidly) obese adults 
(12-13). TBW proved to be superior to LBW in morbidly obese adults (13) 
even though LBW had been proposed to capture the nonlinear increase in 
propofol clearance in adults (23). In the present study, lean body weight 
estimated by the equation of Peters et al. (15) developed for children, was a 
better body size descriptor than lean body weight estimated by the equation 
of Janmahasatian et al. (14) which had been developed for adults. While 
testing all available body size descriptors, and in accordance with findings 
in morbidly obese adults, we found that TBW was the best descriptor for 
propofol clearance in morbidly obese children and adolescents. 
The observed increase in propofol clearance with TBW in morbidly obese 
children and adolescents was described with an allometric function using an 
estimated scaling factor of 0.8. An allometric function with a scaling factor 
of 0.75 is often used to describe the increase of drug clearance values with 
TBW in children, albeit not without debate (24-26). In contrast, for propofol 
clearance in non obese children, both a linear (exponent = 1.0) (8, 27) and an 
allometric function with an exponent of 0.75 (6) has been applied. Aprioiri 
use of a fixed exponent of 0.75 in obese patients would imply that obese 
individuals can be viewed as ‘large individuals’ (a different body size) instead 
of individuals ‘having excess body fat’ (a different body composition) (28). 
For morbidly obese adults an exponent of 0.72 (13) and 0.75 (12) has been 
described. It is however unknown whether these exponents can be used for 
different age ranges i.e. in children. In the present study in morbidly obese 
children and adolescents we estimated a scaling factor of 0.8 which was 
not significantly different from a linear function or fixed exponent of 0.75. 
It therefore seems that a larger study with a wider range in age and TBW is 
needed to conclude on the allometric exponent in morbidly obese children 
and adolescents. 
The present study shows that for morbidly obese children and adolescents the 
equation for propofol clearance as proposed by Schuttler et al.(6) is superior 
to the equation of Kataria et al. (8). The latter which is widely used for target 
controlled infusion (TCI). Extrapolated clearance values using the Kataria et 
al. model (8) show an substantial overestimation of propofol clearance while 
the model of Schuttler et al. only results in a small underprediction (Figure 
4). Besides, it has been shown in non obese children by Coppens et al. that 
the model of Kataria et al. was more biased and inaccurate compared to 
the other available pharmacokinetic models in children such as the model 
of Schuttler et al. (29). However, it should be emphasized that the current 
result only applies to propofol clearance and not to other pharmacokinetic 
parameters. Even though propofol TCI is often applied, the current available 
models are not suitable for morbidly obese children, adolescents or adults 
(13). The developed population model of propofol in morbidly obese children 
and adolescents provides a starting point to be considered for TCI in this 
population.     
This study had a few limitations. We investigated a small cohort of 20 
morbidly obese children and adolescents that included patients with a TBW 
range of 70 – 184 kg and an age range of 9 – 18 years. As mostly patients 
with an age of 16 years old were included in this study, more data is needed 
to describe the influence of excessive overweight for the total age range. In 
addition, for practical reasons we applied an early sampling strategy that did 
not allow us to adequately capture propofol’s rapid initial distribution phase 
(three-compartment model) and to characterize a possible influence of 
excessive body weight on V1. Finally, in order to develop an integrated PK/PD 
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dosing algorithm for propofol in morbidly obese children and adolescents, 
a pharmacodynamic marker, such as BIS monitoring, is urgently needed. 
A prospective study taking into account these concerns is currently being 
planned to evaluate an allometric dosing regimen for propofol in obese and 
morbidly obese children and adolescents based on TBW and BIS monitoring. 
            onclusion 
A pharmacokinetic model for propofol in obese and morbidly obese children 
and adolescents has been derived with total body weight as the major 
determinant for clearance using an allometric function. As a result, it is 
anticipated that propofol for maintenance of anesthesia in morbidly obese 
children and adolescents should be dosed on the basis of total body weight 
in an allometric fashion.
C  
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              bstract 
This study describes a population pharmacokinetic meta-analysis of propofol 
to characterize the influence of body size measures and age in morbidly 
obese and non-obese adults, adolescents and children. Sixty morbidly obese 
and non-obese adult patients (55 – 167 kg, 21 – 79 years) and 34 morbidly 
obese and non-obese adolescents and children (37 – 184 kg, 9 – 20 years) 
were included. The results show that clearance increased with total body 
weight in an allometric function while age was found to influence clearance 
in a bilinear fashion with two distinct slopes, reflecting an initial increase 
and subsequent decrease as a result of aging. Using these two functions, 
the influence of both (over)weight and age on propofol clearance was well 





           ackground  
While total body weight of children and adolescents increases due to 
growth-related processes across childhood, obesity may also substantially 
contribute to increases in body weight (1). As a result, morbidly obese 
children and adolescents may be as heavy as adults, even though growth-
related processes have not yet been completed. The question then arises 
whether total body weight, which is commonly used to adjust dosing in 
children and adolescents, is the appropriate measure to adjust doses of 
drugs in obese children and adolescents. Similarly for adults, there is a lively 
discussion about the best size descriptor for changes in pharmacokinetics due 
to obesity (2, 3). As little is known on how key pharmacokinetic parameters 
such as clearance change in morbidly obese children, adolescents and adults 
compared to their non-obese controls, studies are needed analyzing a wide 
range of ages and related total body weights. 
Propofol is widely used for induction and maintenance of anesthesia in both 
non-obese and (morbidly) obese adults, adolescents and children. Recently, 
the pharmacokinetics of propofol have been compared in premature 
neonates and adults (4), in morbidly obese and obese adults (5, 6) and in 
(morbidly) obese children and adolescents (7). In all these studies, total 
body weight proved the most predictive covariate for clearance, either by 
using a standard allometric function (5-7) or a total body weight dependent 
exponent allometric function (4). However, a meta-analysis on the basis of 
all datasets in morbidly obese adults, adolescents and children together 
with their non-obese controls in which the influence of obesity and ageing is 
disentangled has not been performed.
Therefore, the aim of this study was to perform a population pharmacokinetic 
meta-analysis of propofol combining data from morbidly obese and non-
obese adults, adolescents and children. In order to study how obesity and 
age influence pharmacokinetic parameter estimates in this diverse patient 
group, specific emphasis was placed on the evaluation of the influence of 
total body weight (TBW), body mass index (BMI), ideal body weight (IBW) (8), 
lean body weight (LBW) (9, 10) and/or age on the different pharmacokinetic 
parameters. 
 
                ethods
Patients
Data of five previously published studies were used for this analysis (6, 7, 11-
13). Patient characteristics of the five different studies are provided in Table 
I. Details of the studies are briefly summarized when relevant to the current 
analysis.
Morbidly obese adults (6) 
Twenty morbidly obese adults scheduled for bariatric surgery with a mean 
total body weight of 124 kg (range 98 – 167 kg) received either a propofol 
induction dose of 200 mg or 350 mg. Maintenance propofol infusion rate 
was initiated at 10 mg/kg times total body weight and adjusted in order to 
keep Bispectral index (BIS) values between 40 and 60 (6). 
Non-obese adults (11, 12)  
Forty non-obese adults with a mean total body weight of 74 kg (range 55 – 
98 kg) were included. Twenty-four female patients received a bolus injection 
of 2.5 mg/kg of propofol for induction of anesthesia while anesthesia was 
maintained with isoflurane (11). Of these twenty-four patients, twenty 
patients were included from this study as a height measure of four patients 
was not available. Another twenty non-obese intensive care patients 
received continuous propofol infusions for 2-5 days with propofol doses 
based on the Ramsay six-point scale (12).
Morbidly obese children and adolescents (7)
In twenty morbidly obese adolescents and children scheduled for bariatric 
surgery with mean total body weight 125 kg (range 70 – 184 kg) and mean 
age of 16 years old (range 9 – 18 years) propofol was dosed using dosing 
weight calculated according to the method of Servin et al. (7, 14).
Non-obese children and adolescents (13)
In fourteen non-obese adolescents and children with mean total body 
weight of 54 kg (range 37 – 82 kg) and a mean age of 14 years old (range 
9 – 20 years), anesthesia was induced with a bolus dose of propofol (4 mg/
kg) and maintained with propofol by continuous infusion (2 – 10 mg/kg/h) for 
scoliosis surgery (13). 
B  M 
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Data analysis and internal validation
The analysis was performed by means of non-linear mixed-effects modeling 
using NONMEM (version VI, release 1.1; GloboMax LLC, Hanover, MD) (15) 
with S-plus (version 6.2; Insightful software, Seattle, WA) to visualize the 
data. Discrimination between different models was made by comparison of 
the objective function value (-2 log likelihood (OVF)). A value of p < 0.05, 
representing a decrease of 3.8 in the OVF, was considered statistically 
significant. In addition, goodness-of-fit plots (observed versus individually 
predicted, observed versus population predicted, conditional weighted 
residuals versus time and conditional weighted residuals versus population 
predictions) were used for diagnostic purposes. Furthermore, the 
confidence interval of the parameter estimates, the correlation matrix, and 
visual improvement of the individual plots were used to evaluate the model. 
η-shrinkage as defined by Karlsson et al. (16), was calculated for all model 
parameters for which interindividual variability was estimated. The internal 
validity of the population pharmacokinetic models was assessed by a per 
study stratified bootstrap re-sampling method using 250 replicates (15). 
Pharmacokinetic model
Log transformed propofol concentration data were described by a three-
compartment model (NONMEM VI, ADVAN11, TRANS4) parameterized in 
terms of volume of distribution of the central (V1), first (V2), and second 
peripheral compartment (V3), intercompartmental clearance from the 
central to the first (Q2) and from the central to the second (Q3) peripheral 
compartment, and clearance from the central compartment (CL). 
The interindividual value (post hoc value) of the parameters of the ith subject 
was modeled by: 
 
                
        (Eq. 1)
where θmean is the population mean and ηi is a random variable with mean 
zero and variance ω2, assuming lognormal distribution in the population.  
The intra-individual variability, resulting from assay errors, model 
misspecifications, and other unexplained sources, was best described with 
a proportional error model. This means for the jth observed log transformed 
propofol concentration of the ith individual, the relation (Yij): 
         
         (Eq. 2)
where cpred is the predicted propofol concentration and εij is the random 
variable with mean zero and variance σ2.
Covariate analysis
Covariates were plotted independently against the individual post hoc 
parameter estimates of all pharmacokinetic parameters and the conditioned 
weighted residuals to visualize potential relations. The following covariates 
were tested: total body weight (TBW), body mass index (BMI), ideal body 
weight (IBW) (8) and lean body weight (LBW) (9, 10), gender and age. 
Covariates were tested using linear and power equations:  
        (Eq. 3)
in which Pi and Pp represent individual and population parameter estimates, 
respectively, Cov represents the covariate and Covstandard represents a 
standardized (i.e. 70 kg for TBW) or median value of the covariate for the 
population. z represents the scaling factor, which was fixed to 1 for a linear 
function or an estimated value for a power equation. 
The influence of the covariate age on clearance was also tested using a 
bilinear function with two distinct slopes, i.e. a linear increase in clearance 
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Number 94 20 40 20 14
Gender (M / F) 30/64 4/16 16/24 8/12 2/12
Age (years) 38 (20) 45 (12) 55 (12) 16 (2) 14 (3)
TBW (kg) 94 (35) 124 (20) 74 (11) 125 (29) 54 (13)
BMI (kg/m2) 33 (12) 43 (6) 26 (4) 46 (9) 21 (6)
IBW (kg) 61 (9) 61 (7) 64 (8) 59 (12) 55 (9)
LBW (kg) 54 (14) 60 (9) 50 (10) 63 (14) 37 (8)
Table I  Baseline characteristics of all morbidly obese and non-obese adults, 
adolescents and children included in the current analysis. Data are presented as 
mean with standard deviation (SD).
BMI = body mass index; IBW = ideal body weight (8); F = female; LBW = lean body weight (9); M = male; SD 
= standard deviation; TBW = total body weight. 
Θi =Θmean ∗e
ηi
Yij = logCpred,ij +εij






for age values below the median age and a linear decrease in clearance for 
age values higher than the median age (17) (Equation 4). 
CLi = CLpop * Fage       (Eq. 4)
Fage (age ≤ median age) = (1 + b * (age – median age)) 
Fage (age > median age) = (1 + c * (age – median age))
Potential covariates were separately entered into the model and statistically 
tested by use of the objective function value (OFV) and if applicable the 95% 
confidence interval of the additional parameter. A p < 0.005 was applied to 
evaluate the covariates in the forward inclusion (OFV decrease > 7.9), while 
the backward deletion procedure used a stricter criterion (OFV decrease > 
10.8; p < 0.001). When more than one significant covariate for the simple 
model was found, the covariate-adjusted model with the largest decrease 
in objection function was chosen as a basis to sequentially explore the 
influence of additional covariates using the same criteria. Finally, after 
forward inclusion, a backward exclusion procedure was applied to justify 
the covariate. The choice of the covariate model was further evaluated as 
discussed under Data analysis and internal validation.
            esults
Subjects
Ninety-four adults, adolescents and children with a mean total body 
weight (TBW) of 94 kg (range 37 – 184 kg) were included from which 1652 
concentration measurements were available. Demographic characteristics 
of the morbidly obese patients and non-obese patients are summarized in 
Table I. 
Pharmacokinetics
A three-compartment pharmacokinetic model adequately described the 
time course of the propofol whole blood concentrations in all morbidly 
obese and non-obese adults, adolescents and children. Exploratory plots of 
the tested covariates total body weight, body mass index, ideal body weight, 
lean body weight and age against individual post hoc parameter estimates of 
the simple model without covariates (Model A) showed a potential relation 
between clearance and total body weight, with lower values for children 
and adolescents across the entire body weight range (Figure 1, model A). In 
R 
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Figure 1 Individual post hoc propofol clearance estimates (symbol) versus 
total body weight for the simple model (model A) and three covariate pharmacokinetic models (B, C and D) 
for morbidly obese adults (black circles), adolescents and children (grey circles) and their non-obese controls 
(n=94). In model B, the black line indicates the population clearance values for both the adult and adolescent 
population, in model C the black line indicates the population clearance values for adults and the grey line 
the population clearance values for adolescents and in model D the black dotted lines indicate the population 
clearance values for 15, 41 and 65 years.
addition, potential relationships were observed between central volume of 
distribution (V1) and total body weight or lean body weight, and between 
intercompartmental clearance from the central to the second peripheral 
compartment (Q3) and total body weight (figures not shown). There were no 
visual trends between the explored covariates and other pharmacokinetic 
parameters in the simple model without covariates (model A). 
Subsequently, as depicted in Table II all body size measures and age were 
separately incorporated on clearance, central volume of distribution and 
Q3 in the model and tested for significance (see section Methods, covariate 
analysis). The analysis showed that total body weight was the most predictive 
covariate for propofol clearance when implemented using an allometric 
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p<0.001, Table II). Figure 1 model B (and model A), shows that adolescents 
with the same total body weight as adults had lower clearance values 
(grey versus black symbols, respectively). Therefore, in model C a separate 
value for propofol clearance in adolescents versus adults was estimated. 
This resulted in another reduction in OFV with 23.5 points (p<0.001) with 
individual clearance values for an adolescent of 70 kg and an adult of 70 kg 
of 1.75 mL/min and 2.18 mL/min, respectively (Table II, Model C). The non-
linear increase of propofol clearance with total body weight proved the 
same for both groups and was best described using an allometric function 
with an estimated exponent of 0.73 (CV% 6.9) (Figure 1, Model C). 
However, when the simple model without covariates was evaluated for the 
effect of age (Figure 2, left panel), it was found that clearance increased until 
the median age of 41 years after which it decreased. As a result, instead of 
estimation of two different population values for adolescents versus adults as 
in model C, in model D age was implemented using a bilinear function which 
significantly reduced the OFV (∆OFV compared to model C = -8.2 points, 
p<.0.005). On the basis of the covariates of model D, the interindividual 
variability of propofol clearance was reduced by 50%. Figure 2 right panel, 
shows that after implementation of age in a bilinear function, interindividual 
variability was randomly distributed with age. Figure 1, model D, shows the 
post hoc propofol clearance estimates for model D versus total body weight 
with population predictions for clearance for three different ages (15, 41 
and 65 years), illustrating the bilinear relation with age in model D. The final 
equation for propofol clearance was (Equation 5):
CLi = CLpop • (TBWi/70)0.77 * Fage*    (Eq. 5)
* Age ≤ 41 y: Fage = (1 + 0.0103 * (Age - 41)) 











































Figure 2 Interindividual variability of propofol clearance versus age for the simple model without covariates 
(Model A) and the final covariate model including age and total body weight on propofol clearance (Model E).
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where CLi represents clearance in the ith individual, CLpop is the population 
mean value for clearance in an individual of 70 kg and of 41 years, TBWi is the 
total body weight of the ith individual and 70 is the standard body weight in 
kilograms. 
Concerning covariates for V1, Table II shows there was only a modest 
influence of the body size descriptors on V1 with a trend towards an increase 
in V1 with lean body weight (p>0.005). There was substantial shrinkage (43%) 
on V1, which renders not only plots using post hoc parameter estimates 
less reliable but also indicates that the individual data in the datasets are 
not rich in information about this parameter (18). Therefore, no covariate 
on V1 was incorporated in the final model. In contrast, total body weight as 
covariate for intercompartmental clearance from the central to the second 
peripheral compartment (Q3) significantly improved the model (∆OFV 
= -18.1, p<0.005) (Table II) and was therefore considered the final model 
(model E, Table II). There was no influence of the explored covariates on the 
other pharmacokinetic parameters (Q2 and V2). 
Figure 3 Observed versus population predicted ln propofol concentrations of the final model (Model E). 
Panels represent data of morbidly obese adults, non-obese adults, morbidly obese children and adolescents 
and non-obese children and adolescents. The solid grey line represents the line of identity, x=y.
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Figure 4 Model based predictions of population clearance estimates of propofol versus age for patients with 
different total body weights.
Table III lists all parameter estimates including their coefficients of variation 
(CV values) and objective function values of the simple model (Model A) and 
the final model (model E). The observed versus population predicted plots 
stratified by the different cohorts in Figure 3 confirm that the final model not 
only describes the study population as a whole, but also the individual study 
populations without bias. The stability of the final model was shown by the 
bootstrap analysis (Table III). 
Figure 4 shows population propofol clearance values versus age for different 
total body weights using the final model E. This figure shows both the 
allometric increase of propofol clearance with total body weight as the 
distance between the weight classes decreases with increasing total body 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































07  PK meta-analysis of propofol  
160 161
02
            iscussion
In order to describe the influence of obesity and age on the pharmacokinetics 
of propofol, a population pharmacokinetic meta-analysis was performed 
using data from morbidly obese adults, adolescents and children, and 
their non-obese controls. In the current study, a wide range in total body 
weight (37 – 184 kg) and age (9 – 79 years) was studied, with data from 
(morbidly) obese and non-obese individuals in each age range. The results 
of the systematic analysis shows that a combination of total body weight 
and age proved to best capture changes in propofol clearance as a result of 
obesity and ageing. While it is yet unknown how these results should be put 
in physiological perspective, the current model seems to provide the best 
description of the data from these largely divergent patient populations. 
In recent reports in (morbidly) obese adults it was shown that the increase 
in propofol clearance was related to total body weight and could be best 
described using an allometric function (5, 6). In addition, an allometric 
relationship between total body weight and propofol clearance was found 
in a dataset of morbidly obese adolescents (7). Allometric scaling factors of 
0.72 (6) and 0.80 (7) were estimated for morbidly obese adults and children 
and adolescents, respectively. As these factors are close to the factor of 0.75 
predicted by allometry theory (19), this implies that obese individuals can 
be viewed as ‘large individuals’ (a different body size) instead of individuals 
‘having excess body fat’ (a different body composition) (2). While these 
results were confirmed in the current meta-pharmacokinetic analysis, we 
also showed that morbidly obese adolescents cannot be viewed as ‘adults’ 
as their propofol clearance proved lower than that of morbidly obese 
adults with the same total body weight (Figure 1, model A). This difference 
in propofol clearance could be described with two separate functions for 
propofol clearance; i.e. one equation for children and adolescents and one 
equation for adults (model C). Alternatively and significantly better, age was 
incorporated as covariate on propofol clearance using a bilinear function 
(model D and E). Therefore in the final model, the influence of age and 
obesity on propofol clearance was described using both total body weight 
and age as covariates for propofol clearance. This final equation (equation 
5) is independent of the definitions for age (e.g. adolescents and adults) and 
obesity (e.g. obese and morbidly obese) categories and might prove useful 
for clinical practice. 
In the current study, there was no significant relationship between body size 
measures and volumes of distribution. Previously, age and total body weight 
have been identified as covariates for volumes of distribution of propofol 
D  
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in non-obese and obese patients (5, 14, 20). As a result of the finding that 
lean body weight correlated with central volume of distribution, Ingrande et 
al. suggested to use lean body weight for the induction of anesthesia with 
propofol (21). The lack of significant influence of lean body weight on volume 
of distribution in our analysis may be explained by the fact that the studies 
included in the current analysis mainly contained observations following 
propofol maintenance infusions. As such these datasets did not contain 
sufficient observations just after the induction bolus dose of propofol to 
adequately describe early (re-)distribution and the influence of covariates 
on volumes of distribution. It therefore seems that additional research is 
needed to characterize covariates predictive of volume of distribution that 
will allow estimation of propofol loading doses in morbidly obese adults and 
children.
It remains to be speculated how the influence of total body weight on 
propofol clearance that was found in our study can be explained. Studies 
have shown that obese patients suffer from low-grade inflammation (22), 
which is probably the underlying cause of the high prevalence of non-
alcoholic steatohepatitis (23). It is known that non-alcoholic steatohepatitis 
increases fat deposition in the liver causing sinusoidal narrowing and 
altered functional morphology of the liver (24). In contrast, because of 
increased blood volume and cardiac output, hepatic blood flow is possibly 
increased in obese subjects (25). As a result, increased propofol clearance 
may be anticipated as propofol is a high extraction ratio drug (26) mainly 
metabolized by various UDP-glucuronosyltransferase (UGT) enzymes (27). 
Data on other high extraction drugs and drugs metabolized by UGT suggest 
that both UGT activity (28-30) and liver blood flow (31, 32) are increased in 
obese adults. Furthermore, UGT activity is increased in obese adolescents 
compared to non-obese adolescents (33). Even though this cannot be proven, 
it can be hypothesized that hepatic blood flow is even more increased due 
to prolonged duration of obesity in adults compared to adolescents with 
the same total body weight. This is supported by the fact that age could 
be incorporated as covariate on propofol clearance. As propofol clearance 
is limited by the blood flow through the liver, the effect of both total body 
weight and age on propofol may be explained by changes in liver blood flow. 
            onclusion
In this pharmacokinetic meta-analysis, we developed a model for scaling 
propofol clearance over wide ranges of total body weight and age using 
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non-obese controls. The results show that total body weight was the 
most predictive covariate for propofol clearance across patients when 
implemented as an allometric function. In addition, age was incorporated 
using a bilinear function with two distinct slopes, reflecting an initial increase 
and subsequent decrease in clearance as a result of age. Using these two 
functions, the influence of both (over)weight and age on propofol clearance 
was well characterized, which may provide a basis for dosing across this 
diverse group of patients.
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The influence of 
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              bstract 
The low-molecular-weight heparins are effective as initial therapy for 
pulmonary embolism (PE) in a weight-based dosing regimen up to known 
total body weights of 160 kg. 
The present case reports an extremely obese man of 252 kg (body mass 
index (BMI) 74 kg/m2) with PE who was treated with tinzaparin, dosed on a 
total body weight of 160 kg.
Morbid obesity defined as a BMI higher than 40 kg/m2 is becoming more 
common in general practice, but there are no evidence-based drug dosing 
strategies for these patients. 
This case demonstrates the successful use of a maximum dose of 28,000 
anti-Xa international units of tinzaparin for an extremely obese patient with 





            ase report
A 47-year-old male patient weighing 252 kg, who was scheduled for bariatric 
surgery later that year, was admitted to our hospital because of chest pain 
radiating to his left arm and acute dyspnea. The pain was not exercise-
related and treatment with nitroglycerin did not relieve the symptoms. The 
patient’s weight increased over the last few years; the actual body mass 
index (BMI) was 74 kg/m2 at presentation. His medical history included gout, 
systemic hypertension, primary hyperventilation syndrome, appendectomy 
and cholecystectomy. The patient acknowledged being a smoker (25 
cigarettes/day). There was no history of deep vein thrombosis or pulmonary 
embolism (PE). 
Upon arrival in the emergency room, his blood pressure was 160/75 mm Hg 
with a pulse rate of 75 bpm, a temperature of 37.2 ºC and an arterial oxygen 
saturation of 94% with support of 1 L/min of oxygen. When the patient 
was breathing room air the saturation dropped to 84 %. The laboratory 
results showed increased D-dimer levels of 2,749 µg/L (0-250 µg/L), a pro-
B-type natriuretic peptide value of 75 pg/mL (< 88 pg/mL), a glucose level 
of 6.1 mmol/L and a serum creatinine level of 72 µmol/L. After medical 
examination, there were no clinical signs of deep venous thrombosis, like 
leg pain or other signs of thrombophlebitis in the lower limbs or presence of 
varices expect edema in both ankles due to morbid obesity.
Pulmonary embolism was suspected and a lung ventilation and perfusion 
scan was performed because the patient was unable to pass the CT-
scan. The perfusion scan performed with 192 MBq (instead of 100 MBq) 
macroaggregates of albumin labelled with Technetium-131 (TechneScan® 
LyoMAA) and the ventilation scan performed with Krypton-81m gas 
confirmed the diagnosis of PE, with more than two lung segments showing 
no perfusion and normal ventilation.  
According to the local protocol, the patient was treated with tinzaparin. 
Due to overall stability of the patient and in accordance to the guidelines 
of the American College of Chest Physicians, no further interventions were 
considered (1). Tinzaparin was started 3 h after admission with a dose of 175 
IU anti-Xa/kg subcutaneously, according to the labelled dose of tinzaparin, 
which resulted for this total body weight of 252 kg in a total dose of 42,000 
IU (2.7 ml). In consultation with the Department of Clinical Pharmacy, it was 
then decided to continue with a once daily dose of 28,000 IU anti-Xa a day 
(175 IU/kg dose capped at 160 kg instead of 252 kg), because 175 IU/kg based 
on a total body weight of 160 kg had previously been reported to be safe 
and effective and because it was assumed that a total body weight above 
160 kg would not influence the clearance nor the volume of distribution of 
tinzaparin any further (2-4). In addition to this dosing advice, anti-Xa activity 
measurement was proposed to monitor the effect of this dose, thereby 
preventing concentrations lower than 0.5 IU/mL 4-5 h after the s.c. dose (5) 
and targeting at a concentration of 1-2 IU/mL 4-5 h after the s.c. dose at day 
3 of treatment (6). Plasma levels of anti-Xa activity were measured with a 
STA-Rack Evolution (Diagnostica Stago, Asnières, France) using an anti-Xa 
clotting assay (StaClot®Heparin, Diagnostica Stago, Asnières, France). The 
anti-Xa assay standard calibration curve of tinzaparin ranged from 0 to 1.5 
IU/mL. The within assay and among assay precision (coefficient of variation) 
were 4.7% and 4.9%, respectively. Also on day 1, 6 mg of acenocoumarol 
was administrated orally and adjusted based on the measured prothrombin 
time (PT/INR) (Table I). 
During and following treatment with tinzaparin and acenocoumarol, the 
patient was relieved from his pain after 2 days and supplemental oxygen 
could be stopped after 4 days because he recovered from his dyspnea 
symptoms. Anti-Xa levels remained within the predetermined target 
values (Table I). No bleeding, bruising events or other complications 
occurred.  He was discharged after 5 days when an adequate PT/INR > 2.0 
was established (Table I). Both acenocoumarol and tinzaparin (for 3 more 
days) were continued after discharge. Three days after his discharge, the 
patient was readmitted because of constipation. During this readmission 
anti-Xa levels were measured after his last dose of tinzaparin (Table I). 
Five months after this event, the patient was stable without clinical signs 
of venous tromboembolism, and no additional coagulation testing was 
used to determine the presence of any ongoing thrombotic activity. Gastric 
bypass surgery was performed after which the patient recovered and was 
discharged.
 
            iscussion
Obesity is an increasing health risk worldwide, with the US, UK and Australia 
recording a prevalence in adults of around 20 % (7). Approximately 4.8 % 
of the overall population are considered to be morbidly obese with a 
BMI higher than 40 kg/m2 (8-9). While in the overall population in the US 
pulmonary embolism (PE) resulted in approximately 200,000 deaths in 
20 years (10), prospective data indicate that obesity is associated with an 
increased risk for a PE in women (11). In the treatment and prevention of PE, 
low-molecular-weight heparins (LMWH) have proven to be effective (12-13) 
and tinzaparin once daily is labelled for the treatment of PE. According to 
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anti-Xa (IU/mL) Acenocoumarol 
(mg)
PT/INR
1 2:00      
1 5:00 42,000 166.3    
1 20:00   0.54 (= A)   
1 22:00 28,000 110.9  6  
2 8:00   0.72 (= B)  1.1
2 16:00 28,000 110.9    
2 22:00    4  
3 8:00 28,000 110.9    
3 13:40   1.34 (= C)   
3 22:00 28,000 110.9  2  
4 8:00     1.8
4 22:00 28,000 110.9  3  
5 8:00     2.1
5 22:00 28,000 110.9  3  
6 8:00      
6 17:00 28,000 110.9  3  
7 8:00      
7 17:00 28,000 110.9  2  
8 8:00     3.1
8 20:00 28,000 110.9  2  
9 8:00     2.7
9 14:00   0.28 (= D)   
9 20:00    2  
10 8:00     2.3
Table I   Tinzaparin and acenocoumarol doses and anti-Xa and PT/INR levels in the 
252 kg patient.
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the label, tinzaparin dose corresponds to 175 IU/kg and should be based on 
the actual total body weight of the patient (14).  
However, no dosing guidelines are available for the treatment of PE in 
extremely obese patients.  Previously, reports of tinzaparin provided 
information that a safe and effective use of 175 IU/kg total body weight 
could only be guaranteed for total body weights up to 160 kg (2). A similar 
linear weight-based dosing regimen using once daily dalteparin has been 
proposed before, but total body weights were restricted to a maximum of 
190 kg and the indication was treatment of venous tromboembolism instead 
of PE  (14-15). Also for enoxaparin linear weight-based schemes have been 
reported up to a total body weight of 165 kg for the treatment of acute 
venous thromboembolism (16), which is similar to  the proposed weight-
based regimen for nadroparin in the prophylaxis of tromboembolism in 
obese patients up to a total body weight of 152 kg (17). The patient described 
in this report weighs over 250 kg, which results in a very high dose when total 
body weight is used for calculation of the dose, thereby potentially leading 
to bleeding risks. Therefore a fixed dose, capped at a 160 kg was considered, 
similar to a previously proposed dosing regimen for enoxaparin, e.g. a 
standard dose of 40 mg for a BMI up to 50 kg/m2 and 60 mg enoxaparin for a 
BMI higher than 50 kg/m2 (18). For the same reasons of safety issues, more 
recently, a dosage based on lean body weight (LBW) has been proposed (19), 
which results in lower dosages compared to calculations based on total body 
weight in extremely obese patients such as in our case. LBW is based on sex, 
weight and height and does not linearly increase with total body weight and 
is therefore expected to correlate better with the clearance of LMWHs (20). 
However, this study was performed in only 11 patients with a maximum total 
body weight of 120 kg, and therefore, the wide introduction of LBW as a 
basis for dosing in extremely obese patients may be too early. Beside safety 
issues, the final decision to administer a dose capped at a total body weight 
of 160 kg was also based on reports in obese patients that total body weight 
is not a significant predictor for tinzaparin clearance (3). Additionally, based 
on the pharmacokinetic properties of LMWH, the volume of distribution of 
tinzaparin was not expected to have a linear relationship with total body 
weight in extremely obese patients (e.g. BMI > 50 kg/m2 or total body weight 
> 150 kg) as tinzaparin does not expected to distribute in adipose tissue. As 
a result of all these considerations, it was concluded that the use of a linear 
weight-based dosing regimen in extremely obese patients may potentially 
lead to overdosing and higher risks of bleeding (6), and therefore in our case 
a dose cap at 160 kg was chosen together with anti-Xa measurements.
A possibility to evaluate the efficacy of a proposed dosing regimen is to 
monitor anti-Xa levels. Although the relationship between anti-Xa levels 
and efficacy or safety of LMWH treatment is not entirely clear (6, 21), levels 
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Figure 1 Observed anti-Xa levels (circle) in the 252 kg patient with line of best fit according to a one-
compartment model (line) and dosing records of tinzaparin (arrow). Measured anti-Xa levels are plotted in 
the figure (A, B, C and D), for details see table 1. Day 1 is the day the patient arrived at our hospital.
of 1.0- 2.0 IU/mL have been suggested for treatment of PE with once daily 
tinzaparin, when measured  4-5 hours after the subcutaneous injection 
on day 3 (22). Additionally, for enoxaparin, it has been demonstrated that 
anti-Xa concentrations lower than 0.5 IU/mL, 4-6 h after administration 
of the second dose, resulted in an increased risk of mortality at 30 days 
(5). Results from a study in obese volunteers with a maximum total body 
weight of 165 kg (BMI of 61 kg/m2) show that the maximum concentration 
of anti-Xa was 0.81 IU/mL (0.76 – 0.86 IU/mL) 4 h after subcutaneous 
administration of a single dose of 175 IU/kg tinzaparin (2), which seems to 
be in accordance with the previously mentioned target concentrations. Also 
in our patient, we monitored anti-Xa concentrations in order to evaluate 
whether our assumptions on tinzaparin behaviour in extremely obese 
patients were correct. We found that all anti-Xa concentrations were within 
the predetermined target values (see Table I). 
For the purpose of the current report, we retrospectively fitted the anti-
Xa measurements of the patient from Table I using a one-compartment 
pharmacokinetic model (iterative two-stage Bayesian fitting using 
MWPharm 3.50, Mediware, The Netherlands) with pharmacokinetic 
parameters of tinzaparin in non-obese patients (23). It was found that the 
line very adequately described the observed anti-Xa levels in our patient, 
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which seems to confirm our assumption that tinzaparin does not distribute 
any further over adipose tissue in extremely obese patients (Figure 1; 
pharmacokinetic parameters of anti-Xa in this patient were found to be 
1.14 L/h for clearance, 5.28 L for volume of distribution with an assumed 
bioavailability of 59%). From Figure 1 it can also be concluded that, based 
on measurements at day 1, pharmacokinetic modelling can be applied to 
estimate whether the target concentration, which is defined for day 3, will 
be reached, as the line of best fit very adequately describes the observed 
anti-Xa concentrations. However, it should be realized that there is a highly 
degree of uncertainly because the fitted data is based on 4 measurements of 
anti-Xa of only one extremely obese patient, and therefore, more research is 
needed to confirm these findings.
In summary, this case describes the successful treatment of PE in a 252 kg 
patient (BMI 74 kg/m2) with tinzaparin in a fixed dose of 28,000 IU per day, 
corresponding to 175 IU/kg for a total body weight of 160 kg. Larger studies 
are needed to confirm whether this fixed dose of tinzaparin is effective and 
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hromboprophylaxis in obese surgical patients in 
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              bstract 
Background 
Obesity is associated with an increased risk of venous thromboembolism. 
Low-molecular-weight heparins (LMWH) significantly reduce this risk. 
So far there is no consensus on the optimal dose and duration of LMWH 
in obese patients. The aim of this study is to assess the current practice of 
thromboprophylaxis in obese patients in the Netherlands and to describe 
current guidelines for thromboprophylaxis in obese patients.
Methods 
Data on type, duration and dose of thromboprophylaxis for obese patients 
from all the departments of general surgery (n=90) in the Netherlands were 
obtained by online questionnaires and telephone interviews. A literature 
search was conducted to identify available guidelines.
Results 
With a response of 93% (n=84) of institutes, 63% reported the use of an in-
hospital protocol of thromboprophylaxis for surgical patients. In 77% LMWH 
dose was adjusted, based on pre-determined total body weight (72%) or body 
mass index (BMI) (18%). Most hospitals (62%) doubled the standard dose 
above a pre-determined cut-off limit of body weight. These cut-off limits 
varied widely ranging from 70-150 kg total body weight or a BMI from 30-50 
kg/m2. In 13% of hospitals obese patients were given thromboprophylaxis 
for an extended period after discharge, with a maximum of six weeks. None 
of the identified guidelines in the literature search included advice about 
dose adjustments or adjustments in duration of thromboprophylaxis for this 
special group of patients. 
Conclusion 
There is a wide variety in the current practice of thromboprophylaxis in 
obese surgical patients in the Netherlands. As current guidelines lack 





   ntroduction
The prevalence of obesity (body mass index (BMI) > 30kg/m2) has doubled 
worldwide in the last two decades, now affecting a global estimate of over 1.7 
billion individuals (1, 2). Obesity is associated with multiple co-morbidities, 
such as type 2 diabetes mellitus and hypertension (2), and a two to three 
times increased relative risk of venous thromboembolism (VTE) compared 
to non-obese patients (3). 
The administration of low-molecular-weight heparins (LMWH) in surgical 
patients significantly reduces the incidence of VTE postoperatively (4-
6). LMWH derives its antithrombotic activity mainly by binding to anti-
thrombin and thereby trapping factor Xa out of the coagulation. LMWH has 
several benefits over unfractionated heparin, such as a single daily dosing, 
a more predictable dose-response relationship and a higher effectiveness in 
the prevention of VTE following bariatric surgery (7, 8).
The increase in the prevalence of obesity introduces new issues in patient 
care such as the optimal dose and duration of administration of LMWH for 
this group of patients. Only few studies are available on the optimal dosage 
of LMWH in patients with (morbid) obesity (9-11), as this patient group is 
often excluded from clinical trials.
We conducted a survey to analyse the current practice in thromboprophylaxis 
in obese surgical patients in the Netherlands and conducted a literature search 
to identify specific guidelines on dosing and duration of thromboprophylaxis 
in obese patients.
                ethods
Questionnaire
The survey was designed using freely available Google™ Docs tools (Google Inc, 
CA, USA) and was uploaded as a Google™ Docs form. A link to the questionnaire 
with an introductory cover letter was sent by email to one representative 
of each department of general surgery (n=90) in the Netherlands. The 
survey consisted of 10 multiple choice questions and two open questions on 
thromboprophylaxis in obese patients (Table I). Type of coagulation, duration 
and dose of thromboprophylaxis in obese patients were assessed, as well as 
the used definition of obesity and the availability of hospital-based guidelines 
concerning thromboprophylaxis in obese patients. Data were completed by 
repeated mailing and telephone interviews with non-responders.
I  
M 
1. Which low-molecular-weight heparin (LMWH) is used in healthy normal-weight and 
obese patients for thromboprophylaxis? 
2. What LMWH dose is used in healthy normal-weight patients for thrombosis 
prophylaxis?
3. How many days will thromboprophylactic therapy with LMWH be continued after 
general surgical procedures to prevent venous thromboembolic complications 
in normal-weight patients with a healthy kidney function (patients without oral 
anticoagulation)? 
4. Will the prophylactic dose of LMWH be adjusted for obese patients? 
5. Is there a protocol for prophylactic dose adjustment of LMWH in obesity in your 
hospital?
6. If so, to what patient groups does this protocol apply? 
7. What is the cut-off body weight for LMWH adjustment?
8. Based on what body weight will LMWH doses be adjusted? 
9. How will LMWH doses be adjusted in obesity? 
10. How many days will LMWH be continued after general surgical procedures to 
prevent venous thromboembolic complications in obese patients (patients without 
oral anticoagulation and normal kidney function)? 
11. Are anti-Xa levels checked in obese patients receiving venous thromboembolic 
prophylaxis? 
12. Does the surgical department in your hospital perform bariatric procedures? 
Table I Questions of survey on prophylactic doses of low-Aolecular weight heparin in obese surgical 
patients.
Statistical methods
Data analysis was done using SPSS 17.0 (IBM Corporation, NY, USA) for 
Windows. We compared differences in prescription practice in teaching 
hospitals (university and non-university) to non-teaching hospitals, and 
bariatric clinics to non-bariatric clinics using the chi-squared test. The 
probability level accepted for statistical significance was set at p < 0.05 for 
all comparisons.
Guidelines
A literature search for (inter)national guidelines on thromboprophylaxis 
in obese patients was performed in Pubmed and SUM Search. The 
following search terms were used (“Thrombosis”[Mesh] OR “Venous 
Thrombosis”[Mesh] OR “thrombosis” OR “thromboprophylaxis” OR 
“thromboembolism”) AND (“Heparin, Low-Molecular-Weight”[Mesh] 
OR “low-molecular weight heparin” OR “LMWH”) AND (“Guideline” OR 
“Guidelines as Topic”[Mesh] OR “Guideline” [Publication Type]).
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            esults
Questionnaire
Of the 90 contacted surgical departments, questionnaires were completed 
by 84 hospitals (93% response). The most commonly used LMWH for VTE 
prophylaxis was nadroparin (n=62, 74%), followed by dalteparin (n=16, 
19%) and enoxaparin (n=6, 7%). Of the hospitals that used nadroparin, 74% 
(n=55) used nadroparin 2,850 IU once daily as standard dose for non-obese 
patients. Dalteparin was most commonly dosed as 2,500 IU per day (n=13, 
81%), although three hospitals (19%) reported a dosage of 5,000 IU for non-
obese patients. Enoxaparin was either dosed as 20 mg per day (n=3, 50%) 
or 40 mg per day (n=3, 50%) for non-obese patients. The majority of the 
surgical departments continued thromboprophylaxis in non-obese patients 
until discharge (n=69, 82%). In 12% of hospitals (n=10) thromboprophylaxis 
was extended in these patients after discharge until the non-obese patient 
was ambulating well. The duration of thromboprophylaxis was reported to 
be depending on the surgical procedure in 5% of the hospitals. 
Of all institutes, 63% (n=53) reported the use of an in-hospital 
thromboprophylaxis protocol for obese patients. In 65 hospitals (77%), the 
prophylactic LMWH doses were adjusted for obese patients. Adjustments 
were mostly based on total body weight (n=47, 72%) and less commonly 
on pre-determined BMI (n=12, 18%), individual characteristics (n = 1) or in 
consultation with the anaesthesiologist (n = 1). Four hospitals (6%) did not 
report the basis on which the LMWH dose was adjusted. In two hospitals 
(3%), LMWH dose was only adjusted in (morbidly) obese patients undergoing 
bariatric surgery. 
Cut-off limits for dosing adjustment varied widely, with a median BMI of 33 
kg/m2 (range 30 - 50 kg/m2), and a median total body weight of 80 kg (range 
70 - 150 kg). Two hospitals used variable cut-off limits, based on individual 
characteristics. Most centres adjusted LMWH doses by doubling the dose 
used in non-obese patients (n=53, 62%). In other hospitals (n=7, 8%), the 
dose of LMWH was increased with a factor 1.3 - 1.5, resulting for nadroparin 
in 3,800 IU (n=6) and for dalteparin in 7,500 IU (n=1). Five hospitals (6%) 
individualized the LMWH by dosing on IU per kilograms. Eleven hospitals 
(13%) extended the LMWH prophylaxis in patients with obesity, to a duration 
varying from 1 to 6 weeks postoperative. In 7% (n=6) of the hospitals, anti-Xa 
levels were measured in individual cases. However, none of these hospitals 
reported whether and how the dose of LMWH should be adjusted based on 
these anti-Xa levels. 











dalteparin 16 (19) 6 (19) 10 (19)
enoxaparin 6 (7) 5 (16) 1 (2)
nadroparin 62 (74) 21 (66) 41 (79)
Adjusting LMWH dose for obese 65 (77) 38 (73) 27 (84) 0.229
Adjusting LMWH duration for obese 11 (13) 2 (6) 9 (17) 0.145
Existence of hospital protocol for obese 53 (63) 22 (73) 31 (67) 0.582
Anti-Xa tested in obese 6 (7) 1 (3) 5 (10) 0.258
Table II   Survey results of teaching hospitals versus non-teaching hospitals.
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found no significant differences for type of LMWH, adjustment of dose or 
duration, presence of an in-hospital protocol for obese patients or testing of 
anti-Xa levels (Table II). Dose adjustment of LMWH did not significantly vary 
between bariatric (n=27, 32%) and non-bariatric centres (n=57, 68%). Bariatric 
clinics did more often extend the duration of thromboprophylaxis (33% 
versus 4%, p<0.005), however in some of these clinics thromboprophylaxis 
was only extended in patients undergoing bariatric surgery (n=3). Neither 
the choice of LWMH, nor the existence of a protocol for adjusting LMWH 
in obese patients, nor the number of hospitals testing anti-Xa levels did 
significantly differ between bariatric and non-bariatric centres (Table III). 
Guidelines
The most recent guideline on thromboprophylaxis is the guideline of the 
American College of Chest Physicians (ACCP), which has been revised 
in February 2012. This 9th edition advises to follow manufacturers’ 
recommendation for pharmacological thromboprophylaxis (12-14). The 
ACCP guideline recognized obesity as a risk factor for VTE in both medical 
and bariatric surgical patients. It states that even though coagulation 
monitoring is generally not necessary, monitoring in special patient groups, 
including obese patients is advised (14). The guidelines of the National 
Institute for Health and Clinical Excellence (NICE) (15) and the Dutch 
Institute for Healthcare Improvement (16) also recognize obesity as a risk 
factor, but do not include advices about adjustments in dose or duration 














dalteparin 16 (19) 8 (30) 8 (14)
enoxaparin 6 (7) 0 (0) 6 (11)
nadroparin 62 (74) 19 (70) 43 (75)
Adjusting LMWH dose for obese 65 (77) 21 (78) 44 (77) 0.952
Adjusting LMWH duration for obese 11 (13) 9 (33) 2 (4) < 0.05
Existence of hospital protocol for obese 53 (63) 18 (72) 35 (69) 0.764
Anti-Xa tested in obese 6 (7) 2 (8) 4 (7) 0.946
Table III  Survey results of bariatric clinics versus non-bariatric clinics.
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Intercollegiate Guidelines Network (SIGN) does include obesity as a risk 
factor, but consequently states that patients undergoing bariatric surgery 
should receive thromboprophylaxis as recommended for those undergoing 
general surgery. Weight-based dose adjustments are not advised for LMWH 
according to the SIGN guideline, although it is advised to monitor LMWH 
activity in patients at extremes of weight (17). The German guideline describes 
obesity as a moderate risk factor and it recognizes that sometimes weight-
based dose adjustments are made, without any specification or appraisal. 
No specific recommendations regarding dose or duration adjustments 
are made (18). The guideline of the French Society of Anaesthesiology 
and Reanimation only advises dose adjustments of prophylactic LMWH in 
overweight obstetric patients and does not make specific recommendations 
for surgical patients (19).
            iscussion
In this survey we showed that in the majority of hospitals (77%), the LMWH 
dose is increased for obese patients but various regimens are used in clinical 
practice both in terms of dosing and duration of antithrombotic treatment. 
Besides, available guidelines lack practical dosing advices for this special 
group of patients.
Obesity, defined as a BMI > 30 kg/m2 or greater, is a known risk factor for 
D  
venous thromboembolism (VTE) (20) with a more than two times increased 
relative risk for deep venous thrombosis (DVT) (3) and pulmonary embolism 
(PE) for hospitalized patients compared to non-obese (21). A linear 
association between body weight and risk of VTE has been shown with an 
estimated six-fold increase in the risk of PE in women with a BMI > 35 kg/
m2 (22). With the rising incidence of obesity, health services worldwide are 
confronted with an ever increasing number of patients undergoing bariatric 
surgery. Most clinical trials and retrospective analyses on the incidence of 
VTE in (morbidly) obese patients involve the group of patients undergoing 
bariatric surgery. The perioperative incidence of VTE, either symptomatic or 
asymptomatic, after laparoscopic bariatric surgery appears to be relatively 
low (below 1%), regardless of the antithrombotic prophylaxis regimen (23). 
This is probably due to short operation times and short immobilization. The 
incidence of VTE after laparoscopic bariatric surgery for patients receiving 
thromboprophylactic therapy increases to almost 3% up to 6 months 
following surgery (24). Within the bariatric population, several contributing 
risk factors identified for VTE were: previous VTE, age > 55 years, smoking 
and male sex (24). The risk of postoperative VTE in obese patients undergoing 
orthopaedic, major gynaecological of oncologic abdominal surgery may be 
higher, underlining the need for optimal and individualized prophylactic 
therapy in this special group of patients.
Different dosing strategies for LMWH in obese patients have been proposed 
but most reports are inconclusive on how to individualize the LMWH dosing 
regimen (9-11). Retrospective subgroup analyses from large VTE prophylaxis 
trials using a similar standard dose of LMWH in obese and non-obese 
hospitalized patients show no significant difference in postoperative VTE 
in both groups (25, 26). Prospective studies on different dosing regimens 
for VTE prophylaxis in morbidly obese subjects, mostly involving patients 
undergoing bariatric surgery, show equivocal results. Kalfarentos et al. 
comparing two doses of nadroparin (5,700 IU vs. 9,500 IU) in a randomized 
study among morbidly obese patients undergoing Roux-en-Y gastric bypass 
surgery, reported no VTE events in both groups. However, the higher dose 
resulted in two major haemorrhages while no major bleeding event occurred 
in patients receiving the lower dose (27). A higher dose of 40 mg enoxaparin 
showed to reduce non-fatal VTE compared to 30 mg for obese patients (0.6% 
vs. 5.4%) without increased incidence of bleeding complications (28). Singh 
et al. found no VTE events in 170 morbidly obese patients (BMI 40-59 kg/m2) 
using a BMI-stratified enoxaparin dosing schedule, with doses ranging for 
30 to 60 mg (29). These results support the evidence to increase the LMWH 
dose for obese patients, although the optimal dose is still unknown. 
As there are currently no evidence-based dosing guidelines available for 
prophylactic LMWH therapy in obese patients, monitoring of anti-Xa levels 
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four hours after the first dose is often recommended (30). No therapeutic 
range has been defined for obese patients, but it seems rational to aim 
for the prophylactic range in non-obese patients of 0.2-0.5 IU/mL at four 
hours after administration of LMWH (11). Most studies have focused on the 
effect of increased LMWH doses on anti-Xa levels. Rowan et al. achieved 
a higher percentage of therapeutic anti-Xa levels (9% vs. 41.7%) for 40 mg 
enoxaparin compared to 30 mg enoxaparin (31). Although therapeutic levels 
were not reached in over 50% of patients, no VTE events were reported. In 
another study less subtherapeutic levels (0% vs. 40%) were achieved with a 
higher dose of 60 mg enoxaparin compared to 40 mg enoxaparin, without 
increasing the number of bleeding complications (32). Both studies involved 
patient groups with a mean BMI of 48 kg/m2 (31, 32). Although results of 
some of the aforementioned studies may seem inconclusive, it appears that 
a standard dose of LMWH as used in the non-obese population is insufficient 
in the (morbidly) obese population and dose adjustments are warranted. 
A recent review by Nutescu et al. recommended a 30% higher dose for 
morbidly obese patients, as well as monitoring anti-Xa levels in individuals 
weighting over 190 kilograms (11). 
In a previous study among bariatric patients we showed that after a double 
dose of nadroparin compared to non-obese patients, still 50% of the morbidly 
obese patients showed peak anti-Xa levels below the recommended range. 
These peak anti-Xa levels correlated with lean body weight and therefore 
lean body weight was proposed as dosing scalar for thromboprophylaxis 
with LMWH nadroparin (33). In addition, peak anti-Xa levels in morbidly 
obese patients were not found to correlate with total body weight or BMI 
(34). As LMWH distribute mainly to the intravascular compartment, instead 
of tissues and body fat, these findings might be explained by the non-linear 
increase of plasma volume with the increase in total body weight (35). 
The currently available guidelines do not specifically advise dose adjustment 
of LMWH in morbidly obese patients, and most recommend to use product 
labels (12-19). This advice is often ignored, as proven by Barras et al., showing 
that 96% of questioned hospitals had a LMWH strategy that contravened 
with product labels (9). In clinical practice in Dutch hospitals, 62% of the 
hospital doubled the LMWH dose for thromboprophylactic therapy in obese 
patients. However, the cut-off point for body weight above which the LMWH 
dose was increased differed between hospitals.
Beside the optimal dose, there is debate about the duration of prophylaxis 
after surgery. Our study shows that extended duration of prophylaxis is not 
yet common practice in the Netherlands. Only 13% of respondents indicate 
to adjust duration of prophylaxis in obese patients. Significantly more 
surgical departments performing bariatric surgery (33%, p<0.05) extended 
the duration of thromboprophylaxis after discharge. The benefits of 
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extended duration of prophylaxis have been studied in bariatric populations 
and showed a reduced incidence of thromboembolic complications in 
patients receiving prophylaxis up to ten days post-discharge (10, 36, 37). To 
date, guidelines do not include this evidence. 
As bariatric procedures are exponentially increasing worldwide this 
patient group could be a target population for the study of perioperative 
thromboprophylaxis regimen in the subset of obese patients. As the 
incidence of post-operative VTE appears to be rather low in the bariatric 
population, future studies should focus on risk groups within this population, 
i.e. patients within the highest ranges of BMI or comorbidities. Prospective 
studies should identify the optimal dosing schedules for the obese patients 
and clarify the benefit of extended prophylaxis. The increasing numbers 
of obese surgical patients and the current wide variety in the practice of 
thromboprophylaxis demonstrate the necessity of uniform guidelines for 
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              bstract 
Background 
Morbidly obese patients (BMI > 40 kg/m2) are at increased risk for venous 
thromboembolism, especially after surgery. Despite limited evidence, 
morbidly obese patients are often administered a double dose of nadroparin 
for thromboprophylaxis compared to non-obese patients. The aim of this 
study was to evaluate the influence of different body size descriptors on 
anti-Xa levels after a double dose of nadroparin (5,700 IU) in morbidly obese 
patients. 
Methods 
In 27 morbidly obese patients with a mean total body weight (TBW) of 148 kg 
(range 107 – 260 kg), anti-Xa levels were determined peri-operatively until 
24 h after administration of a subcutaneous dose of 5,700 IU of nadroparin. 
Results 
Anti-Xa level 4 h after administration (A4h, mean 0.22 ± 0.07 IU/ml) negatively 
correlated strongly with lean body weight (LBW) (r = -0.66 (p<0.001)), 
moderately with TBW (r = -0.56 (p=0.003)) and did not correlate with BMI 
(r = -0.26 (p=0.187)). The area under the anti-Xa level-time curve from 0 to 
24 h (AUA0-24h, mean 2.80 ± 0.97 h*IU/ml) correlated with LBW (r = -0.63 
(p=0.007)), but did not correlate with TBW (r = -0.44 (p=0.075)) or BMI (r = 
-0.10 (p=0.709)).
Conclusion 
Following a subcutaneous dose of nadroparin 5,700 IU, A4h and AUA0-24h 
were found to negatively correlate strongly with LBW. From these results, 
individualized dosing of nadroparin based on LBW should be considered in 




   ntroduction
Currently more than 30% of the US population is obese (Body Mass Index 
(BMI)>30 kg/m2) and 2.8% of adult men and 6.9% of adult women are 
morbidly obese (BMI>40 kg/m2) (1). Consequently, there is a marked 
increase of this special group of patients presenting for various types of 
surgery, including bariatric surgery. In obese patients, the relative risk for 
venous thromboembolism (VTE) is more than doubled compared to non-
obese patients, and even five times higher in obese patients with an age of 
40 years or younger (2). 
Low-molecular-weight heparins (LMWH) have shown to substantially 
reduce the risk for VTE by inactivating clotting factor Xa (3-4). Compared 
to unfractionated heparin, LMWH have a more favourable benefit-risk 
ratio and a more predictable dose-response relationship (5). In the ACCP 
guidelines, LMWH are recommended for prophylactic use in morbidly obese 
patients albeit without any specific recommendation for the dose in this 
special population (5-6). These guidelines recommend to monitor the effect 
of LMWH in morbidly obese patients using anti-Xa levels (6). Since LMWH 
are a mixture of polysaccharides that includes biologically inactive species, it 
is not possible to measure LMWH levels directly (4). The commonly reported 
prophylactic range of anti-Xa levels for non-obese patients is 0.2 – 0.5 IU/ml 
4 h after administration (7). 
In the lack of specific dosing guidelines for dose adjustment of LMWH 
in morbidly obese patients, different body size descriptors have been 
proposed, such as total body weight (TBW) (8) and BMI (9-10). However, in 
clinical practice the prophylactic dose of LMWH is often doubled in morbidly 
obese patients resulting in 5,700 IU nadroparin (11). The aim of this study 
was to evaluate the influence of different body size descriptors on anti-Xa 
levels following a dose of 5,700 IU of nadroparin in morbidly obese patients. 
In this study, anti-Xa levels 4 h after administration (A4h) and the area under 
the anti-Xa level-time curve from 0 to 24 h (AUA0-24h) were considered and 
studied for a correlation with LBW (12), TBW and BMI.
                aterials and methods
Patients
Twenty-seven morbidly obese patients scheduled to undergo laparoscopic 
gastric banding or gastric bypass surgery were enrolled in two prospective 
studies (ClinicalTrials.gov identifier cohort 1: NCT01097148 and cohort 
2: NCT01309152). Patients were included if they were between 18 and 60 
years old, had an American Society of Anesthesiologists (ASA) physical 
status classification of II or III, a normal renal and liver function as assessed 
by routine laboratory testing, and a BMI of over 40 kg/m2 at the day of 
screening. Exclusion criteria included a BMI lower than 35 kg/m2 at the day 
of surgery, LMWH administration within 48 h preceding surgery, pregnancy, 
breast feeding, epilepsy and known allergy for propofol, soy bean oil or 
egg lecithin. Both study protocols were approved by the hospitals ethics 
committee and written informed consent was signed by each participating 
patient. 
Procedure
In both cohorts, before induction, an antecubital infusion line, an indwelling 
arterial blood pressure line and a three-lead ECG were installed. No pre-
anaesthetic medication was given, and all patients were fasting for 6 h 
before surgery to minimize the risk of aspiration during induction. Following 
a propofol bolus injection of 350 mg, intravenous fentanyl and cefazolin were 
given in fixed doses of 250 μg and 2 g, respectively, followed by 5,700 IU 
(0.6 ml) nadroparin subcutaneously administered in the thigh. Anaesthesia 
was maintained with continuous infusions of propofol and remifentanil after 
induction of anaesthesia according to routine clinical practice. 
Blood sampling and analytical methods
Blood samples for determination of anti-Xa-levels were collected before 
induction of anaesthesia (t=0), at 10, 30, 60, 90, 120, 180, 240, 300 and 
420 minutes after nadroparin dosing and the next morning within 24 h 
after administration in cohort 1, and before induction of anaesthesia, 120 
and 240 minutes after nadroparin dosing and the next morning within 24 
h after administration in cohort 2. Blood samples were collected in 3.2% 
buffered sodium citrate containing tubes and were immediately stored on 
ice until centrifugation. All samples were centrifuged at 4 ºC within one 
hour after collection to obtain plasma samples, and stored at –80 ºC until 
analysis within 1 month after collection. Plasma levels of anti-Xa activity 
were measured with a STA-Rack Evolution (Diagnostica Stago, Asnières, 
France) using an anti-Xa clotting assay (StaClot®Heparin, Diagnostica 
Stago, Asnières, France). The rate of chromophobe appearance at 405 nm 
was measured. Calibration occurred with eight concentrations of nadroparin 
(STA® Multi Calibrator) in normal pooled plasma. The calibration curve was 
found to be linear between 0.00 and 1.60 IU/ml. The within assay and among 
assay precision (coefficient of variation) were 4.7 % and 4.9 %, respectively. 
Regression analysis was used to determine the calibration curve values from 
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which the experimental values were obtained. 
Data analysis
Statistical software (PASW Statistics 19.0 for Windows; IBM, Chicago, 
IL, US) was used for statistical analysis. Continuous data were expressed 
as mean ± SD. To study the association between anti-Xa level 4 h after 
administration (A4h) and the area under the anti-Xa level-time curve from 
0 to 24 h (AUA0-24h) and different body size descriptors (TBW, BMI and LBW 
(12)) the Pearson’s correlations coefficient (r) was calculated. A p<0.05 was 
considered significant. The area under the anti-Xa level-time curve from 0 to 
24 h (AUA0-24h) was calculated using the linear trapezoidal method (13) with 
estimating the levels at t = 24 h using the last two or three samples. Lean 
body weight, which is considered to closely approximate fat free mass (12), 
was calculated using formulas of Janmahasatian et al, for men: (9,270 * TBW 
(kg)) / (6,680 + 216 * BMI) and for women: (9,270 * TBW (kg)) / (8,780 + 244 
* BMI) (12). 
            esults 
Patients and Data
Twenty-seven morbidly obese patients with a mean TBW of 149 kg (range 
107 - 260 kg) were enrolled and a total of 240 blood samples were available. 
Nineteen patients were included from cohort 1, and eight patients from 
cohort 2. All demographic characteristics of the morbidly obese patients 
from cohort 1, cohort 2 and total study population are provided in Table I.
Anti-Xa levels 4 h after administration (A4h) were available in all 27 patients 
of cohort 1 and 2. While in cohort 2 there were insufficient data to calculate 
the area under the anti-Xa level-time curve from 0 to 24 h (AUA0-24h), AUA0-24h 
could be analyzed in 17 patients of cohort 1. 
Anti-Xa levels
Mean anti-Xa levels 4 h after administration (A4h) after the administration 
of 5,700 IU nadroparin in those morbidly obese patients and the area under 
the anti-Xa level-time curve from 0 to 24 h (AUA0-24h) are shown in Table II. 
Thirteen morbidly obese patients (48%) showed anti-Xa-levels below the 
prophylactic range of 0.20 - 0.50 IU/ml . 
Figure 1 shows that A4h strongly correlated with LBW (r = -0.66, p<0.001), 
moderately correlated with TBW (r = -0.56, p=0.003) and did not correlate 
with BMI (r = 0.26, p=0.187). Figure 2 demonstrates that AUA0-24h strongly 
negatively correlated with LBW (r = -0.78, p=0.007) and did not correlate 
R 






Patients (n) 27 19 8
Age (y) 44 (9) 45 (10) 40 (6)
Sex (M / F) 10 / 17 9 / 10 1 / 7
TBW (kg) 149 (32) 153 (35) 140 (23)
IBW (kg) 67 (10) 68 (11) 64 (7)
LBW (kg) 71 (14) 74 (15) 66 (9)
BMI (kg/m2) 49 (10) 50 (10) 47 (6)
Table I   Patient characteristics of twenty-seven morbidly obese patients receiving 
5,700 IU nadroparin subcutaneously.
BMI = body mass index; F = female; IBW = ideal body weight (28); LBW = lean body weight(12); M = male; 
SD = standard deviation; TBW = total body weight
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Mean (SD) Number
A4h (IU/mL) 0.22 ± 0.07 27
A4h percentage below prophylactic range (%) 48%
AUA0-24h (h * IU/mL) 2.80 ± 0.97 17
Table II   Mean anti-Xa levels 4 h after administration (A4h) and mean area under 
the anti-Xa level-time curve from 0 to 24 h (AUA0-24h) after 5,700 IU of nadroparin 
(prophylactic range of anti-Xa levels 4 h after administration is 0.2 – 0.5 IU/ml for 
non-obese patients (7)).
with TBW (r = -0.44, p=0.075) or BMI (r = -0.10, p=0.709). 
Figure 3 shows the results of both A4h and AUA0-24h from this study together 
with previously reported values in the literature of non-obese (14-19) and 
(morbidly) obese patients (11, 19) versus nadroparin dose. The figure 
demonstrates that in non-obese patients there is a linear dose-response 
curve for both A4h and AUA0-24h. The results of this study after administration 
of 5,700 IU nadroparin in morbidly obese patients show an A4h and AUA0-
24h that are lower than would be expected from these dose-response 
relationships. Similar results are shown for anti-Xa levels in obese patients 
























































































































































































































































































































































































































































































































































Figure 3 Mean anti-Xa level 4 h after administration (A4h) and mean area under the anti-Xa level-time curve 
from 0 to 24 h (AUA0-24h) with standard deviation reported in the current study in 27 morbidly obese patients 
(black square), in previous reports in non-obese patients (grey diamond) including linear trend line (14-19) 
and in previous reports in (morbidly) obese patients (grey triangle) (11, 19).
            iscussion
As obese patients are at increased risk of venous thromboembolism (VTE) 
(2), evidence on how to adjust the dose of LMWH in case of increased body 
weights is important. Different dosing strategies for LMWH in obese patients 
have been proposed but reports on how to individualize the LMWH dosing 
regimen in morbidly obese patients are inconclusive. In this study, A4h and 




this body size descriptor deserves further study in morbidly obese patients. 
As stated before, measurement of anti-Xa levels is recommended in 
morbidly obese patients (6, 20) in absence of established dosing protocols 
for LMWH for these patients. Although no range has been established in 
morbidly obese patients and morbidly obese patients are at increased risk 
for VTE (2), it seems rational to aim for at least anti-Xa levels of 0.2 - 0.5 
IU/mL, which is the reported prophylactic range for non-obese patients 
(7). Half of the morbidly obese patients in this study (48 %) showed anti-Xa 
levels below this window, suggesting increased doses might be necessary. In 
addition, since the relationship between anti-Xa levels and the occurrence of 
bleedings (21) or VTE (22) is unknown, studies on this relationship in morbidly 
obese patients receiving prophylaxis with LMWH are urgently needed to 
define the optimal window of anti-Xa levels in morbidly obese patients.
It has been reported before by Heizmann et al. that a linear increase in 
nadroparin dose does not result in a linear increase in maximum anti-Xa 
levels after 4 h and AUA levels in obese patients and that dosing should 
not be based on TBW (19). The reported anti-Xa levels were, however, not 
correlated to other body size descriptors and, therefore, no conclusions 
could be drawn on how to optimize nadroparin doses in obese patients. 
Similarly, for enoxaparin, peak anti-Xa levels in morbidly obese patients 
were not found to correlate with TBW or BMI (8). A dosing regimen based 
on LBW instead of TBW would seem to make more sense since it has a 
non-linear increase with height and TBW. It has therefore been proposed 
before for the therapeutic dose of enoxaparin for patients weighing more 
than 100 kg (23). LBW, representing fat free mass in individuals, can be 
measured with bioelectrical impedance analysis (BIA) or dual-energy x-ray 
absorptiometry (DXA). To estimate LBW, the formula by Janmahasatian et 
al. (12) is the most commonly used method as it was found to provide good 
predictive performance of the Fat Free Mass measured with bioelectrical 
impedance analysis (BIA) or dual-energy x-ray absorptiometry (DXA) (12). 
In this study, we investigated the correlation between LBW (12) and anti-Xa 
levels and AUA0-24h. As shown in Figure 3, there is a substantial influence of 
excessive body weight on anti-Xa levels after subcutaneous administration 
of nadroparin in morbidly obese patients as the results of morbidly obese 
patients are well below the line for non-obese patients. These results seem 
in accordance with the correlation described in this study between LBW (12) 
and A4h. As LMWH are mainly distributed over vascular tissue and blood, an 
explanation for this relation for A4h may be the non-linear increase of plasma 
volume with body weight (24). Since there are no reports available indicating 
a reduced biological availability of LMWH in obese patients (25-26), it may 
be anticipated that the lower AUA0-24h in morbidly obese patients compared 
to non-obese patients is caused by an increased glomerular filtration in 
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morbidly obese patients (27) which increases nadroparin clearance. These 
hypotheses need clarification in future studies.
In conclusion, both anti-Xa levels 4 h after administration and the area under 
the anti-Xa level-time curve from 0 to 24 h after subcutaneous administration 
of nadroparin in morbidly obese patients were negatively correlated strongly 
with LBW (12). From these results, individualized dosing on the basis of LBW 
should be considered in morbidly obese patients.
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              bstract 
Background 
In absence of specific dosing guidelines, the optimal dose of low-molecular-
weight heparins for thrombosis prophylaxis in morbidly obese patients 
(BMI > 40 kg/m2) remains unknown. In order to guide dosing in this 
patient group, a pharmacodynamics model is developed for nadroparin in 
morbidly obese and non-obese patients using anti-Xa levels as an endpoint, 
thereby characterizing the influence of excessive body weight on different 
pharmacodynamic model parameters.
Methods 
Twenty-eight morbidly obese and seven non-obese patients receiving 5,700 
IU and 2,850 IU s.c. nadroparin for surgery, respectively, were included 
with a mean total body weight (TBW) of 135 kg (range 72–252 kg). Up to 
11 anti-Xa levels were collected from start until 24 hours after nadroparin 
administration. Population pharmacodynamic modelling with covariate 
analysis was performed using NONMEM.  
Results 
In a two-compartment pharmacodynamic model with baseline endogenous 
anti-Xa levels, the effect of nadroparin was found to be delayed and could be 
best described using a transit compartment. TBW was the most predictive 
covariate for clearance (CL = 23.0 mL/min * (TBW/70)), while lean body 
weight (LBW) proved the most predictive covariate for central volume of 
distribution (V1 = 7.0 L * (LBW/60)). 
Conclusion 
A pharmacodynamic model was developed characterizing anti-Xa levels 
after s.c. administration of nadroparin in patients weighing between 72 
to 252 kg with TBW and LBW as the major determinant for clearance and 
volume of distribution, respectively. Based on simulations using the final 
covariate pharmacodynamic model it appeared that a dose of 5,700 IU 
nadroparin will lead to target anti-Xa levels in morbidly obese patients with 




   ntroduction
Western countries, the incidence of obesity (body mass index (BMI) > 30 
kg/m2) is increasing resulting in a percentage of 30% of the population of 
the United States (1). In addition, the incidence of morbidly obese patients 
(BMI > 40 kg/m2) is on the rise as well (2, 3). Obesity is associated with a two 
times increased relative risk of venous thromboembolism (VTE) compared 
to non-obese patients (4). More specifically, the prevalence of pulmonary 
embolism in hospitalized patients is higher in obese patients than in non-
obese patients (5).
Low-molecular-weight heparins (LMWHs) are widely used for the prevention 
of VTE both in non-obese patients and (morbidly) obese patients, even 
though for the latter population dosing advices largely vary (6). In addition, 
different weight scales have been proposed to adjust the dose of LMWH in 
obese patients, such as total body weight (TBW) (7) and BMI (8, 9). In clinical 
practice, the prophylactic dose of LMWH for morbidly obese patients is 
often capped at a certain dose, resulting for instance for nadroparin in a 
fixed dose of 5,700 IU (= 0.6 mL) for the heterogeneous group of morbidly 
obese patients in which body weights are still increasing (10). 
Population modelling is a well-established approach for the characterization 
of the pharmacokinetics and pharmacodynamics of a drug and can serve as 
the scientific basis for the development of rational and individualized dosing 
schemes (11). Population pharmacodynamic studies of LMWHs describing 
the influence of body weight are scarce and do often not include morbidly 
obese patients. For enoxaparin in non-obese patients, both lean body weight 
(LBW) and TBW have been identified as the best size descriptor for clearance 
and volume of distribution (12-16). In a population pharmacodynamic 
analysis of enoxaparin in non-obese and obese patients (TBW range 66 - 160 
kg), LBW proved to be the best size descriptor for clearance, while for central 
volume of distribution TBW was identified (17). As body weights of patients 
are still increasing, data should be gathered across a wide body weight 
range including morbidly obese patients to properly study the influence of 
different weight-based covariates on the pharmacodynamics of LMWHs.
Therefore, in this study a population pharmacodynamic model of nadroparin 
used for thrombotic prophylaxis is developed in morbidly obese and non-
obese patients, using anti Xa-levels as a pharmacodynamic endpoint, in 
order to characterize the influence of excessive body weight on different 
pharmacodynamic model parameters. In a systematic covariate analysis, 
potential factors (TBW, BMI, ideal body weight (IBW) and LBW (18)) 
influencing the pharmacodynamic parameters of nadroparin are tested 
for their influence, ultimately to provide a guide for dosing nadroparin in 
morbidly obese patients.
 
                ethods
Patients
A total of thirty-five patients were included in two prospective clinical 
studies: twenty-eight morbidly obese patients (BMI > 40 kg/m2) which were 
scheduled to undergo laparoscopic gastric banding or gastric bypass surgery 
and seven non-obese patients which underwent laparoscopic Toupet 
fundoplication surgery (Study 1: 20 morbidly obese patients, ClinicalTrials.
gov/ NCT01097148 (19) and Study 2: 8 morbidly obese patients and 7 non-
obese patients, ClinicalTrials/gov/ NCT01309152). Clinical data of 27 of the 
28 morbidly obese patients have been published before in a descriptive 
paper (19). Patients were included if they were between 18 and 60 years 
old, had an American Society of Anesthesiologists (ASA) physical status 
classification of II or III in case of morbidly obese patients and I or II for non-
obese patients and had a normal renal and liver function as assessed by 
routine laboratory testing. Exclusion criteria included LMWH administration 
within 48 hours preceding surgery, pregnancy, breast feeding, epilepsy and 
known allergy for propofol, soybean oil or egg lecithin. Both study protocols 
were approved by the hospitals Ethics Committee and written informed 
consent was signed by each participating patient. 
Procedure
In both studies, before induction of anesthesia an antecubital infusion line, an 
indwelling arterial blood pressure line and a three-lead ECG were installed. 
No pre-anesthetic medication was given and all patients were fasting for 
6 hours before surgery to minimize the risk of aspiration during induction. 
Following a propofol bolus injection, intravenous fentanyl and cefazolin 
were given in fixed doses of 250 μg and 2 g, respectively. Then 5,700 IU (0.6 
ml) nadroparin for morbidly obese patients and 2,850 IU (0.3 ml) nadroparin 
for non-obese patients was administered subcutaneously in the thigh, the 
exact time being recorded. Anesthesia was maintained with continuous 
infusions of propofol and remifentanil according to routine clinical practice. 
Blood sampling and analysis
Blood samples for determination of anti-Xa levels were collected before 
induction of anesthesia (t=0), at 10, 30, 60, 90, 120, 180, 240, 300 and 420 
minutes after nadroparin dosing and the next morning within 24 hours 
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after administration in the 20 morbidly obese patients of Study 1 and 7 
non-obese patients of Study 2, and before induction of anesthesia, 120 and 
240 minutes after nadroparin dosing and the next morning within 24 hours 
after administration in 8 morbidly obese patients of Study 2. Blood samples 
were collected in 3.2% buffered sodium citrate containing tubes and were 
immediately stored on ice until centrifugation. All samples were centrifuged 
at 4 ºC within one hour after collection to obtain plasma samples, and 
stored at –80 ºC until analysis within one month after collection. Plasma 
levels of anti-Xa activity were measured with a STA-Rack Evolution 
(Diagnostica Stago, Asnières, France) using an anti-Xa clotting assay (STA 
Rotachrom®Heparin 4, Diagnostica Stago, Asnières, France). The rate of 
chromophobe appearance at 405 nm was measured. Calibration occurred 
with eight concentrations of nadroparin (Lot number used for patients) in 
normal pooled plasma. The calibration curve was found to be linear between 
0.00-1.60 IU/ml. The within assay and among assay precision (coefficient of 
variation) were 4.2% and 4.7%, respectively. Regression analysis was used to 
determine the calibration curve values from which the experimental values 
were obtained. 
Data analysis and internal validation
The analysis was performed by means of non-linear mixed effects modelling 
using NONMEM (version VI, release 1.1; GloboMax LLC, Hanover, MD, 
USA) (20) with S-plus (version 6.2; Insightful software, Seattle, WA, USA) 
for data visualization. Discrimination between different models was made 
by comparison of the objective function value (OFV, i.e.−2 log likelihood). 
A significance level of p<0.05, corresponding to a decrease of 3.8 in OFV, 
was considered statistically significant. In addition, goodness-of-fit plots 
(observed versus individually-predicted anti-Xa level-time, observed versus 
population-predicted anti-Xa level-time, conditional weighted residuals 
versus time and conditional weighted residuals versus population-predicted 
anti-Xa level-time plots) were used for diagnostic purposes. Furthermore, 
the confidence interval of the parameter estimates, the correlation matrix 
and visual improvement of the individual plots were used to evaluate the 
models. 
The internal validity of the models was assessed by the bootstrap re-
sampling method using 250 replicates (20). Parameters obtained with the 
bootstrap replicates were compared with the estimates obtained from the 
original data set. Besides, normalized prediction distribution errors (NPDE) 
method was used to validate the model (21). This method was implemented 
using the NPDE add-on software package that was run in R. In this study, 
each observation was simulated 1000 times. The results of NPDE method are 
visualized in different graphs: (i) a histogram showing the distribution of the 
NPDEs, which are expected to follow normal distribution; (ii) a scatterplot 
NPDE vs. time; and (iii) a scatterplot NPDE vs. predicted anti-Xa levels. 
Pharmacodynamic model of nadroparin
A one-compartment and a two-compartment model were tested to 
fit observed anti-Xa levels. To describe the observed delay in effect of 
subcutaneously administrated nadroparin, different absorption models 
were evaluated including a lag time model (20) and a model with one or 
more additional transit compartments (22). Transit compartments were 
described using a first-order rate constant describing the transfer from the 
dose compartment into the transit compartment and subsequently into the 
central compartment (22).
The individual value (empirical Bayes estimate) of the parameters of the ith 
individual was modeled by (equation 1): 
         (Eq. 1)
where θmean is the population mean, and ηi is a random variable with a 
mean of zero and variance of ω2, assuming log-normal distribution in the 
population. 
The intraindividual variability, resulting from assay errors, model 
misspecifications and other unexplained sources, was best described with 
an additive error model while a proportional error model and a combination 
of an additive and a proportional error model were tested as well. This 
means for the jth observed anti-Xa level of the ith individual, the relation (Yij) 
is described by equation 2. 
 
Yij =Cpred,ij +εij +BLS       (Eq. 2)
where cpred is the predicted anti-Xa level, and εij is a random variable with a 
mean of zero and variance of σ2. Incorporation of baseline endogenous anti-
Xa levels (BLS) into the model was explored as reported before (23, 24). This 
means for the jth observed anti-Xa level of the ith individual, the relation (Yij) 
is described by equation 2, where BLS represents the baseline endogenous 
anti-Xa level.
Covariate analysis
Covariates were plotted independently against the individual empirical 
Bayes estimates of the pharmacodynamic parameters to visualize potential 
relations. The following continuous covariates were tested: total body 
weight (TBW), body mass index (BMI), ideal body weight (IBW) (25), lean 





body weight (LBW) (18) and age. For calculating LBW, equations 3 and 4 
were used (18):
    
LBWmale(kg) =
9270∗TBW
6680+ 216*BMI     (Eq. 3)




Continuous covariates were tested using linear and power equations:   
    
 
        (Eq. 5)
in which Pi and Pp represent individual and population parameter estimates, 
respectively, Cov represents the covariate and Covstandard represents a 
standardized (i.e. 70 kg for TBW) or median value of the covariate for the 
population. The exponent z represents the exponential scaling factor, which 
was fixed at 1 for a linear function or an estimated value for a power equation, 
while also a 0.75 fixed value of the exponent was tested when TBW was the 
covariate (26). Categorical covariates (e.g. the subgroups morbidly obese 
patients and non-obese patients, and sex) were tested by estimation of an 
additional parameter on a structural parameter for one of the categories. 
Potential covariates were separately entered into the model and statistically 
tested using the objective function and if applicable the 95% confidence 
interval values of the additional parameter. A p<0.005 was applied to 
evaluate the covariates in the forward inclusion (OFV decrease >7.9), while 
the backward deletion procedure used a stricter criterion (OFV decrease 
>10.8, p<0.001). When two or more covariates were found to significantly 
improve the model, the covariate causing the largest reduction in objective 
function was left in the model. Additional covariates had to reduce this OFV 
further to be retained in the model. The choice of the covariate model was 
further evaluated as under the section Data analysis and internal validation.
Simulations
Based on the final pharmacodynamic model, simulations in morbidly obese 
patients were performed to aim for a target anti-Xa level of 0.2 IU/ml 4 hours 
after administration (27). 
            
            esults
Patients and data
A total of 35 patients were enrolled in two studies resulting in a total of 28 
morbidly obese patients and 7 non-obese patients, from which 319 anti-Xa 
levels were available. Clinical data of 27 of the 28 morbidly obese patients 
were published before in a descriptive manner (19). Morbidly obese patients 
had a mean total body weight (TBW) of 148 kg (range 107 – 252 kg) and a 
mean BMI of 49 kg /m2 (38 – 79 kg/m2) while non-obese patients had a TBW of 
86 kg (72 – 105 kg) and a mean BMI of 28 kg/m2 (24 – 31 kg/m2). Demographic 
characteristics are summarized in Table I. 
R 













Number (n) 35 20 8 7
Gender (M / F) 14/21 9/11 1/7 4/3
Age (years) 45 (22 – 59) 44 (11) 40 (6) 53 (6)
Total body weight (kg) 135 (72 – 252) 151 (33) 140 (23) 86 (12)
Ideal body weight (kg) 66 (50 – 86) 67 (11) 64 (7) 68 (9)
Lean body weight (kg) (18) 68 (44 – 100) 73 (15) 66 (9) 58 (11)
Body mass index (kg/m2) 45 (24 – 79) 50 (10) 47 (6) 28 (3)
TableI I   Patient characteristics of the total study population of thirty-five patients 
consisting of twenty-eight morbidly obese patients and seven non-obese patients 
from two studies.
SD = standard deviation
Pharmacodynamic analysis
A two-compartment pharmacodynamic model (NONMEM  VI) parameterized 
in ADVAN5 adequately described the time course of the anti-Xa levels after 
subcutaneous dosing of nadroparin, parameterized in terms of the volume 
of distribution of the central compartment (V1), volume of distribution of 
the peripheral compartment (V2), inter-compartmental clearance from the 
central compartment to the peripheral compartment (Q) and clearance from 
the central compartment (CL) (Figure 1). A two-compartment model was 
superior over a one-compartment model, showing a reduction in objective 
function value (OFV) of 28 points and significantly improved diagnostic 
plots. In the two-compartment model, the peripheral compartment was set 
equal to the volume of the central compartment for statistical reasons (i.e. 






























































































































































































































































































































































































































































































































































































































Figure 1 Schematic representation of the pharmacodynamic model for nadroparin based on a two-
compartment pharmacodynamic model with a single transit compartment with parameters ktr and ka.
Figure 2 Empirical Bayes estimates for clearance versus total body weight and central volume versus 
lean body weight for the base two-compartment pharmacodynamic model for nadroparin in twenty-eight 
morbidly obese patients and seven non-obese patients using anti-Xa levels as an endpoint.






























convergence), which resulted in adequate diagnostic plots and improvement 
of the fit of the data compared with a one-compartment model.
The observed delay in appearance of anti-Xa levels after subcutaneous 
administration of nadroparin was described with a single transit 
compartment (see Figure 1), which proved superior over a lag time model 
(20) or a model with a first order rate absorption. Incorporation of additional 
transit compartments did not improve the fit of the data any further. It 
appeared that the model improved significantly (OFV reduction = 15 points 
, p<0.05) when ka and ktr were estimated separately. Implementation of a 
basal anti-Xa level (BLS) into the model was found to largely improve the 
diagnostic plots. 
The results of the systematic covariate analysis are shown in Table II and 
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Figure 2. TBW proved the most significant covariate on the basis of a linear 
function (-17.2 points, 10 degrees of freedom, p<0.005) compared a power 
function (- 19.1 points, 11 degrees of freedom, p<0.005) given the objective 
function in relation to the number of structural parameters (Table II). Adding 
lean body weight (LBW) as a linear covariate on V1 further improved the 
model in a significant manner (-11.9 points, p<0.005). No covariates were 
identified for the other pharmacodynamic parameters. After incorporation 
of these two covariates, interindividual variability on clearance and volume 
of distribution substantially decreased (Table III), and both individual plots 
and goodness-of-fit plots improved (Figure 3). The pharmacodynamic 
parameter estimates of the base model without covariates and the final 
covariate model along with the results of the bootstrap analysis are shown 
in Table 3. Figure 4 shows the results of the NPDE validation in all patients. 
The histogram follows a normal distribution expected by the solid line with 







CL/F (ml/min) 41.1 (7)
CL70 kg /F (ml/min)
# 23.0 (7) 99
V1/F (ml) 7380 (12)
V160 kg LBW /F (ml/min)
* 7020 (4) 100
V2/F (ml) = V1/F
Q/F (ml/min) 81.2 (11) 85.5 (2) 100
ktr (min
-1) 0.031 (18) 0.032 (17) 99
ka (min
-1) 0.0073 (7) 0.0076 (7) 103
BLS (anti-Xa IU) 0.022 (37) 0.021 (20) 100
OFV - 1909 - 1938 101
Interindividual variability (%)
CL 56.4 % (40) 38.9 % (29) 100
V1 35.4 % (33) 27.7 % (33) 98
ktr 87.9 % (39) 82.0 % (41) 96
BLS 111.6 % (47) 109.6 % (33) 105
Additive intraindividual error 0.00041 (17) 0.00041 (13) 99
#: CLi = CL70kg * (TBW/70)
*: V1i = V160kg * (LBW/60)
BLS = Baseline; CL = clearance; CL70kg = clearance in an individual of 70 kg; CLi = clearance in the ith individual; 
CV = coefficient of variation of the parameter values; ka = absorption rate constant; ktr = transit rate constant; 
OFV = objective function value; Q = compartmental clearance between V1 and V2; TBW = total body weight; 
V1 = central volume of distribution; V2 = peripheral volume of distribution. 
Table III   Population pharmacodynamic parameters for the base model and final 
model for nadroparin in thirty-five morbidly patients and non-obese patients
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Figure 4  Results of the internal validation with the NPDE method. The histograms show the NPDE frequency 
distribution for anti-Xa levels, the solid line indicates a normal distribution. The distribution of NPDE versus 
time and NPDE versus anti-Xa levels are also shown. The dotted lines represent the 90% distribution of the 
NPDE.
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Figure 3 Diagnostic plots for nadroparin pharmacodynamics in morbidly obese and non-obese patients 
showing individual anti-Xa level predictions versus observed anti-Xa levels, (A) population model anti-Xa 
level predictions versus anti-Xa levels (B), conditional weighted residuals versus population predicted anti-
Xa levels (C) and time (D) for both the base model and final covariate model. The solid grey line represents 
the line of identity, x=y.  
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            iscussion
In order to study the influence of body weight on the pharmacodynamics of 
low-molecular weight heparin (LMWH) nadroparin in morbidly obese and 
non-obese patients, a population pharmacodynamic model was developed 
using anti-Xa levels as endpoint. In this model, clearance proved to scale 
best with total body weight (TBW) and central volume of distribution with 
lean body weight (LBW). 
D


































Trad itional fixed dose r egimen M odel based dosing regimen
Figure 5 Model based predictions of anti-Xa levels upon a traditional fixed dose dosing regimen of 5,700 
IU =0.6 mL nadroparin for all morbidly obese patients (left panel) and upon a model based dosing regimen 
of 5,700 IU =0.6 mL nadroparin for patients with a lean body weight (LBW) lower than 90 kg and 7,600 IU 
(=0.8 mL) nadroparin for patients with a LBW higher than 90 kg (right panel). Profiles are simulated in three 
representative morbidly obese patients of the current study (grey solid line = total body weight (TBW) 107 kg 
and LBW of 53 kg, grey dotted line = TBW 135 kg and LBW = 65 kg and black solid line = TBW 162 kg and LBW 
= 94 kg.) . The horizontal dotted line represents the lower limit of prophylactic range (0.2 IU/mL).
Simulations
Based on the final pharmacodynamic model, simulations were performed 
aiming for anti-Xa levels of 0.2 IU/mL  4 hours after administration for morbidly 
obese patients. For these simulations, typical values without interindividual 
variability for all parameters were used to illustrate the influence of the 
covariates that were identified in this study. Supported by the results of the 
final covariate model, it seemed that morbidly obese patients with a lean 
body weight higher than 90 kg should receive 7,600 IU (0.8 ml) nadroparin 
and morbidly obese patients with a lean body weight lower or equal to 90 kg 
5,700 IU (0.6 ml) nadroparin. Results of the simulation of the traditional dose 
of 5,700 IU (0.6 mL) nadroparin and the model based dose of nadroparin in 
three representative morbidly obese patients are depicted in Figure 5.
 
As body weights are still increasing, there is high interest in the 
characterization of the influence of excessive body weight on 
pharmacokinetic and pharmacodynamics parameters of drugs in order to 
guide dosing in this special group of patient. For LMWHs such as nadroparin, 
central volume of distribution is the parameter of interest as this parameter 
mainly determines the maximum anti-Xa level, which is attained around 
4 hours after administration, and for which a prophylactic range has been 
defined (27). As LMWH are assumed to mainly distribute over vascular 
tissue and blood, and plasma volume is known to increase in a non-linear 
manner with TBW (28) and most probably with LBW, it has been suggested 
before to guide safe and effective dosing of a LMWH on the basis of LBW 
(29). However, in patients up to 160 kg, TBW proved the best size descriptor 
for central volume of enoxaparin, which is another LMWH (15-17, 30). 
The current study is the first study describing the pharmacodynamics of 
nadroparin for patients up to 252 kg. For this wide body wide range, LBW 
proved the best body size descriptor for central volume in this analysis of 
both non-obese and morbidly obese patients.
While there are no other reports on the pharmacodynamics of nadroparin 
in morbidly obese patients, previous reports on enoxaparin concerning 
the best body size descriptor for clearance of anti-Xa in non-obese adults 
suggest a non-linear function for TBW (16). However, for patients up to 160 
kg, the increase in clearance was described with a linear function using LBW 
as body size descriptor (17). However, this study used an outdated formula 
to calculate LBW that was found to be inconsistent at extremes of size (31). 
A recently reported formula for LBW that we used in our analysis, proved to 
be more reliable to estimate the fat free mass in both non-obese and obese 
patients (18) and was found to provide good predictive performance of the 
measured fat free mass in another study (1). Another way to describe the 
non-linear increase of clearance with TBW is allometric scaling (26), which 
has gained popularity most recently. The a priori use of allometry in obese 
patients is however considered to imply that obese individuals can be viewed 
as ‘large individuals’ (a different body size) instead of individuals ‘having 
excess body fat’ (a different body composition) (32). In the present study in 
morbidly obese and non-obese patients, we estimated an allometric scaling 
factor of 1.4, which was not significantly different from a linear function 
requiring a smaller number of structural parameters. As such, while testing 
all available body size descriptors, in this analysis in which a very large range 
in TBW (72 – 252 kg) could be evaluated, TBW was the best descriptor for 
clearance of anti-Xa in both morbidly obese and non-obese patients using a 
linear function.
In this study we found a delay in anti-Xa appearance in plasma. Different 
ways to describe the observed delay in effect were investigated. Using a lag 
11  PD model for nadroparin    
218 219
03
11  PD model for nadroparin    
time model (20), the time of dosing shifts as if the drug was administered at 
a delayed time point. In a transit model, the absorption delay is described as 
a drug transition through one or a chain of compartments that are linked to 
the central compartment (22). The latter approach in which the absorption 
rate gradually increases was found to adequately describe the observed 
profile of nadroparin in blood over time and proved superior over a lag time 
model. 
In the current study, we incorporated baseline anti-Xa activity into the 
structural model of nadroparin in both non-obese and morbidly obese 
patients. The activity of clotting factor Xa is generally used as a surrogate 
concentration measure as LMWH are mixture of substances (33) and 
therefore a kinetic assessment is complicated. It is known however that 
(low) endogenous anti-Xa activity may be present without the use of LMWH. 
While it is anticipated that this endogenous anti-Xa is due to the heparan 
sulfates that originate from the endothelial (34), basal activity is not often 
reported, even though a basal activity is obviously present in some of the 
reports (35-37). Although interindividual variability of BLS values was large 
for the entire population of morbidly obese and non-obese patients, the 
incorporation of a BLS as suggested by Schoemaker et al. (16) and which 
was also reported for tinzaparin (24), resulted in an improved description of 
the observations in our study. 
Since there are no reports available indicating a reduced biological availability 
of LMWH in obese patients (38, 39), it may be anticipated that the increased 
apparent clearance observed in morbidly obese patients compared with non-
obese patients is caused by an increased glomerular filtration in morbidly 
obese patients (40). Creatinine levels and age have been suggested before 
as covariates for anti-Xa levels after tinzaparin administration (24). In our 
study, we could not identify any influence of these covariates, possibly due 
to the small in range of age and creatinine levels. 
As stated before, measurement of anti-Xa levels is recommended in morbidly 
obese patients (41, 42) in absence of established dosing protocols for LMWH 
for these patients. Reports on these anti-Xa levels show that almost half of 
the morbidly obese patients exhibit anti-Xa levels below the prophylactic 
range for non-obese patients 0.2 - 0.5 IU/mL (19), suggesting that increased 
doses might be necessary. From the current study it seems that 5,700 IU (0.6 
ml) nadroparin is appropriate for morbidly obese patients up to a LBW of 90 
kg, while for morbidly obese patients with a LBW higher than 90 kg a larger 
dose of 7,600 IU (0.8 ml) is needed. This dosing regimen based on LBW 
should be explored as it aims for at least the same anti-Xa levels as non-obese 
patients (0.2 - 0.5 IU/mL (27)) while it is known that morbidly obese patients 
are at increased risk for VTE (4). The current pharmacodynamic model can 
be used even when in the future new target anti-Xa levels are established 
for thromboprophylaxis for this special group of patients. Therefore, it is 
advised to carefully monitor morbidly obese patients on bleedings and 
thrombotic events, as the exact relationship between anti-Xa levels and the 
occurrence of bleedings or VTE may not be known (43, 44).
            onclusion
In this study, we have developed a pharmacodynamic model for LMWH 
nadroparin using anti-Xa levels as endpoint in both morbidly obese and 
non-obese patients for a total body weight range from 72 kg until 252 kg. 
In the structural model, baseline anti-Xa activity was incorporated and 
the observed delayed effect of anti-Xa levels was described with a transit 
compartment. Based on the data available here, it appeared that clearance 
scaled with total body weight while lean body weight proved the major 
determinant for volume of distribution. Based on simulations using the 
final covariate pharmacodynamic model it appeared that a dose of 5,700 IU 
nadroparin will lead to target anti-Xa levels in morbidly obese patients with 
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    ntroduction
For most commonly used drugs in morbidly obese patients evidence 
based dosing guidelines are not available. Therefore, current dosing is 
based on experience of the prescriber rather than on clinical evidence. 
Pharmacokinetic and pharmacodynamics data in non-obese patients are 
extrapolated without proper exploration of influence of overweight on the 
dose-exposure-effect relationship.
The research described in this thesis focused on two commonly used drugs, 
propofol and the low-molecular-weight heparin (LMWH) nadroparin with 
the aim to develop weight appropriate dosing algorithms for these drugs 
in morbidly obese patients based on population pharmacokinetic and 
pharmacodynamics analysis. As an introduction to this thesis, in Chapter 2, 
a comprehensive overview is presented of clinical studies that reported on 
drug clearance estimates in both obese and non-obese patients. Most drug 
clearance values in obese patients were increased compared to non-obese 
patients, while clearance values of cytochrome P450 (CYP) 3A4 substrates 
were lower in obese as compared with non-obese patients. Very limited 
information was available in obese children.
        he influence of morbidly obesity on the pharmacokinetics and 
pharmacodynamics of propofol in adults, adolescents and children
In Chapter 3 we described that propofol clearance in morbidly obese adults 
can be predicted based on total body weight in an allometric function. The 
clearance of propofol could be predicted for a wide range of total body 
weights from 55 kg to 167 kg. The scaling factor of 0.72 did not change when 
the data in morbidly obese patients were combined with data of non-obese 
adults and proved to be in accordance with results from previous studies 
in non-obese patients (1, 2). Another aim was to explore the influence of 






using the Bispectral index (BIS) as pharmacodynamic endpoint. A two-
compartment biophase-distribution pharmacodynamic model, similar to 
a model described in non-obese patients (3-5), described our data well. 
Redistribution of propofol within the central nervous system was considered 
the most likely explanation for the observed biphasic distribution process. 
While the impact of obesity on pharmacodynamics parameters is rather 
unexplored, there are indications that obesity and related comorbidities can 
alter the pharmacodynamic response to drugs. For instance, obese patients 
showed an increased pain sensation as compared to non-obese patients 
(6). For propofol, we could not show a relationship between obesity and 
pharmacodynamic effect as none of the tested covariates in our morbidly 
obese patients significantly improved the pharmacodynamic model fit. 
The obtained pharmacodynamic parameters in morbidly obese patients 
were in accordance with previously reported pharmacodynamic parameter 
estimates of propofol in non-obese patients (3, 7). Therefore, our study 
provided the first preliminary data to suggest that there are no apparent 
differences between morbidly obese and non-obese patients in propofol 
effects as measured by the BIS. Of course, this finding has to be confirmed 
in a larger cohort and by analysing obese and non-obese pharmacodynamic 
patient data simultaneously. With the large between and within patient 
variability and the targeted BIS between 40 and 60 in morbidly obese 
patients, it is possible that more patient data covering a wider BIS range 
are needed to capture any influence of excessive body weight on the 
pharmacodynamics of propofol using the BIS. Based on the final propofol 
pharmacokinetic pharmacodynamic model, we derived a dosing algorithm 
for propofol-remifentanil anaesthesia targeting a BIS value of 40. In this 
model-based dosing algorithm, propofol infusion rates (in mg per kg per 
hour) are based on the adjusted body weight (according to ABW = 70 kg * 
(total body weight/70 kg)0.72).
In addition to these results, in Chapter 4 we showed that there are no 
differences in the individual pharmacokinetic or pharmacodynamic 
parameter estimates of propofol in morbidly obese patients receiving 
maintenance propofol-remifentanil or propofol-epidural anaesthesia 
using BIS values as pharmacodynamic endpoint. For non-obese patients, 
study results of the influence of remifentanil on propofol requirements are 
conflicting (8, 9). It cannot be excluded, however, that the exact influence 
of remifentanil on the level of anaesthesia may not be captured by the BIS. 
As the pharmacokinetic and pharmacodynamic study described in Chapter 
4 was a pilot study in only six morbidly obese patients receiving epidural 
anaesthesia, the results have to be confirmed in a larger population. 
In Chapter 5 the model based dosing algorithm developed in Chapter 3 
was prospectively evaluated in two different hospitals using BIS values 
as pharmacodynamic endpoint. To our knowledge this is the first study 
prospectively evaluating a model based dosing algorithm in morbidly 
obese patients. Fifty-one morbidly obese patients ranging in total body 
weight from 95 kg to 210 kg received stable and effective maintenance 
anaesthesia on the basis of BIS, blood pressure and heart rate. However, 
there were still concerns during the first twenty minutes after the propofol 
bolus dose as mean blood pressure then dropped more than 30% from 
pre-operative baseline values. In the study all patients received a fixed 
bolus dose of 350 mg propofol whereas individualisation of the induction 
dose might have alleviated some of these concerns. Recently, lean body 
weight has been suggested as a more appropriate dosing scalar to calculate 
propofol induction dose for morbidly obese patients and should therefore 
be considered instead of dose capping (10). Volumes of distribution are 
often used to calculate the loading dose of a drug resulting in a larger 
loading dose for a larger volume of distribution. In the pharmacokinetic and 
pharmacodynamic model derived in Chapter 3, there were no significant 
covariates to predict the central volume of distribution (V1), as V1 was 4.51 
L (SD 13.0) when analysed in morbidly obese patients versus 3.10 L (SD 8.3) 
when analysed in both non-obese and morbidly obese patients. In our view, 
this non-significant increase in V1 may be seen as a partial explanation for 
the drop in blood pressures during the first twenty minutes of anaesthesia 
described in Chapter 5. However, the concept of a loading dose for drugs 
that exhibit multi-compartmental pharmacokinetics even in non-obese 
patients is complex, and therefore the use of V1 as the major determinant 
of the loading dose may not be justified. Therefore, a well-designed study 
is needed to determine factors predicting the optimal propofol induction 
dose in combination with the propofol-remifentanil maintenance dose as 
described in Chapter 3. 
In Chapter 6 we described the effect of excessive weight on the 
pharmacokinetics of propofol in children and adolescents. While the 
prevalence of childhood obesity increased to 17% in 2008 in the US (11), 
studies providing adequate pharmacokinetic and pharmacodynamic data in 
these patients are lacking. In accordance with the effect of morbid obesity 
on the pharmacokinetics of propofol in adults as described in Chapter 3, 
propofol clearance in morbidly obese children and adolescents proved 
to scale best with total body weight using an allometric function with an 
estimated scaling factor of 0.80. These unique results were in accordance 
with the observed non-linear increase of propofol clearance with total body 
weight in non-obese children (1, 2, 12). Based on these results, propofol 
maintenance dose may be based on this non-linear relationship using total 
body weight. This finding will have to be confirmed using a pharmacodynamic 
endpoint such as the BIS.
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In order to fully characterize the influence of obesity and age, we performed 
in Chapter 7 a population pharmacokinetic meta-analysis for propofol on 
the basis of data from morbidly obese adults, adolescents and children and 
their non-obese controls. This model was based on data with a wide total 
body weight range of 37 – 184 kg and an age range of 9 – 79 years. The 
results showed that total body weight was the most predictive covariate 
for propofol clearance across all patients when implemented as a power 
function with a scaling factor of 0.77. Increased blood volume and cardiac 
output in obese patients may increase liver blood flow (13) and this may 
explain the observed increase of both propofol clearance and other high 
extraction drug clearance values such as paclitaxel (14). In addition, age was 
identified as a significant covariate using a bilinear function with two distinct 
slopes, reflecting an initial increase and subsequent decrease in clearance 
depending on age. The potential generalizability of this pharmacokinetic 
model with total body weight and age as covariates of propofol clearance 
may increase the applicability of this type of models to scale clearance of 
other drugs over wide total body weight and age ranges. 
Conclusions and recommendations
−  The increase in propofol clearance due to obesity in adults, adolescents 
and children can be described using total body weight as the body size 
descriptor using an allometric function with a scaling factor of 0.77.
−  The pharmacodynamics of propofol as measured by the BIS did not show 
an effect of excessive body weight in morbidly obese adults. This finding 
should be confirmed in a combined analysis of data obtained from both 
non-obese and (morbidly) obese adults, adolescents and children.
−  A model based dosing algorithm using an adjusted dosing weight for 
propofol maintenance infusion was successfully evaluated in a prospective 
study in morbidly obese adults and can therefore be implemented in daily 
practice.
−  The pharmacokinetic meta-analysis suggests to use a lower propofol 
maintenance dose in morbidly obese adolescents with the same body 
weight as morbidly obese adults.
    he influence of morbidly obesity on the pharmacodynamics of low 
molecular weight heparins 
 
As up to now, no dosing guidelines for low-molecular-weight heparins 
(LMWH) in morbidly obese patients are available, it is recommended to 
dose adjust based on anticoagulant effect using anti-Xa levels (15). In 
Chapter 8 we showed in a morbidly obese patient with pulmonary embolism 
weighing 252 kg, that effective anti-thrombotic therapy can be achieved 
using a lower dose based on anti-Xa levels as opposed to the recommended 
standard units per total body weight dose. The results suggested that the 
pharmacodynamics of LMWH are influenced by extreme overweight and 
therefore we investigated current dosing strategies for LMWH dosing and 
monitoring for (morbidly) obese patients. 
We conducted an online and telephone survey as described in Chapter 
9 among Dutch hospitals. Dosing adjustments in obese patients in Dutch 
hospital were found to differ widely. In the majority of the hospitals, LMWH 
dose was increased by body weight to a maximum dose based on a cut-off 
weight value (dosing cap). These cut-off weight values differed widely per 
institution and were based either on total body weight or BMI. Importantly, 
monitoring of the LMWH anticoagulant effect in morbidly obese patients 
using anti-Xa levels was not standard practice in any of the hospitals. 
In order to determine the most appropriate dose for LMWH in morbidly 
obese patients, we investigated the influence of excessive body weight on 
the nadroparin effect following a bolus dose as described in Chapter 10. In 
morbidly obese patients anti-Xa levels four hours after drug administration 
strongly correlated with lean body weight. Lean body weight has been 
proposed previously to estimate the therapeutic dose of enoxaparin 
another LMWH, in patients weighing more than 100 kg (16). In accordance 
with the present results, it has been reported that an increase in nadroparin 
dose did not result in a linear increase in maximum anti-Xa levels four hours 
after administration in obese patients (17). We showed that lean body 
weight based dosing correlates well with anti-Xa levels four hours after 
administration in morbidly obese patients and this method therefore is 
suggested as a suitable dosing scalar for nadroparin dosing.
In order to fully characterize the influence of excessive body weight on the 
pharmacodynamics of nadroparin we also measured anti-Xa levels after a 
bolus dose nadroparin in non-obese patients. Population pharmacodynamic 
modeling was used to describe the influence of body weight on each 
individual PD parameter in the model in order to develop a model-based 
dosing algorithm. In the final pharmacodynamic model for nadroparin 
described in Chapter 11 and in accordance with Chapter 10, we showed that 
in both non-obese and morbidly obese patients lean body weight was the 
best body size descriptor for the central volume of distribution. In addition, 
31% of the variability of clearance between patients could be explained with 
total body weight as body size descriptor. The pharmacodynamic model 
was based on a rich anti-Xa sampling schedule in patients over a wide total 
body weight range from 72 kg to 252 kg. Previous reports on the influence 
of excessive weight on the pharmacodynamics of other LMWH (enoxaparin, 
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tinzaparin and dalteparin) showed that obese patients have much higher 
total drug clearances than non-obese patients (18). For some other renally 
cleared drugs such as vancomycin, daptomycin and carboplatin it is known 
that clearance is increased, related to higher glomerular filtration rates in 
obese patients as described in Chapter 2 (19-21). Renal function is affected 
by excessive body weight as it has been shown that obese patients have 
a 62% increase in estimated glomerular filtration rate (22). Therefore, the 
observed increased clearance values and their association with total body 
weight are likely due to increased glomerular filtration in (morbidly) obese 
patients. For LMWH, the central volume of distribution is the parameter of 
interest as this parameter predominantly determines the maximum anti-Xa 
level, which is reached around four hours after administration, and for which 
a therapeutic target for prophylaxis has been defined in non-obese patients 
(18). LMWH are assumed to mainly distribute over blood and vascular 
tissues, and plasma volume is known to increase in a non-linear fashion 
with total body weight (23) and most probably also with lean body weight. 
Therefore, it has been suggested to guide safe and effective dosing of a 
LMWH on the basis of lean body weight (16). Although the prophylactic anti-
Xa target range is established for non-obese patients and not for morbidly 
obese patients, this model can be used as a clinically useful starting point 
until future research identifies alternate anti-Xa targets for safe and effective 
thromboprophylaxis in this special patient population. 
Conclusions and recommendations
−  There are large differences in the practice of thromboprophylaxis in 
morbidly obese surgical patients in Dutch hospitals, and current guidelines 
lack evidence-based dosing recommendations.
−  The central volume of distribution and peak anti-Xa levels correlate with 
lean body weight, suggesting that lean body weight is clinically useful for 
nadroparin dosing.
−  The developed pharmacodynamic model for nadroparin in non-obese and 
morbidly obese patients can be used as a starting point to further identify 
the appropriate anti-Xa targets in morbidly obese patients. 
    erspectives
In this thesis the focus was on studying the influence of morbid obesity on 
the pharmacokinetics and pharmacodynamics of propofol and nadroparin 
with the goal to develop safe and evidence-based dosing strategies. A 
non-linear relationship was found between propofol clearance and total 
body weight in both morbidly obese and non-obese adults, adolescents 
and children. Furthermore, the influence of age on propofol clearance was 
described using a bilinear function. For nadroparin in both morbidly obese 
and non-obese patients, total body clearance increased linearly with total 
body weight whereas the central of volume distribution increased linearly 
with lean body weight. 
As there is still an unmet clinical need for evidence based dosing 
algorithms for many commonly used drugs in morbidly obese patients, 
it should be emphasized that pharmaceutical companies need to be 
encouraged to start including (morbidly) obese patients in their clinical 
trials to identify the influence of excessive weight on the pharmacokinetics 
and pharmacodynamics of drugs and as part of the (early) phases of 
drug development. In the meantime, continued pharmacokinetic and 
pharmacodynamics research is desperately needed for most commonly 
used drugs in the morbidly obese population. These studies should focus on 
describing the influence of excessive overweight on the pharmacokinetic 
and pharmacodynamics parameters and include testing of all available 
body size descriptors. In this thesis, all available body size descriptors were 
tested and the most statistically significant covariates were incorporated 
into the final models. These empirical functions were based on model fit 
of the observed concentrations and observed effects. An alternative way 
to describe the influence of excessive body weight on pharmacokinetics 
has been proposed and entails the incorporation of lean body weight 
for all clearance values of all drugs using one allometric exponent of 0.66 
(24). This proposal was based on a meta-analysis of covariate relationships 
between clearance and body size of a series of different drugs (24). This 
suggestion is in line with the allometric scaling principles (25). The theory 
of allometry is based on the empirical observation that over a wide weight 
range, metabolic rates in animal species increase with body weight to the 
power of 0.75 (26). While this empirical allometric exponent has no obvious 
biological or physiological meaning and even for scaling between species, 
the existence of one unique value for the allometric clearance exponent is 
widely disputed (27-30). In spite of this, allometry has gained popularity for 
scaling ‘within’ a population of a single species, i.e. the human range (25). As 
obesity is related to body composition and the accumulation of excess body 
fat, we think that one should be careful in applying the theory of allometry 
or to use one body size descriptor for all drugs in (morbidly) obese patients. 
As shown in Chapter 2 of this thesis, not all metabolic activity is increasing 
with body weight as for instance CYP3A mediated clearance seems to 
decrease. In order to develop evidence based dosing guidelines for drugs 
in morbidly obese patients the influence of body weight on each of the 
pharmacokinetic and pharmacodynamic parameter should be characterized 
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by testing all available obesity and body size descriptors and be based on the 
characteristics of a drug. Instead of the common a priori use of total body 
weight for dosing guidelines, detailed information on pharmacokinetics and 
potentially also the pharmacodynamics needs to be considered in order to 
define effective and safe dosing regimens over a large body weight range.
Beside the identification of predictive body size descriptors for variability 
pharmacokinetic and pharmacodynamic parameters, the final covariate 
model should be validated and prospectively be evaluated. Before the 
final model based dosing algorithm is prospectively tested for accuracy as 
described in Chapter 5, a framework for model evaluation should be used. As 
shown by a literature review, most pharmacokinetic and pharmacodynamic 
modeling papers do not adequately describe all available evaluation steps 
(31). Model misspecification leads to poor predictive performance and 
could have far-reaching consequences when such pharmacokinetic and 
pharmacodynamic models are used as a basis for dosing algorithms in obese 
patients. Therefore, the accuracy of the covariate relationships across the 
entire range of covariate values should be evaluated during model building. 
Six evaluation criteria are suggested to be performed and reported during 
model building using data of (morbidly) obese patients and this is adapted 
from guidelines for pharmacokinetic and pharmacodynamic modeling in 
children (32). First, the influence of each covariate on the parameters is 
examined separately by implementing into exploratory covariate models 
which are compared with the simple base model (no covariates) using 
the objective function value. In addition, goodness-of-fit plots are used to 
evaluate if the model is able to describe the data accurately and without 
bias. If different data sets are combined, for example non-obese and obese 
data, goodness-of-fit plots should be generated for each data set separately 
in order to evaluate if the final covariate model is able to describe the data 
for the different (sub)groups (33). In order to judge the accuracy of the 
estimated parameters, confidence intervals or standard errors should be 
reported. Incorporated covariates need to describe the relationship with 
the parameter across the entire range of covariate values. Therefore, the 
eta distribution of the parameter with covariates should be plotted against 
this covariate. Finally, at least two internal validation steps should be used, 
e.g. bootstrap (34), visual predictive check (35) and/or normalised prediction 
distribution errors (36). 
The question remains how to further investigate drug dosing in obese 
patients in the future. As the prevalence of obesity and total body weights 
of both children and adults are still increasing and as this trend will persist, 
future studies assessing the impact of morbid obesity on specific drug 
elimination pathways in both children and adults are warranted. In the 
traditional pharmacokinetic and pharmacodynamics modeling approaches 
rather empirical models such as the Hill equation are used to describe in vivo 
dose-concentration-effect relationships. These equations do not provide 
insight into physiology or factors determining the concentration-effect 
relationship. In theory, the relationship between drug concentration and 
biological response depends on drug and biological system specific factors 
(37). The classical modeling can ultimately lead to physiological based 
pharmacokinetic modeling as can be done using software such as the Simcyp 
software (Simcyp Ltd, UK) (38, 39). Using this software the obesity related 
(patho)-physiological changes such as for example blood volume, liver blood 
flow, kidney function and metabolic processes can be incorporated in the 
model. Furthermore, physicochemical drug properties like the molecular 
mass, the octanol/water partition coefficient (logP) and the acid dissociation 
constant (pKa) are taken into account. As data of specific (patho)-
physiological processes in (morbidly) obese patients may not all be available, 
these models currently also rely on assumptions and on in vitro parameters. 
Therefore, information generated using traditional pharmacokinetic and 
pharmacodynamic modeling may be of added value to obtain evidence 
based dosing guidelines and to gain information about the influence of 
excessive body weight on the pharmacokinetics and pharmacodynamics. 
However, it is unlikely that thoroughly validated pharmacokinetic covariate 
models will be developed for every existing drug prescribed for (morbidly) 
obese patients across the entire weight range. Therefore, more efficient 
approaches have to be set up to develop safe and effective dosing regimens 
for this special group of patients. In Chapter 2, we described the current 
knowledge of the impact of obesity on drug metabolism and elimination 
and how it differs per drug based on metabolic or elimination pathway. This 
implies that covariate relationships describing the influence of obesity on 
the clearance of a specific drug may be extrapolated to other drugs if cleared 
through the same pathway, which has been described before in children (40, 
41). The extrapolation of covariate models between drugs would expedite 
the development of obesity pharmacokinetic and pharmacodynamics 
models, which in its turn could help with the individualization of drug dosing 
in first-in-obese studies and in facilitating the development of evidence-
based dosing recommendations for obese patients.
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     utch summaryD
   ntroductie
Voor morbide obese patiënten zijn voor de meest gebruikte geneesmiddelen 
geen wetenschappelijk onderbouwde doseringsrichtlijnen beschikbaar. 
De gekozen dosering wordt met name gebaseerd op de ervaring van 
de voorschrijver in plaats van op klinisch bewijs. Daarnaast worden 
farmacokinetische en farmacodynamische gegevens van niet-obese 
patiënten geëxtrapoleerd zonder een goede verkenning van de invloed van 
overgewicht op de dosis-blootstelling-effect relatie.
Het onderzoek beschreven in dit proefschrift richt zich op twee 
veelgebruikte geneesmiddelen rondom chirurgische ingrepen: propofol 
en de laagmoleculair gewicht heparine (LMWH) nadroparine. Het doel 
is om voor morbide obese patiënten onderbouwde doseringsalgoritmen 
te ontwikkelen met behulp van populatie farmacokinetische en 
farmacodynamische analyses. Als inleiding op dit proefschrift wordt in 
hoofdstuk 2 een uitgebreid overzicht gegeven van de klinische studies 
waarin schattingen van de geneesmiddelklaring in zowel obese als niet-
obese patiënten worden beschreven. Voor obese kinderen was slechts zeer 
beperkte informatie beschikbaar.
           e invloed van morbide obesitas op de farmacokinetiek en 
farmacodynamiek van propofol in volwassenen, adolescenten en kinderen
In hoofdstuk 3 beschreven we dat de propofol klaring van morbide obese 
volwassenen kan worden voorspeld op basis van het totale lichaamsgewicht 
met behulp van een allometrische functie met een exponent van 0,72. 
Dit was van toepassing voor patiënten met een totaal lichaamsgewicht 
variërend van 55 kg tot 167 kg. De gevonden exponent van 0,72 veranderde 
niet wanneer de gegevens van morbide obese patiënten werden 
gecombineerd met gegevens van niet-obese volwassenen. Tevens werd 
in dit hoofdstuk de invloed van overgewicht op de farmacodynamiek 
van propofol anesthesie, gemeten met behulp van de Bispectral index 
(BIS), verkend. Een twee-compartimenten farmacodynamisch model, 
vergelijkbaar met een model beschreven in niet-obese patiënten (1-3), 
bleek de data goed te beschrijven. Herverdeling van propofol binnen 
het centrale zenuwstelsel werd beschouwd als de meest waarschijnlijke 





invloed van obesitas op farmacodynamische parameters een onontgonnen 
onderzoeksgebied is, waren er aanwijzingen dat obesitas en gerelateerde 
comorbiditeiten de farmacodynamische respons op geneesmiddelen 
kunnen veranderen. Zo bleken obese patiënten bijvoorbeeld een verhoogde 
pijnsensatie te vertonen in vergelijking tot niet-obese patiënten (4). 
Aangezien geen van de geteste covariaten het beschrijvend vermogen 
van het farmacodynamische model verbeterde, werd er geen invloed 
van overgewicht op de farmacodynamiek van propofol in morbide obese 
patiënten aangetoond. De verkregen farmacodynamische parameters 
in morbide obese patiënten waren in overeenstemming met eerder 
gerapporteerde farmacodynamische parameters van propofol in niet-obese 
patiënten (1, 5). Dit is de eerste analyse die erop wijst dat er geen duidelijke 
verschillen zijn in de concentratie-effect relatie van propofol gemeten met 
behulp van de BIS tussen morbide obese en niet-obese patiënten. Het lijkt 
van belang deze bevindingen te bevestigen in een groter cohort en door 
het tegelijkertijd analyseren van obese en niet-obese farmacodynamische 
patiëntgegevens. Op basis van het uiteindelijke propofol farmacokinetisch 
en farmacodynamisch model hebben we een doseeralgoritme voor 
propofol-remifentanil anesthesie afgeleid, gericht op een BIS waarde van 
40. In dit doseringsalgoritme worden propofol infusiesnelheden (in mg/
kg/uur) berekend op een gecorrigeerd lichaamsgewicht ( = 70 kg * (totaal 
lichaamsgewicht/70 kg)0,72).
In aansluiting op deze resultaten hebben we in hoofdstuk 4 laten zien dat 
er geen verschillen zijn in de farmacokinetische en farmacodynamische 
parameters van propofol in morbide obese patiënten die onderhoud propofol-
remifentanil of propofol-epidurale anesthesie kregen met BIS-waarden als 
farmacodynamische eindpunt. Terwijl we in morbide obese patienten geen 
aanwijzingen vonden voor invloed van remifentanil op de farmacokinetische 
en farmacodynamische parameters, zijn de studieresultaten voor niet-obese 
patiënten conflicterend en afhankelijk van het gekozen eindpunt (6, 7). Van 
belang hierbij is dat niet kan worden uitgesloten dat de precieze invloed van 
remifentanil op het niveau van anesthesie mogelijk niet goed kan worden 
beschreven met behulp van de BIS. Daarom moeten de resultaten van deze 
pilot in zes morbide obese patiënten worden bevestigd in een groter cohort 
waarbij verschillende eindpunten worden meegenomen.
In hoofdstuk 5 is het op het farmacokinetische en farmacodynamische 
model gebaseerde doseringsalgoritme zoals beschreven in hoofdstuk 3 
prospectief geëvalueerd in twee verschillende ziekenhuizen met behulp van 
BIS waarden als farmacodynamische eindpunt. Voor zover ons bekend is dit 
de eerste studie, die prospectief een doseringsalgoritme gebaseerd op een 
farmacokinetiek en farmacoynamiek model bij morbide obese patiënten, 
evalueert. In 51 morbide obese patiënten variërend in totaal lichaamsgewicht 
van 95 kg tot 210 kg werd stabiele en effectieve onderhoudsanesthesie 
verkregen gemeten op basis van de BIS, bloeddruk en hartslag. Tijdens 
de eerste twintig minuten na de bolusinjectie van propofol daalde de 
gemiddelde bloeddruk echter met meer dan 30% ten opzichte van de 
preoperatieve bloeddruk. Dit kan wellicht verklaard worden doordat in de 
studie alle patiënten een bolus dosis van 350 mg propofol kregen, terwijl 
individualisering van de inductiedosis deze bloeddrukdaling mogelijk zou 
hebben kunnen verminderd. Onlangs is lean body weight voorgesteld 
als een meer geschikte doseermaat om de propofol inductie dosis te 
berekenen in morbide obese patiënten (8). Verdelingsvolumina worden 
vaak gebruikt om de initiële dosis van een geneesmiddel te berekenen, 
resulterend in een grotere oplaaddosis voor een groter verdelingsvolume. 
In het farmacokinetische en farmacodynamische model beschreven in 
hoofdstuk 3 werden geen significante covariaten gevonden voor het centrale 
verdelingsvolume (V1). Wel was het geschatte V1 in morbide obese patiënten 
groter dan het V1 in de analyse van de gezamenlijke data van niet-obese en 
morbide obese patiënten  (4,51 L (SD 13,0) versus 3,10 L (SD 8,3)). Naar onze 
mening kan deze niet-significante toename in V1 worden gezien als een 
gedeeltelijke verklaring voor de daling van de bloeddruk tijdens de eerste 
twintig minuten van de anesthesie beschreven in hoofdstuk 5. Het concept 
van een bolus dosis voor geneesmiddelen die meerdere compartimenten 
farmacokinetiek vertonen is complex en daarom is het gebruik van V1 als 
de belangrijkste determinant van de oplaaddosis mogelijk niet geheel 
gerechtvaardigd. Een studie is nodig om voorspellende factoren van de 
optimale propofol inductiedosis in combinatie met de propofol-remifentanil 
onderhoudsdosering als beschreven in hoofdstuk 3 nader te bepalen. 
In hoofdstuk 6 beschrijven we de effecten van overgewicht op de 
farmacokinetiek van propofol in kinderen en adolescenten. Terwijl in de 
VS in 2008 de prevalentie van obesitas onder kinderen steeg tot 17% (9), 
ontbreken er adequate farmacokinetische en farmacodynamische gegevens 
in deze patiënten. Analoog aan het effect van morbide obesitas op de 
farmacokinetiek van propofol bij volwassenen zoals beschreven in hoofdstuk 
3, bleek de propofol klaring van morbide obese kinderen en adolescenten het 
beste te schalen met totale lichaamsgewicht in een allometrische functie met 
een exponent van 0,80. Deze unieke resultaten waren in overeenstemming 
met de waargenomen niet-lineaire stijging van de propofol klaring met 
het totale lichaamsgewicht in niet-obese kinderen (10-12). Op basis van de 
huidige resultaten kan de propofol onderhoudsdosering worden gebaseerd 
op deze niet-lineaire relatie tussen de klaring van propofol en het totale 
lichaamsgewicht. Deze bevinding moet worden bevestigd met behulp van 
evaluaties van farmacodynamische eindpunten, zoals de BIS, zodat de 
farmacokinetiek farmacodynamiek relatie in morbide obese kinderen kan 




Om de gehele invloed van obesitas en leeftijd op de farmacokinetiek 
van propofol te kunnen karakteriseren, voerden we in hoofdstuk 7 
een populatie farmacokinetische meta-analyse uit met gegevens van 
morbide obese volwassenen, adolescenten en kinderen en hun niet-obese 
controle patiënten. Het uiteindelijke model is gebaseerd op gegevens van 
patiënten met een brede spreiding aan totale lichaamsgewichten (37 - 
184 kg) en leeftijden (9 - 79 jaar). De resultaten lieten zien dat het totale 
lichaamsgewicht met behulp van een allometrische functie met een 
exponent van 0,77 de meest voorspellende covariaat is om de verandering in 
propofol klaring voor alle patiënten te beschrijven. Een mogelijke verklaring 
voor deze toename van de propofol klaring met het totale lichaamsgewicht 
is, net als voor andere “high extraction drugs”, zoals paclitaxel (13), een 
verhoogd bloedvolume en cardiale output, waardoor de bloedtoevoer naar 
de lever vergroot is (14). Daarnaast werd leeftijd als significante covariaat 
beschreven met een bilineaire functie met twee verschillende hellingen: 
een aanvankelijke stijging met daaropvolgend een afname in klaring met 
de leeftijd. Het verdient aanbeveling dat dit farmacokinetische model 
met totaal lichaamsgewicht en leeftijd als covariaten voor klaring nader 
te onderzoeken bij data analyse van andere geneesmiddelen in patiënten 
cohorten met sterk uiteenlopende gewichten en leeftijden. 
Conclusies en aanbevelingen
-  De toename in propofol klaring als gevolg van (morbide) obesitas bij 
volwassenen, adolescenten en kinderen kan worden beschreven met 
behulp van het totale lichaamsgewicht als de gewichtsmaat in een 
allometrische functie met een exponent van 0,77.
-  De farmacodynamiek van propofol gemeten met de BIS liet geen effect 
van overgewicht in morbide obese volwassenen zien. Deze bevinding moet 
worden bevestigd in een gecombineerde analyse van gegevens van zowel 
niet-obese als (morbide) obese volwassenen, adolescenten en kinderen.
-  De propofol onderhoudsdosering gebaseerd op het farmacokinetiek 
en farmacodynamiek model, gebruikmakend van een gecorrigeerd 
lichaamsgewicht werd met succes geëvalueerd in een prospectieve studie 
in morbide obese volwassenen en kan daarom worden toegepast in de 
dagelijkse praktijk.
-  De farmacokinetische meta-analyse laat zien dat een lagere propofol 
onderhoudsdosis gebruikt moet worden in een morbide obese adolescent 
met hetzelfde lichaamsgewicht als een morbide obese volwassene.
           e invloed van morbide obesitas op de farmacodynamiek van 
laagmoleculair gewicht heparines
Aangezien er op dit moment geen richtlijnen beschikbaar zijn voor het 
doseren van laagmoleculair gewicht heparines (LMWHs) bij morbide obese 
patiënten, wordt aanbevolen de dosis te baseren op het antistollingseffect, 
gemeten met behulp van anti-Xa spiegels (15). In hoofdstuk 8 hebben 
we laten zien, dat in een morbide obese patiënt van 252 kg met een 
gediagnostiseerde longembolie, effectieve anti-Xa spiegels worden bereikt 
met een lagere dosis dan de aanbevolen dosis op basis van het totale 
lichaamsgewicht. Het resultaat suggereerde dat de farmacodynamiek 
van LMWHs wordt beïnvloed door extreem overgewicht. Dit was voor 
ons de aanleiding om het huidige beleid voor het doseren van LMWHs 
in (morbide) obese patiënten in kaart te brengen. Daarvoor hebben wij 
in hoofdstuk 9 online en telefonisch een enquête uitgevoerd onder alle 
Nederlandse ziekenhuizen. Dosisaanpassingen in obese patiënten in de 
Nederlandse ziekenhuizen bleken sterk uiteen te lopen. In het merendeel 
van de ziekenhuizen werd de LMWH dosis verhoogd boven een bepaalde 
cut-off waarde van het gewicht. Deze waarde was gebaseerd op het totale 
lichaamsgewicht of BMI en verschilde per instelling. Opvallend was dat 
controle van het antistollingseffect door LMWHs in morbide obese patiënten 
met behulp van anti-Xa spiegels niet gangbaar was in de ziekenhuizen.
Om de meest geschikte dosis LMWH in morbide obese patiënten te 
bepalen, onderzochten we in hoofdstuk 10 de invloed van overgewicht op 
het effect van een bolus dosis nadroparine. De anti-Xa spiegels vier uur na 
toediening bleken te correleren met lean body weight. Lean body weight 
is eerder voorgesteld als doseermaat voor de therapeutische dosis van 
enoxaparine, een ander LMWH, bij patiënten met een gewicht boven de 100 
kg (16). In overeenstemming met onze resultaten, is eerder beschreven dat 
het verhogen van de nadroparine dosering resulteerde in een niet-lineaire 
toename van de maximale anti-Xa spiegel vier uur na toediening in obese 
patiënten (17). Wij stellen daarom voor lean body weight te gebruiken als 
doseermaat voor nadroparine.
Om de invloed van overgewicht op de farmacodynamiek van nadroparine 
volledig te karakteriseren, zijn ook anti-Xa spiegels gemeten na een 
bolusdosis nadroparine in niet-obese patiënten. Een farmacodynamische 
populatie analysemethode werd gebruikt om de invloed van het 
lichaamsgewicht op elke afzonderlijke farmacodynamische parameter te 
beschrijven om zo een onderbouwd doseringsalgoritme te ontwikkelen. In 
het farmacodynamische model voor nadroparine beschreven in hoofdstuk 
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D
Conclusies en anbevelingen
-  De toename in propofol l ri  l  l  van (morbide) obesitas bij 
volwa senen, adolescenten en i r   orden beschreven met 
behulp van het totale li i  l   gewichtsmaat in e n 
allometrische functie met en exponent van 0, 7.
-  De farmacodynamiek van propofol    BIS liet ge n effect 
van overgewicht in morbide obese volwassenen zien. Deze bevinding 
moet worden bevestigd in een g combi eerd  analyse a  gegevens 
van zow l niet- bese als (morbide) obese volwa s en, adolesc nten 
n kinderen.
-  De propofol onderhoudsdosering gebaseerd op het farmacokineti k 
en farmacodynamiek model, gebruikmakend va  een gecorrigeerd 
lichaamsgewicht werd met succes geëv lueerd in een prospectieve 
studie in morbide obese volwassenen en kan daarom worden toegepast 
in de dagelijks  praktijk.
-  De farmacokinetische meta-analyse laat zien dat een lagere propofol 
onderhoudsdosis gebruikt moet worden in een morbide obese adolescent 
met hetzelfde lichaamsgewicht als een morbide obese volwassene.
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11 hebben we laten zien dat zowel in niet-obese als morbide obese patiënten lean 
body weight de beste gewichtsmaat voor het centrale verdelingsvolume was. 
Bovendien kon 31% van de interindividuele variatie in de klaring worden verklaard 
met het totale lichaamsgewicht. Het farmacodynamische model is gebaseerd op 
een groot aantal anti-Xa spiegels per patiënt uit patiënten die sterk varieerden 
in lichaamsgewicht (72 kg tot 252 kg). Eerdere publicaties over de invloed 
van overgewicht op de farmacodynamiek van andere LMWHs (enoxaparine, 
tinzaparin en dalteparine) toonden aan dat patiënten met obesitas een hogere 
totale geneesmiddel klaring hebben dan niet-obese patiënten (18). Voor enkele 
andere renaal geklaarde geneesmiddelen zoals vancomycine, daptomycine en 
carboplatine is bekend dat de klaring is verhoogd, wat gerelateerd wordt aan een 
hogere glomerulaire filtratiesnelheid bij obese patiënten, zoals ook is beschreven 
in hoofdstuk 2 (19-21). De nierfunctie wordt beïnvloed door overgewicht, omdat 
obese patiënten een 62% toename van de geschatte glomerulaire filtratiesnelheid 
hebben (22). Daarom wordt de verhoogde klaring van nadroparine met het totale 
lichaamsgewicht waarschijnlijk veroorzaakt door een toegenomen glomerulaire 
filtratie in (morbide) obese patiënten. Voor LMWH is het centrale verdelingsvolume 
de belangrijkste parameter, omdat deze parameter voornamelijk de maximale anti-
Xa spiegel vier uur na toediening, bepaalt en waarvoor een profylactische range is 
gedefinieerd in niet-obese patiënten (18). Er wordt verondersteld dat LMWH zich 
voornamelijk verdelen over bloed en vasculaire weefsels. Daarnaast is bekend 
dat het plasmavolume niet-lineair toeneemt met het totale lichaamsgewicht 
(23) en waarschijnlijk lineair met lean body weight. Daarom is eerder al lean body 
weight voorgesteld als doseermaat voor het doseren van LMWH (16). Omdat de 
profylactische anti-Xa streefspiegels zijn vastgesteld voor niet-obese patiënten, 
kan het zijn dat in de toekomst andere anti-Xa streefspiegels voor morbide obese 
patiënten worden vastgesteld. Het huidige model kan dan gebruikt worden 
om veilige en effectieve doseringen voor tromboseprofylaxe in deze bijzondere 
patiëntenpopulatie te bepalen waarbij deze streefspiegels daadwerkelijk in alle 
morbide obese patiënten met variërende lichaamsgewichten worden bereikt. 
Conclusies en aanbevelingen
-  Er zijn grote verschillen in de praktijk van tromboseprofylaxe in (morbide) 
obese chirurgische patiënten in Nederlandse ziekenhuizen. In de huidige 
richtlijnen ontbreken onderbouwde dosis aanbevelingen.
-  Het centrale distributievolume en de maximale anti-Xa spiegel zijn 
gecorreleerd met lean body weight, hetgeen suggereert dat lean body 
weight gebruikt kan worden voor het doseren van nadroparine. 
-  Het ontwikkelde farmacodynamische model voor nadroparine kan in 
de toekomst worden gebruikt om met de juiste anti-Xa streefspiegels 
voor morbide obese patiënten veilige en effectieve doseringen voor 
tromboseprofylaxe in deze bijzondere patiëntenpopulatie te bepalen.
           e invloed van obesitas op de farmacokinetiek en farmacodynamiek 
van geneesmiddelen in adolescenten en volwassenen: perspectieven van 
het onderzoek
In dit proefschrift lag de nadruk op het bestuderen van de invloed van 
morbide obesitas op de farmacokinetiek en farmacodynamiek van propofol 
en nadroparine met als doel veilige en wetenschappelijk onderbouwde 
doseringsrichtlijnen te ontwikkelen. Aangezien er grote klinische behoefte is 
aan onderbouwde doseringsrichtlijnen voor veel gebruikte geneesmiddelen 
in morbide obese patiënten zou er niet alleen onderzoek zoals beschreven in 
dit proefschrift uitgevoerd moeten worden, de farmaceutische industrie zou 
tevens moeten worden aangemoedigd deze patiënten in klinische studies te 
includeren. Alleen dan kan de invloed van overgewicht op de farmacokinetiek 
en farmacodynamiek van geneesmiddelen tijdens de eerste fasen van 
geneesmiddelontwikkeling worden geïdentificeerd. In de uit te voeren 
farmacokinetische en farmacodynamische studies in deze patientengroep 
zouden alle beschikbare gewichtsmaten zoals totaal lichaamsgewicht, 
BMI en lean body weight moeten worden onderzocht. In dit proefschrift 
werden deze gewichtsmaten getest en de meest significante gewichtsmaat 
werd opgenomen in het uiteindelijke model. Alternatieve methoden om 
de invloed van overgewicht op de farmacokinetiek te beschrijven zijn lean 
body weight met een exponent van 0,66 voor alle geneesmiddelklaringen 
te gebruiken (24) of het hanteren van de allometrische theorie (25). 
Laatstgenoemde theorie is gebaseerd op empirische observaties dat de 
stofwisseling tussen diersoorten toeneemt met het lichaamsgewicht 
met een exponent van 0,75 (26). Zoals beschreven in hoofdstuk 2 van dit 
proefschrift, nemen niet alle metabolische activiteiten tussen mensen toe 
met het lichaamsgewicht. CYP3A gemedieerde geneesmiddelklaringen 
lijken daarbij zelfs af te nemen. Daarbij is obesitas, naast de ophoping van 
overtollig vet, een aandoening die de (patho)fysiologie beïnvloedt, waardoor 
men voorzichtig moet zijn bij het gebruik van de allometrische theorie of 
het gebruik van één lichaamsmaat voor alle geneesmiddelen in (morbide) 
obese patiënten. Naast de identificatie van voorspellende gewichtsmaten 
voor de variabiliteit van de farmacokinetische en farmacodynamische 
parameters, moet het uiteindelijke model worden gevalideerd en 
prospectief geëvalueerd, zoals beschreven in hoofdstuk 5. Uit de literatuur 
blijkt dat de meeste farmacokinetische en farmacodynamische studies niet 
adequaat alle beschikbare evaluatie- en validatiestappen te beschrijven (27). 
Misspecificatie van modellen kan leiden tot slechte voorspellende waarden 
van het model en het kan verstrekkende gevolgen hebben wanneer deze 
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Conclusies en anbevelingen
-  Er zijn grote verschi len i  ij  van tromboseprofylaxe in (morbide) 
obese chirurgische patiënten i  i i . In de huidige 
richtlijnen ontbreken onderbouwde do is anbevelingen.
-  Het centrale distributievolu e  i l  anti-Xa spiegel zijn 
gecorrel erd met lean body s ereert dat lean body 
weight gebruikt kan worden v or het doseren van nadroparine. 
-  Het ontwi kelde far acodyna ische l  nadroparine kan in 
de toekomst worden gebruikt e juiste anti-Xa stre fspiegels 
v or morbide obese ti t   effectieve doseringen vo r 
tromboseprofylaxe in deze bijzondere patiëntenpopulatie te bepalen.
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farmacokinetische en farmacodynamische modellen worden gebruikt als 
basis voor het doseren van geneesmiddelen in morbide obese patiënten. De 
nauwkeurigheid van de gewichtsmaten in het uiteindelijke model moeten 
daarom worden geëvalueerd over de gehele gewichtsrange. In hoofdstuk 
12 worden zes evaluatiecriteria voorgesteld om te worden uitgevoerd en 
gerapporteerd bij de validatie van farmacokinetische en farmacodynamische 
modellen voor morbide obese patienten. Deze criteria zijn een bewerking 
van richtlijnen voor farmacokinetisch en farmacodynamisch onderzoek 
in kinderen (28). De vraag blijft hoe de dosering voor geneesmiddelen in 
morbide obese patiënten in de toekomst moeten worden onderzocht. 
Aangezien de prevalentie van obesitas en de totale lichaamsgewichten van 
zowel kinderen als volwassenen nog steeds toenemen, zijn studies naar de 
impact van morbide obesitas op specifieke geneesmiddel eliminatieroutes 
in zowel kinderen als volwassenen gerechtvaardigd. De traditionele 
farmacokinetische en farmacodynamische modellen hanteren veelal 
empirische modellen zoals de Hill vergelijking die wordt gebruikt om in vivo 
dosis-concentratie-effect relaties te beschrijven. Deze vergelijkingen geven 
niet altijd inzicht in de fysiologie of in factoren die de concentratie-effect 
relatie beïnvloeden. In theorie is de relatie tussen geneesmiddelconcentratie 
en biologische respons afhankelijk van geneesmiddelfactoren en biologische 
factoren (29). De klassieke farmacokinetische en farmacodynamische 
modellen kunnen uiteindelijk wel leiden tot een fysiologisch model, al 
dan niet ondersteund met behulp van de Simcyp software (Simcyp Ltd, 
UK) (30, 31). Met deze software kunnen naast de obesitas gerelateerde 
(patho)fysiologische veranderingen zoals bijvoorbeeld bloedvolume en 
metabole processen ook fysische eigenschappen van het geneesmiddel 
worden opgenomen in het model. Het is onwaarschijnlijk dat voor elk 
bestaand geneesmiddel in (morbide) obese patiënten grondig gevalideerde 
farmacokinetische modellen zullen worden ontwikkeld. Een efficiëntere 
benadering moet daarom worden opgezet om veilige en effectieve 
doseringsschema’s voor deze speciale groep patiënten te ontwikkelen. In 
hoofdstuk 2 werd beschreven hoe de invloed van obesitas op het metabolisme 
en de eliminatie van geneesmiddelen per route verschilt. Voorgesteld wordt 
om de gewichtsmaat en functie die de invloed van obesitas op de klaring 
van een bepaald geneesmiddel beschrijft, te extrapoleren naar andere 
geneesmiddelen die via dezelfde route worden geklaard uit het lichaam. De 
extrapolatie van deze modellen kan de ontwikkeling van farmacokinetische 
en farmacodynamische modellen voor geneesmiddelen in (morbide) obese 
patiënten versnellen en kan helpen bij de individualisering van de dosering 
van geneesmiddelen.
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De tocht van het promoveren doet me denken aan mijn hobby wielrennen. 
Onderweg kom je allerlei hindernissen tegen die je wil en moet overwinnen: 
lekke banden maar ook beklimmingen naar de top en als je het lukt is de 
afdeling daarna heerlijk genieten. Met doorzettingsvermogen bereik je de 
finish: moe maar voldaan. Naast dat alleen promoveren onmogelijk is, is het 
net zoals alleen fietsen ook heel erg saai. Ik ben blij dat ik dit proefschrift 
samen met velen heb weten te realiseren. Iedereen die heeft bijgedragen 
aan de totstandkoming van dit proefschrift wil ik bedanken waarbij ik een 
aantal bijzondere mensen specifiek wil benoemen.
Beste Catherijne, jij bent degene die mij de mogelijkheid heeft gegeven 
dit project te realiseren. Ik kwam het St. Antonius binnen met een passie 
voor het vak ziekenhuisapotheker en ga nu weg met een extra passie; 
PKPD onderzoek. Tijdens mijn opleiding tot ziekenhuisapotheker kwam ik 
er achter dat ik alleen bij jou zou willen promoveren. Je steun gedurende 
dit traject heeft mij er doorheen getrokken. Ik heb erg veel waardering voor 
de manier waarop je mensen kan motiveren met je enthousiasme voor het 
onderzoek. 
Beste Sander, jij hebt mij de kans geboden om 3 maanden onderzoek te 
kunnen doen in het Cincinnati Children’s Hospital en dit heeft unieke data 
van obese kinderen opgeleverd. Daarnaast heb je mij tijdens mijn bezoek 
aan de VS aangespoord om vol te houden tot het einde en zie daar. De goede 
en unieke samenwerking tussen Nieuwegein en Cincinnati blijft hopelijk in 
stand.
Beste Eric, je gedreven uitleg over de vier pijlers van de anesthesie en je 
onvoorwaardelijke hulp tijdens de voorbereidingen en ook tijdens het 
includeren hebben er voor gezorgd dat er in korte tijd veel data kon worden 
verzameld. 
Beste Bert, ik werd aangestoken door het enthousiasme van je om de 
onderzoekslijn bariatrie in het St. Antonius Ziekenhuis uit te breiden en 
overal nieuwe mogelijkheden te zien voor vervolg onderzoeken. Jij maakt 
ons onderzoek mogelijk door ons te ‘gedogen’ tijdens jouw operaties. 
Beste Mathieu, ten eerste ben ik natuurlijk heel dankbaar dat jij mij ooit 
hebt aangenomen in het St. Antonius Ziekenhuis voor de opleiding tot 
ziekenhuisapotheker. De kracht om met plezier nieuwe ontwikkelingen en 
uitdagingen aan te gaan hebben mij geïnspireerd, zeker ook bij dit onderzoek. 
Als niet academisch ziekenhuis zo veel onderzoek doen, maakt promoveren 
in het St. Antonius Ziekenhuis bijzonder. Dank voor je onvoorwaardelijke 
steun en je humor. Hopelijk blijven we elkaar zien in het kleine wereldje van 
de ziekenhuisfarmacie.
Ik wil alle medewerkers van de afdelingen Anesthesie, Heelkunde, Klinische 
Chemie en het Farmaceutisch Tox Lab bedanken voor hun hulp tijdens dit 




In het bijzonder dank ik Brigitte, Silvia, Koos en Lilian voor hun hulp. Ook 
alle patiënten die toestemming hebben gegeven om mee te doen aan dit 
onderzoek dank ik. Zonder data geen onderzoek. Het PK-PD modelleren 
heb ik ook zeker geleerd van de medewerkers van LAP&P Consultants. In 
het bijzonder Tamara van Steeg bedankt voor je enthousiaste en duidelijke 
uitleg. De studenten die mij hebben geholpen met allerlei klussen en 
onderzoeken en het ook gezellig hebben gemaakt, wil ik hier graag noemen: 
Margot, Esther en Christine. De interactie hield mij scherp. Simone en Aletta, 
jullie wil ik danken voor alle hulp vooral tijdens de inclusie. 
tCollega’s van de Klinische Farmacie met in het bijzonder mijn 
onderzoeksmaatjes Rifka, Magreke en Anne en de apothekers waarmee 
ik mijn opleiding tot ziekenhuisapotheker heb gedaan Ewoudt, Ankie, 
Roeland, Bas en Tanja: ik heb genoten van alle inhoudelijke discussies maar 
ook van al het plezier op de afdeling. Hopelijk houden we de etentjes en de 
kleine biertjes drinken erin. I, I follow…
Marly na het zien van je afstuurprojecten van de Design Academy wist ik 
dat jij voor mij het boekje moest vormgeven. Ik ben super tevreden met 
het resultaat en zal reclame voor je blijven maken. Al jouw werk maakt het 
boekje voor mij nog persoonlijker.
Ik ben gezegend met een vriendengroep die me erg dierbaar is. Jullie zorgen 
voor de ontspanning naast het werk. Zonder iedereen te noemen wil ik 
jullie wel allemaal bedanken. Maar in het bijzonder de Boys, we zijn met z’n 
achten al vanaf de middelbare school bij elkaar. Dat is zo uniek en ik geniet 
van alle feestjes, etentjes en vakanties samen. Hopelijk volgen er nog veel.
Lieve Sabine, ik vond het super om jouw paranimf te zijn maar ben nog 
trotser dat jij dadelijk naast mij staat. Hopelijk volgen er nog veel etentjes 
en vinden we altijd wel weer een reden om bubbels te schenken.
Boertje, naast je aanstekelijke humor ben ik ook erg blij met onze 
gezamenlijke passie voor de zorg. Hopelijk krijgen we het een keer voor het 
zeggen in de zorg: dan wordt alles beter. Ik ben erg trost dat jij mijn paranimf 
bent. 
Lieve pap en mam, de eeuwige steun en liefde die jullie uitstralen naar mij 
doet al 34 jaar heel goed. Dank voor alles.
Nu nog het beste van het stel: Marieke. Je Rotterdamse nuchtere humor en 
je liefde voor mij zijn onbetaalbaar. We hebben zo veel gemeen maar zijn 
soms ook zo anders. Daarom zijn we het beste stel. Ik verheug me op ons 
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